Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Washington, D.C. 20549
Form 10-K
þ | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
| For the fiscal year ended December 31, 2007 | ||
or | ||
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
| For the transition period from to | ||
Commission File Number000-51329
XenoPort, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 94-3330837 | |
(State or other Jurisdiction of Incorporation or Organization) | (IRS Employer Identification No.) | |
3410 Central Expressway, Santa Clara, California (Address of principal executive offices) | 95051 (Zip Code) | |
(408) 616-7200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Name of Each Exchange on Which Registered | |
| Common stock, par value $0.001 per share | The NASDAQ Stock Market LLC | |
| Preferred share purchase rights |
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 ofRegulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of thisForm 10-K or any amendment to thisForm 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o | Smaller reporting company o | |||
| (Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined inRule 12b-2 of the Exchange Act). Yes o No þ
As of June 29, 2007 (the last business day of the registrant’s most recently completed second quarter), the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately $722.4 million based on the closing sale price as reported on The NASDAQ Global Market for such date. Excludes an aggregate of 8,683,055 shares of the registrant’s common stock held by officers, directors and affiliated stockholders. For purposes of determining whether a stockholder was an affiliate of the registrant at June 29, 2007, the registrant assumed that a stockholder was an affiliate of the registrant at June 29, 2007 if such stockholder (i) beneficially owned 10% or more of the registrant’s common stockand/or (ii) was affiliated with an executive officer or director of the registrant at June 29, 2007. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.
Class | Outstanding at February 1, 2008 | |
| Common stock, par value $0.001 per share | 25,087,907 shares |
DOCUMENTS INCORPORATED BY REFERENCE
Document | Parts Into Which Incorporated | |
Portions of the Definitive Proxy Statement for the Annual Meeting of Stockholders to be held on or about May 8, 2008 (Proxy Statement) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by thisForm 10-K are incorporated by reference | Part III, Items 10-14 |
XENOPORT, INC.
TABLE OF CONTENTS
2
Table of Contents
This Annual Report onForm 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including any projections or earnings. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential” and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in this Annual Report onForm 10-K in greater detail under the heading “Risk Factors.” Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this Annual Report onForm 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
PART I.
| Item 1. | Business. |
Overview
We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. We intend to focus our development and commercialization efforts on potential treatments of central nervous system, or CNS, disorders. Our most advanced product candidate, XP13512, is currently being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program in the United States and has also successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia, or PHN, in the United States. One of our partners, Astellas Pharma Inc., is evaluating this product candidate in two separate Phase 2 clinical trials in Japan for the treatment of painful diabetic neuropathy, or PDN, and RLS. Another of our partners, Glaxo Group Limited, or GSK, plans to evaluate XP13512 for PHN, PDN and migraine prophylaxis. We are evaluating our second product candidate, XP19986, for the potential treatment of gastroesophageal reflux disease, or GERD, and for the potential treatment of spasticity in separate Phase 2 clinical trials. We initiated a Phase 1 clinical trial of our third product candidate, XP21279, that we plan to evaluate as a potential treatment for Parkinson’s disease.
Each of our product candidates is an orally available, patented or patentable new chemical entity that addresses large potential markets. Our innovative product candidates, which we refer to as Transported Prodrugs, are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct deficiencies in the oral absorption, distributionand/or metabolism of the parent drug. We have designed our current Transported Prodrugs to be actively transported from the gastrointestinal, or GI, tract into the bloodstream, where they are metabolized to release the parent drug.
A key component of our strategy is to reduce the risks and time associated with drug development by capitalizing on the known safety, efficacy and established drug development history of the parent drugs. In addition, our product candidates are designed to be metabolized to release the parent drugs and natural substances with favorable safety characteristics. We believe that these features will increase the probability of successfully developing our product candidates. In addition, we intend to seek approval of our product candidates in indications for which the parent drugs have not been approved, but are nevertheless used off-label after having demonstrated efficacy in clinical trials. We believe that the improved characteristics of our product candidates will provide
3
Table of Contents
meaningful therapeutic benefits compared to existing drugs, as well as allow for approval to market in indications for which the parent drugs are not currently approved or promoted.
We plan to enter into agreements with pharmaceutical companies: (1) when access to a primary care physician sales force is necessary to maximize the commercial potential of our product candidates in the United States; (2) for the development and commercialization of our product candidates outside the United States; or (3) to develop and commercialize product candidates that fall outside our primary CNS focus. To date, we have entered into two separate agreements for the development and commercialization of XP13512. In December 2005, we entered into an agreement in which we licensed to Astellas exclusive rights to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan (collectively referred to as the Astellas territory). In February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 in all countries of the world other than the Astellas territory. In October 2007, we announced an exclusive license agreement with Xanodyne Pharmaceuticals, Inc. in which we licensed to Xanodyne exclusive rights to develop and commercialize another of our product candidates, XP21510, in the United States for the potential treatment of women diagnosed with menorrhagia, or heavy menstrual bleeding.
Our current portfolio of proprietary product candidates includes the following:
| • | XP13512 for RLS. XP13512 is a Transported Prodrug of gabapentin. XP13512 is currently being evaluated for the treatment of RLS in a Phase 3 clinical program in the United States and in a Phase 2 clinical trial in Japan. RLS is characterized by an irresistible urge to move one’s legs, usually accompanied by unpleasant sensations or pain in the legs. We have announced top-line data from two RLS Phase 3 clinical trials that demonstrated statistically significant improvements compared to placebo on the primary endpoints of these trials and that XP13512 was generally well tolerated. | |
| • | XP13512 for Neuropathic Pain. We have also shown in a Phase 2a clinical trial that XP13512 is effective for the management of PHN, a chronic type of neuropathic pain that can follow the resolution of shingles. XP13512 is being studied by our partner, Astellas, in a Phase 2 clinical trial in Japan for the treatment of PDN, a chronic type of neuropathic pain that results from diabetes. Our partner, GSK, has announced that it intends to initiate in the first quarter of this year a neuropathic pain program that will include two Phase 2 clinical trials designed to show the safety and efficacy of XP13512 in the management of PHN, as well as a Phase 2 clinical trial designed to show the safety and efficacy of XP13512 in the treatment of PDN. | |
| • | XP13512 for Migraine Prophylaxis. Migraine is a neurological disorder characterized by recurrent headache attacks that are usually accompanied by various combinations of symptoms, including nausea and vomiting, as well as distorted vision and sensitivity to light and sound. Migraine prophylaxis is designed to reduce the frequency and severity of migraine attacks. GSK has announced plans to initiate in the second half of this year parallel, pivotal Phase 3 clinical trials designed to show the safety and efficacy of XP13512 in preventing migraines in patients, along with a long-term clinical trial designed to establish safety in this patient population, following agreement with the U.S. Food and Drug Administration, or FDA. | |
| • | XP19986 for GERD. XP19986 is a Transported Prodrug of R-baclofen that we are developing for the treatment of GERD, which is a digestive system disorder caused primarily by transient relaxations of the lower esophageal sphincter, which is a combination of muscles that controls the junction between the esophagus and the stomach. GERD is characterized by the frequent, undesirable passage of stomach contents into the esophagus that results in discomfort and potential damage to the lining of the esophagus. We have successfully completed a Phase 2a clinical trial indicating that single doses of XP19986 were well tolerated and produced statistically significant reductions in the number of reflux episodes in patients with GERD. We initiated a second Phase 2 clinical trial of XP19986 in patients with GERD in the fourth quarter of 2007. | |
| • | XP19986 for Spasticity. XP19986 is also a potential treatment for spasticity, a condition in which certain muscles are continuously contracted, causing stiffness or tightness of muscles that interferes with movement or speech. Racemic baclofen, which contains both R-baclofen and S-baclofen, is currently approved in the United States for the treatment of spasticity resulting from multiple sclerosis, spinal cord injury and other spinal cord diseases. We believe that spasticity patients may benefit from XP19986 due to less frequent |
4
Table of Contents
| dosing and a more desirable pharmacokinetic profile than racemic baclofen. We initiated a Phase 2 clinical trial of XP19986 in spinal cord injury patients with spasticity in the fourth quarter of 2007. |
| • | XP21279 for Parkinson’s Disease. XP21279 is a Transported Prodrug of levodopa, or L-Dopa, that we are developing for the treatment of Parkinson’s disease, a neurological disorder of the elderly, characterized by tremor, rigidity and loss of reflexes. We initiated a Phase 1 clinical trial to evaluate the safety and pharmacokinetics of XP21279 in the fourth quarter of 2007. | |
| • | XP20925 for Migraine. XP20925 is a Transported Prodrug of propofol that is in preclinical development for the treatment of migraine. We have commenced preclinical development activities to support the filing of an investigational new drug application, or IND, for XP20925. | |
| • | XP21510 for the Treatment of Women with Menorrhagia. XP21510 is a Transported Prodrug of tranexamic acid. Tranexamic acid is a man-made derivative of the naturally occurring amino acid lysine and works to inhibit, on a molecular basis, the break down of blood clots. It is approved in many countries in Europe and Asia for the treatment of women with menorrhagia, or heavy menstrual bleeding. In October 2007, we announced an exclusive license agreement for the development and commercialization of XP21510 by Xanodyne in the United States. |
Transported Prodrugs
Critical to the success of any drug is its ability to access the targeted tissues, achieve and maintain effective concentrations at the site of therapeutic action for an appropriate period of time and have minimal side effects. In addition, convenient administration is frequently necessary to ensure patient compliance. Many marketed drugs do not possess all of these attributes, leading to limitations in their therapeutic benefit and commercial potential.
The conventional approach to designing new oral drugs is to rely on the drug’s ability to passively diffuse through the intestinal wall to enter the bloodstream and reach the targeted tissue. However, this can be a difficult task, since the chemical and physical properties that allow a drug to bind to its cellular target and cause the intended therapeutic effect frequently impair the drug’s ability to passively diffuse through the wall of the intestines. If the medical need is high, drugs with poor absorption from the GI tract are still developed and marketed, but with suboptimal therapeutic benefit. In some cases, drugs that are poorly absorbed from the GI tract are marketed as injected medicines, which is inconvenient for patients. Another problem frequently encountered by drug designers occurs when a drug is well absorbed from the intestines but does not last in the bloodstream for a sufficient period of time to maintain a therapeutic benefit. In this situation, frequent oral dosing is required, which is inconvenient for patients and can lead to poor compliance. In addition, drugs requiring frequent dosing often exhibit unwanted side effects when the drug is present in high concentration and then ineffectiveness when the concentration of the drug is insufficient. Sustained-release formulations that deliver medicine slowly as a pill travels through the entire GI tract can sometimes improve the utility of drugs that exhibit suboptimal therapeutic properties. However, drugs absorbed only in the upper GI tract do not benefit from sustained-release formulations.
Since most nutrients contain chemical features that prevent effective passive diffusion through cellular barriers, the human body contains specific membrane proteins, known as transporters, that are responsible for carrying nutrients into cells and across cell barriers. There are hundreds of different transporters in the human body that vary in the types of molecules they recognize and their localization to certain cells and tissue barriers. Active transport refers to cellular transporter mechanisms that capture nutrients and carry them across membranes.
Our proprietary technology utilizes the body’s natural mechanisms for actively transporting nutrients through cellular barriers to permit certain parent drugs with suboptimal oral absorption to be effectively and efficiently delivered into the body after the oral administration of our product candidate.
Our scientists identify specific, high-capacity nutrient transporter proteins in the intestines and chemically modify the structure of the parent drug to create a Transported Prodrug that utilizes these transporters to gain efficient absorption into the bloodstream through active transport. Our Transported Prodrugs are engineered to split apart, releasing the parent drug and natural substances that generally have well-studied, favorable safety characteristics. In some cases, our product candidates target transporter proteins that are present throughout the entire GI tract, including the colon, so they can be formulated using sustained-release technology and thereby maintain
5
Table of Contents
effective blood concentrations for an extended period after dosing. As a result of their improved oral absorption, our product candidates may have improved therapeutic benefits compared to the parent drugs, such as superior clinical efficacy, reduced side effects and less frequent dosing, which result in improved patient convenience and compliance.
Our Product Candidates
The following table summarizes our first five product candidates:
| XenoPort Product | ||||||
Candidate | Commercialization Rights | Target Indications | Development Status | |||
XP13512 | XenoPort: U.S. co-promotion option with GSK | • Restless legs syndrome • Post-herpetic neuralgia | • U.S. Phase 3 clinical program ongoing • Phase 2a successfully completed | |||
| Partner Designation: | ||||||
| ASP8825 | Astellas: six Asian countries | • Restless legs syndrome | • Japan Phase 2 clinical trial ongoing | |||
| • Painful diabetic neuropathy | • Japan Phase 2 clinical trial ongoing | |||||
| GSK1838262 | GSK: worldwide, excluding the Astellas territory | • Restless legs syndrome | • Polysomnography trials planned for the second half of 2008 | |||
| • Migraine prophylaxis | • Phase 3 clinical trials planned for the second half of 2008, pending FDA agreement | |||||
| • Painful diabetic neuropathy | • Phase 2 clinical trial planned for the first quarter of 2008 | |||||
| • Post-herpetic neuralgia | • Phase 2 clinical trial planned for the first quarter of 2008 | |||||
XP19986 | Retained by XenoPort | • Gastroesophageal reflux disease | • Second Phase 2 clinical trial ongoing | |||
| • Spasticity | • Phase 2 clinical trial ongoing | |||||
XP21279 | Retained by XenoPort | • Parkinson’s disease | • Phase 1 clinical trial ongoing | |||
XP20925 | Retained by XenoPort | • Migraine | • Preclinical | |||
XP21510 | XenoPort: worldwide, excluding the U.S. | • Menorrhagia | • Preclinical | |||
| Xanodyne: U.S. |
XP13512 — A Transported Prodrug of Gabapentin
Our most advanced product candidate, XP13512, is currently being developed for the treatment of RLS and neuropathic pain. Our partner, GSK, also plans to develop XP13512 for migraine prophylaxis. We holdcomposition-of-matter patents and methods of synthesis patents on XP13512 in the United States andcomposition-of-matter, formulation and methods of use patents on XP13512 outside of the United States. We
6
Table of Contents
also hold pending patent applications in the United States and outside the United States that are directed to composition of matter, formulations and methods of synthesis and use of XP13512.
Parent Drug Background
XP13512 is metabolized by the body to release gabapentin, a drug that has been sold by Pfizer Inc as Neurontin since 1993 and is currently sold as a generic drug by a number of companies. Gabapentin is approved for marketing in the United States as adjunctive therapy in the treatment of partial seizures in patients with epilepsy and for the management of PHN. In addition, based on a variety of medical studies showing its safety and efficacy, gabapentin is prescribed by physicians, off-label, to treat a wide range of psychiatric, neurological and pain conditions, including RLS and other forms of neuropathic pain besides PHN. Gabapentin has a side effect profile that is considered very favorable, with dizziness and somnolence, or drowsiness, as the most commonly reported side effects. Neurontin achieved peak sales of approximately $2.7 billion worldwide in 2004, before the launch in the United States of generic gabapentin in October 2004. According to the IMS Health NPA Plus Report, in the United States, annual prescriptions for gabapentin totaled approximately 20 million in 2007.
Despite its substantial commercial success, we believe that gabapentin therapy can be significantly improved. For example, in the clinical trials used to support the approval of gabapentin for the treatment of partial seizures in patients with epilepsy and the management of PHN, only 26% and 32% of the patients responded to gabapentin at the highest approved dose, respectively. Gabapentin absorption is highly variable among patients, and there is a limit on the gabapentin exposure that can be achieved. Published results from clinical trials of gabapentin in epilepsy patients indicated that, for the same dose level, some patients absorbed as little as 10% of the dose of gabapentin administered while others absorbed more than 70%. We have also conducted a clinical trial of gabapentin in neuropathic pain patients in which the high variability of gabapentin absorption was demonstrated. In addition, the short duration of gabapentin in blood after oral dosing requires that it be administered three times a day, which may lead to poor compliance with the dosing regimen and, therefore, reduced efficacy in some patients.
We believe that these suboptimal characteristics of gabapentin result from the mechanism responsible for the absorption of gabapentin. Gabapentin is actively transported across the GI tract after administration. However, the specific transporter mechanism responsible for gabapentin absorption appears to have limited capacity, which seems to vary among individuals, and which is predominantly expressed in the upper GI tract. Due to gabapentin’s poor absorption in the lower GI tract, the use of sustained-release formulations to correct the frequent dosing requirement has not been possible.
Our Transported Prodrug
XP13512 addresses the deficiencies of gabapentin by targeting high-capacity nutrient transporter mechanisms expressed throughout the length of the intestines. We believe that this approach can overcome the variable and suboptimal exposure to gabapentin experienced by patients. By targeting transporters expressed throughout the length of the intestines, we have been able to develop a sustained-release formulation of XP13512 that we believe has overcome the need for frequent dosing of gabapentin.
XP13512 is designed to rapidly convert to gabapentin once absorbed from the GI tract, resulting in limited systemic exposure to the intact Transported Prodrug. In addition to producing gabapentin, XP13512 is metabolized to release other components with well-studied, favorable safety characteristics. We believe that XP13512 will have a favorable safety profile in humans, comparable to that of gabapentin, due to the inherently safe nature of its metabolic breakdown products.
Phase 1 Clinical Trials
We have completed multiple safety, tolerability and pharmacokinetic Phase 1 clinical trials of XP13512. The results of all of these Phase 1 clinical trials indicated that XP13512 was generally well tolerated at all doses. Reported adverse events were consistent with those reported previously for gabapentin. In addition, these clinical trials indicated that XP13512 was rapidly absorbed and converted to gabapentin. Exposure to the intact Transported Prodrug was low and transient compared to the level of gabapentin produced at all dose levels.
7
Table of Contents
Initial Target Indications
Restless Legs Syndrome
Background on RLS. RLS is a common, under-diagnosed neurological condition that frequently manifests itself as a sleep disorder. Patients who suffer from RLS experience an irresistible urge to move their legs. This urge is usually accompanied by unpleasant sensations of burning, creeping, tugging or tingling inside the patients’ legs, ranging in severity from uncomfortable to painful. These RLS-related symptoms typically begin or worsen during periods of rest or inactivity, particularly when lying down or sitting, and may be temporarily relieved by movement such as walking or massaging the legs. Symptoms often worsen at night, and disturbed sleep is a common result of RLS. Left untreated, RLS may cause exhaustion, daytime fatigue, inability to concentrate and impaired memory.
Potential Market. According to the National Institute of Neurological Disorders and Stroke, RLS is the third largest sleep disorder, after insomnia and sleep apnea. Although the exact prevalence rate of RLS is uncertain, a study published in the May 2004 issue ofSleep Medicine indicated that approximately 10% of patients visiting primary care physicians in the United States and four European countries (France, Germany, Spain and the United Kingdom) experience RLS symptoms at least weekly, with approximately 2% of patients visiting primary care physicians suffering from symptoms severe enough to disrupt their quality of life.
Current Treatments. Current treatments of RLS include dopamine agonists, opioids, benzodiazepines and anticonvulsants, such as gabapentin. In May 2005, GSK received approval from the FDA to market the dopamine agonist ropinirole, known as Requip, for the treatment ofmoderate-to-severe RLS. In addition, in November 2006, Boehringer Ingelheim GmbH received approval from the FDA to market pramipexole, known as Mirapex, for the treatment ofmoderate-to-severe RLS. In April 2006, both ropinirole and pramipexole were approved in the European Union by the European Commission for the treatment ofmoderate-to-severe RLS.
In a study published in the journalNeurologyin 2002, gabapentin was shown to be effective in treating patients with RLS in terms of statistically significant improvements versus placebo in both the International Restless Legs Syndrome, or IRLS, rating scale and measures of sleep quality. We believe that XP13512 may provide better efficacy than gabapentin in RLS patients because of its potential ability to maintain higher levels of gabapentin in the blood throughout the night.
Phase 2a Clinical Trial Results. We have completed a Phase 2a clinical trial of XP13512 as a treatment for RLS. The trial included 38 patients diagnosed with RLS using the International RLS Study Group diagnostic criteria at nine clinical sites in the United States. The objective of this Phase 2a clinical trial was to further assess the safety and pharmacokinetics of the sustained-release tablet formulation of XP13512, as well as to assess preliminary efficacy in patients after two weeks of XP13512 therapy. The trial was a randomized, double-blind, placebo-controlled, crossover clinical trial designed to test XP13512 versus placebo in patients with RLS. XP13512 was dosed twice a day, once at 5:00 p.m. (600 mg) and again one hour before bedtime (1200 mg). The primary endpoint of the clinical trial was the change in the IRLS rating scale score from baseline to the end of the treatment period. A number of secondary endpoints were also examined, including objective sleep measures obtained by polysomnogram, or sleep laboratory measurements, which were conducted prior to, and at the end of, each treatment.
This Phase 2a clinical trial demonstrated that after 14 days of therapy, XP13512 produced a highly statistically significant improvement in the IRLS rating scale score compared to placebo. We determined statistical significance based on a widely used, conventional statistical method that establishes the p-value of clinical results. The statistical significance level for comparing XP13512 to placebo was p<0.0001. A p-value of 0.05 or less generally represents a statistically significant difference in treatments. A lower p-value indicates greater confidence in the result. A statistically significant improvement in the IRLS rating scale score was also seen after one week of XP13512 treatment. Twenty-nine patients (85% of the patients who completed the trial) reported themselves “much improved” or “very much improved” at the end of the XP13512 treatment period as compared to five patients (15%) at the end of the placebo treatment period. Additionally, compared to placebo, XP13512 was associated with statistically significant improvements in a number of objective sleep measures, including an increase in total sleep time, an increase in the amount of slow-wave sleep, a reduction in the amount of time awake after sleep onset and a reduction in the number of times periodic limb movements woke patients from sleep. XP13512 was well tolerated.
8
Table of Contents
The most common side effects of XP13512 were dizziness and somnolence, which are established side effects of gabapentin.
Phase 2b Clinical Trial Results. We have completed a Phase 2b clinical trial of XP13512 as a treatment for RLS. The trial included 95 patients diagnosed with RLS using the International RLS Study Group diagnostic criteria at 14 clinical sites in the United States. The objective of this Phase 2b clinical trial was to assess the safety and efficacy of lower doses of XP13512 given once daily. The trial was a randomized, double-blind, placebo-controlled clinical trial designed to test 600 mg and 1200 mg of XP13512 versus placebo administered once per day at evening meal for 14 days. The primary endpoint of the clinical trial was the change in the IRLS rating scale score from baseline to the end of the treatment period. A number of secondary endpoints were also examined, including Patient and Investigator Clinical Global Impression of Improvement, or CGI-I, scales, which are recognized measures of patient and physician assessments of clinical change, subjective measures of sleep and symptom severity throughout the day, assessed with a24-hour diary.
The Phase 2b clinical trial demonstrated that treatment with 1200 mg of XP13512 was associated with a highly statistically significant improvement in the IRLS rating scale score at the end of 14 days of treatment (mean change from baseline: -16.1 for 1200 mg of XP13512; -8.9 for placebo; p<0.0001). A statistically significant improvement in the IRLS rating scale score was also seen after one week of treatment with 1200 mg of XP13512. Treatment with 1200 mg of XP13512 resulted in a statistically significant improvement in both Patient and Investigator CGI-I scales (both p<0.0001 compared to placebo), which were used to assess overall patient improvements. Based on Investigator CGI-I, 81% of the patients who received 1200 mg of XP13512 were “much improved” or “very much improved,” as compared to 48% of patients who received placebo. Treatment with 1200 mg of XP13512 was associated with statistically significant improvements in a number of subjective measures of sleep, including overall quality of sleep, the number of awakenings per night due to RLS symptoms and the number of hours awake per night due to RLS symptoms (all p<0.005 compared to placebo). Finally, treatment with 1200 mg of XP13512, compared to placebo, was associated with a statistically significant reduction in the severity of RLS symptoms in the evening (8:00 p.m. to midnight) as measured using a24-hour RLS symptom diary on the final day of treatment (p=0.01 compared to placebo). Clinical effects measured by the above endpoints in patients treated with 600 mg of XP13512 were not statistically different from patients treated with placebo.
XP13512 was generally well tolerated. There were no serious adverse events. The most common side effects were somnolence (15% placebo, 14% 600 mg of XP13512 and 36% 1200 mg of XP13512) and dizziness (3% placebo, 14% 600 mg of XP13512 and 18% 1200 mg of XP13512). Similar side effects have been reported previously for gabapentin.
Phase 3 Clinical Program and Planned Regulatory Filing. Based on the results of our Phase 2 clinical trials, we are currently evaluating XP13512 in a Phase 3 clinical program for the treatment of RLS. The Phase 3 clinical program encompasses multiple U.S. trials, including one 12-week, randomized, double-blind, placebo-controlled trial, XP052, designed to evaluate the safety and efficacy of 1200 mg of XP13512 versus placebo administered once a day at approximately 5:00 p.m., and a second 12-week randomized, double-blind, placebo-controlled trial, XP053, designed to evaluate the safety and efficacy of 600 mg or 1200 mg of XP13512 versus placebo administered once a day at approximately 5:00 p.m. The co-primary outcome measures for these trials are defined to be the change from baseline in the IRLS rating scale score and the Investigator CGI-I scale at the end of treatment. Secondary endpoints for both trials include onset of efficacy and subjective sleep, pain, mood and quality of life assessments.
The XP052 trial, which commenced in March 2006, enrolled 222 patients at 23 sites who were diagnosed withmoderate-to-severe primary RLS. In April 2007, we reported top-line results that demonstrated that treatment with 1200 mg of XP13512 was associated with a statistically significant improvement in the co-primary endpoints compared to placebo. Improvements in the IRLS rating scale were significantly greater for XP13512 than for placebo (−13.2 vs. −8.8; p=0.0002). At the end of treatment, significantly more patients treated with XP13512 were reported as “much improved” or “very much improved” on the Investigator CGI-I scale compared to those treated with placebo (76% vs. 39%; p < 0.0001). During treatment over the 12-week period, the most commonly reported adverse events for XP13512 versus placebo were somnolence (27% XP13512; 7% placebo) and dizziness (20% XP13512; 5% placebo). There were no reported serious adverse events in XP13512-treated patients.
9
Table of Contents
The XP053 trial was initiated in August 2006, and we concluded enrollment in August 2007. We expect to announce the results of this clinical trial in the first quarter of this year.
In addition to these two 12-week trials, the Phase 3 program also includes a clinical trial, XP060, to assess the long-term efficacy of XP13512. The trial, which commenced in May 2006, was designed to evaluate the potential of XP13512 to maintain efficacy over the course of nine months in patients with RLS. The multi-center, double-blind, randomized, placebo-controlled, parallel-group clinical trial enrolled 327 patients diagnosed withmoderate-to-severe primary RLS. All patients were administered 1200 mg of XP13512, taken at approximately 5:00 p.m., for 24 weeks. Patients were assessed to determine treatment response at the end of this single-blind phase, and responders then entered the 12-week, randomized, double-blind phase of the clinical trial. Patients randomized to the placebo group received 600 mg of XP13512 for two weeks and then received placebo for an additional ten weeks. Patients randomized to the XP13512 treatment group continued to receive 1200 mg of XP13512 for the entire 12-week, double-blind period. In January 2008, we reported top-line results that showed that XP13512 was generally well-tolerated during the treatment period and that there was a statistically significant difference between the percentage of patients treated with XP13512 and placebo who met a pre-specified relapse criteria during the randomized phase of the study. Two hundred twenty one patients completed the 24-week, single-blind portion of the clinical trial, of which 194 (88%) met the responder criteria and were randomized to double-blind treatment. Analysis of the primary endpoint indicated that treatment with XP13512 resulted in a statistically significant lower proportion of relapses compared to placebo during the double-blind treatment period (23% placebo compared to 9% XP13512; p= 0.0158).
The most commonly reported adverse events during the single-blind phase of the clinical trial were somnolence (30%) and dizziness (22%), which were generally mild or moderate in intensity and transient in nature. The incidence of somnolence and dizziness in XP13512-treated patients during the double-blind portion of the trial were 3% and 2%, respectively. During the trial, there was one death that was determined to be unrelated to XP13512 treatment. There were five other serious adverse events, only one of which was judged as possibly related to XP13512 treatment.
Clinical Development of XP13512 in Restless Legs Syndrome. We are also collecting information that is typically required for submission of a new drug application, or NDA, to the FDA, including an examination of the exposure/response relationship, pharmacokinetics in a special population, drug/drug interactions, cognition, driving proficiency and cardiovascular safety. In addition, we are conducting an extension study that includes patients from the two 12-week clinical trials to enable assessment of the safety of XP13512 treatment extending up to 12 months. Data from this trial will also be included in the NDA filing. The results of the Phase 3 clinical trials, combined with the results from other XP13512 clinical trials in RLS patients, are intended to meet the International Committee for Harmonization, or ICH, guidelines for safety assessment.
Following our clinical development, and provided that we obtain positive clinical trial results from the ongoing analysis, pursuant to the terms of our agreement, GSK will be responsible for filing an NDA with the FDA for XP13512 as a treatment for RLS, which is currently planned for the third quarter of 2008.
In addition, GSK has announced plans to initiate two polysomnography, or sleep laboratory measurement, studies of XP13512 in RLS patients in the second half of 2008 to explore further the potential benefits of XP13512 in sleep. Successful results of these trials could potentially lead to additional labeling of XP13512 for improved sleep in RLS patients.
In September 2007, Astellas initiated a 12-week randomized, double-blind, placebo-controlled Phase 2 clinical trial in RLS patients in Japan.
Neuropathic Pain
Background on Neuropathic Pain. Neuropathic pain is pain that results from damage to nerves. The damage may result from a variety of causes, including injury or illnesses such as diabetes, HIV and shingles. In addition, the
10
Table of Contents
toxic effects of therapy used to treat patients with cancer or HIV may also cause nerve damage leading to neuropathic pain.
One form of chronic neuropathic pain is PHN. PHN is a complication of shingles, a painful outbreak of rash or blisters on the skin caused by a reactivation of the same virus that causes chicken pox. PHN is often characterized as constant stabbing, burning or electric shock-like sensations in the area affected by shingles after the rash has cleared. Approximately 10% to 15% of all patients with shingles develop PHN, which can persist for many years.
PDN is another form of neuropathic pain that is associated with a family of nerve disorders caused by diabetes. Over time, people with diabetes can have damage to nerves that leads to numbness and sometimes pain and weakness in the hands, arms, feet and legs.
Potential Market. Decision Resources estimates that the prevalence of PHN during 2007 was 552,000 patients in the United States and six other major pharmaceutical markets, collectively. In May 2006, Merck & Co. received FDA approval for Zostavax, a live attenuated vaccine, to help prevent shingles. In October 2006, the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously to recommend that adults 60 years of age and older be vaccinated with Zostavax for the prevention of shingles. While Zostavax is not a treatment for shingles or PHN, the availability of this vaccine could impact the future market for therapies for PHN.
According to the National Diabetes Clearing House, a service of The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 20.8 million people, or 7% of the U.S. population, have diabetes. Diabetes is the leading cause of neuropathy in the Western world, and neuropathy is the most common complication and greatest source of morbidity and mortality in diabetes patients. Although not all diabetics with neuropathy have symptoms, an estimated 60% to 70% of people with diabetes have mild to severe forms of nervous system damage. Decision Resources estimates that the prevalence of PDN during 2007 was 6.8 million patients in the United States and six other major pharmaceutical markets, collectively.
Current Treatments. Current classes of drugs used to treat patients with neuropathic pain include anticonvulsants, antidepressants and opioids, with anticonvulsants representing the largest share of the neuropathic pain market. Of the anticonvulsants, gabapentin is the market leader for the treatment of neuropathic pain. Local application of capsaicin and lidocaine is also used in selected patients. Neurontin was the first oral drug approved by the FDA for the management of PHN. In September 2005, Pfizer launched pregabalin for the treatment of epilepsy and of neuropathic pain associated with diabetic peripheral neuropathy and PHN. Pfizer is marketing pregabalin under the trade name Lyrica. Pfizer received European Commission approval in July 2004 to market Lyrica in European Union member states for the treatment of peripheral neuropathic pain and approval in September 2006 to market Lyrica in European Union member states for the treatment of central neuropathic pain. Eli Lilly and Company has also received approval from the FDA to market duloxetine, under the trade name Cymbalta, for the management of diabetic peripheral neuropathy.
Phase 2a Clinical Trial Results. We have completed a Phase 2a clinical trial of XP13512 for the management of PHN. The trial included 101 patients at 18 clinical sites in the United States. The objective of this randomized, double-blind, placebo-controlled clinical trial was to assess the preliminary safety, tolerability, pharmacokinetics and efficacy of 1200 mg of XP13512 administered twice a day for 14 days and to compare the response to XP13512 against the response to placebo. While clinical trials required for obtaining FDA approval to market product candidates for the management of PHN have required treatment periods of eight weeks, published studies of gabapentin for the management of PHN have shown efficacy in as short as 14 days of treatment.
After establishing baseline pain scores and prior to entering the randomized treatment period, all patients in this clinical trial received increasing doses of Neurontin of up to 1800 mg per day and were maintained at this dose for seven days. At the end of this Neurontin treatment period, pharmacokinetics and clinical endpoints were assessed. Patients were then immediately randomized to 1200 mg of XP13512 administered twice a day or placebo treatment. Treatment continued for an additional 14 days, at which time pharmacokinetics and clinical endpoints were again assessed. The primary endpoint of this clinical trial was the change in average pain score between the seven days of baseline assessment to the final seven days of XP13512 or placebo treatment using an 11-point numerical pain scale.
11
Table of Contents
This Phase 2a clinical trial demonstrated that treatment with XP13512 was associated with a statistically significant reduction in pain as measured by an 11-point numerical pain scale (p=0.032) compared to placebo. Statistically significant improvements in pain were also observed using a different pain scale. Additionally, compared to placebo, treatment with XP13512 was associated with a statistically significant reduction in sleep interference. The clinical benefit of XP13512 over placebo was also supported by observed statistically significant improvements in both Patient and Investigator CGI-I scales. XP13512 was well tolerated. The most common side effect of XP13512 was dizziness, which is an established side effect of gabapentin.
Because of the structure of this Phase 2a clinical trial, we were able to compare blood levels of Neurontin and to test for a trend toward improved pain reduction with XP13512 compared to Neurontin in the same patients. Accordingly, additional analyses were conducted on data from those patients who received both Neurontin and XP13512 and for whom pharmacokinetic data was complete. A daily dose of 2400 mg of XP13512 has the potential to release 1248 mg per day of gabapentin into the bloodstream, which equates to approximately two-thirds of the daily dose administered during the Neurontin treatment period. Despite this lower dose, XP13512 produced on average a 17% increase in the steady-state average blood concentration of gabapentin compared to that produced by Neurontin dosing (p=0.014) in the evaluated patients because of the higher bioavailability of XP13512. Thirty-six percent of evaluated patients had an increased steady-state average blood concentration of greater than 30%. For all patients who received XP13512, the change in average pain score between the last seven days of the Neurontin treatment and the final seven days of XP13512 treatment was determined. A statistically significant reduction in pain score at the end of XP13512 treatment was observed (p=0.045).
Clinical Development of XP13512 in Neuropathic Pain. In July 2007, our partner, Astellas, initiated aneight-week, double-blind, placebo-controlled Phase 2 clinical trial of XP13512 (known by Astellas as ASP8825) in patients with PDN.
In December 2007, GSK announced that it intends to initiate in the first quarter of 2008 a neuropathic pain program that will include separate dose-ranging, Phase 2 clinical trials of XP13512 (known by GSK as GSK1838262) in PHN and PDN, as well as a Phase 2 clinical trial in PHN patients who have not responded to treatment with gabapentin.
Migraine Prophylaxis
Background on Migraine. Migraine is a neurological disorder characterized by recurrent headache attacks that are usually accompanied by various combinations of symptoms, including nausea and vomiting, as well as distorted vision and sensitivity to light and sound.
Potential Market. According to the American Migraine Prevalence and Prevention Study, migraine affects approximately 30 million individuals in the United States and approximately 40% of migraine sufferers could benefit from preventive therapies.
Current Treatments. Current treatments for migraine include abortive therapies for individual migraine episodes and prophylactic therapies that are designed to prevent or reduce the number of migraine attacks. Abortive therapies include non-prescription analgesics, such as aspirin, ibuprofen and acetaminophen, and prescription drugs. According to Decision Resources, the most widely prescribed prescription drugs are triptans, and include sumatriptan (Imitrex) from GSK, rizatriptan (Maxalt) from Merck &Co./Eisai/Kyorin, zolmitriptan (Zomig) from AstraZeneca and eletriptan (Relpax) from Pfizer.
Migraine prophylaxis is designed to reduce the frequency and severity of migraine attacks, to make acute migraine attacks more responsive to abortive therapy and to improve the quality of life for patients. According to Decision Resources, the leading branded prescription treatments for migraine prophylaxis are topiramate (Topamax) from Johnson & Johnson and divalproex sodium (Depakote) from Abbott Laboratories.
Planned Development. Our partner, GSK, has announced plans to enter Phase 3 clinical development of XP13512 for migraine prophylaxis in the second half of 2008, subject to agreement with the FDA.
12
Table of Contents
Development and Commercialization Strategy
Due to the large markets for which we intend to seek regulatory approval for XP13512, the requirement of a primary care physician sales force to address these markets in the United States and our desire to focus our commercialization efforts in the United States, we have entered into agreements with pharmaceutical partners to maximize the potential commercial value of XP13512. In December 2005, we entered into a license agreement with Astellas for exclusive rights to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan, which we collectively refer to as the Astellas territory. Astellas made an up-front payment to us of $25.0 million, has paid additional milestones of $15.0 million and may make additional milestone payments to us of up to $45.0 million. We will receive royalties on any sales of XP13512 in the Astellas territory. Astellas may terminate the collaboration at its discretion. In such event, all XP13512 product rights would revert to us and we would be entitled to specified transition assistance from Astellas.
Additionally, in February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 worldwide, excluding the Astellas territory. GSK made an up-front payment to us of $75.0 million, has paid additional milestones of $32.0 million and may make additional payments of up to $243.0 million upon the achievement of clinical and regulatory milestones and up to $290.0 million upon the achievement of specified sales levels. Under the terms of the agreement, GSK is responsible for all future development costs, with the exception of specified development costs that we will assume in connection with the development of XP13512 for RLS in the United States. We would be entitled to a percentage of sales of XP13512 in the GSK territory for a specified period of time, unless we elect the option to co-promote XP13512 in the United States. In the event that we elect the co-promotion option for XP13512, we would share marketing and commercialization costs and would be entitled to a share of operating profits from sales of XP13512 in the United States for so long as XP13512 is sold, as well as receive payments on details we perform in the United States on Requip XL, GSK’s development-stage product candidate for Parkinson’s disease. Upon approval from the FDA of the NDA for XP13512, we would co-promote XP13512 in the United States to those same prescribers. We have granted GSK an exclusive license to develop and market XP13512 in all markets outside the United States other than the Astellas territory. GSK has the right to terminate the agreement in its entirety for any reason at its discretion upon60-days’ written notice to us prior to, and120-days’ written notice to us following, the first commercial sale of XP13512. In such event, all XP13512 product rights would revert to us and we would be entitled to specified transition assistance from GSK. In the event of a termination by GSK after it has obtained marketing approval and has commercially launched XP13512 for neuropathic pain in certain identified countries, we will be obligated to pay to GSK royalties on sales of the product for at least ten years.
XP19986 — A Transported Prodrug of R-baclofen
We are developing our product candidate, XP19986, a Transported Prodrug of R-baclofen, for the treatment of patients with GERD and for the potential treatment of the symptoms of spasticity. We hold acomposition-of-matter U.S. patent on XP19986 and have filed patent applications directed to the XP19986 methods of synthesis and use in the United States and other jurisdictions.
Parent Drug Background
Baclofen is thought to act selectively on the target that is known as the GABA(B) receptor. Baclofen is racemic, which means it is a mixture of R and S isomers. Only the R isomer is active at GABA(B) receptors. Baclofen, which is now sold as a generic drug in the United States, has been used since 1977 for the alleviation of the signs and symptoms of spasticity in patients with multiple sclerosis, stroke or cerebral palsy, as well as other pain and spasm conditions. According to the IMS National Prescription Audit Report, in 2007, there were approximately 3.7 million prescriptions written for baclofen in the United States. Published studies indicate that baclofen may also be effective in treating GERD. Although baclofen has acceptable oral absorption, its short duration in blood of three to four hours necessitates dosing at least three times per day. This dosing regimen produces substantial peaks and troughs in drug exposure, which may be the cause of side effects such as significant drowsiness, weakness and dizziness during peak drug levels and diminished efficacy during trough drug levels. However, due to its poor absorption in the colon, a less frequently dosed sustained-release formulation of baclofen that produces a more constant level of baclofen in the blood is not technically feasible. To address these deficiencies of oral baclofen, an
13
Table of Contents
implantable pump that delivers baclofen directly into the spinal cord fluid via a catheter has been developed. However, physicians typically reserve this invasive surgical procedure for those few patients who are not suitable for oral baclofen.
Our Transported Prodrug
XP19986 was designed to address the deficiencies of baclofen by targeting high-capacity nutrient transporter mechanisms expressed throughout the length of the entire GI tract, including the colon. By targeting these transporters, we believe that XP19986 can be formulated in a sustained-release pill and thereby require less frequent dosing than baclofen. XP19986 is a chiral molecule, which means that it exists as a single isomeric form, and produces only the R isomer of baclofen, known as R-baclofen.
XP19986 was designed to rapidly convert to R-baclofen upon absorption, with limited systemic exposure to the intact Transported Prodrug. Once absorbed, XP19986 converts to R-baclofen and natural substances that have well-studied, favorable safety characteristics. We believe that the inherently safe nature of the metabolic breakdown products of XP19986 should provide XP19986 with a safety profile that is at least comparable to, and potentially better than, that seen with racemic baclofen.
We are developing sustained-release formulations of XP19986 that may be suitable for once- or twice-daily dosing. We believe that XP19986, if successfully developed, will be superior to baclofen as a treatment for spasticity and as a potential treatment for GERD because of its reduced dosing frequency, improved patient compliance, improved efficacyand/or reduced side effects.
Phase 1 Clinical Trials
We have completed four Phase 1 clinical trials of XP19986 that included a total of 196 healthy volunteers.
| • | In a two-stage safety, tolerability and pharmacokinetics trial in 60 healthy adult volunteers, we administered three different capsule formulations of XP19986. One of the formulations was an immediate-release formulation, while the other two formulations were intended to release XP19986 in a more sustained fashion. Results from this initial Phase 1 trial indicated that XP19986 was well tolerated under the tested conditions. Subjects reported few adverse events. All reported adverse effects were mild in nature and have been reported previously for racemic baclofen. One of these formulations produced a pharmacokinetic profile suitable fortwice-a-day dosing and was selected for further studies. | |
| • | In a safety, tolerability and pharmacokinetics trial of XP19986 in 59 healthy adult volunteers, a controlled-release capsule formulation of XP19986 taken orally was shown to produce dose-proportional blood levels of R-baclofen. XP199886 was well tolerated with few reports of drug-related adverse effects at doses below 80 mg. At the 80 mg dose level, subjects receiving XP19986 reported a number of central nervous system side effects that have been previously reported for baclofen, with somnolence being reported by three of eight subjects. There were no serious adverse events in the trial. | |
| • | In a safety, tolerability and pharmacokinetics trial of novel formulations of XP19986 in 30 healthy adult volunteers, three different sustained-release tablet formulations of XP19986 were administered with or without food. One of these formulations produced sustained exposure to R-baclofen in blood, consistent with requirements for dosing once daily in the treatment of patients with GERD. A second formulation produced a profile that potentially would be suitable for twice-daily treatment of patients with spasticity. Results from this Phase 1 trial also indicated that XP19986 was well tolerated under the tested conditions. Subjects reported few adverse events. All reported adverse events were mild in nature and have been reported previously for racemic baclofen. | |
| • | In a safety, tolerability and pharmacokinetics trial of a formulation of XP19986 previously identified as a once-daily sustained-release tablet formulation, 47 healthy adult volunteers in four separate cohorts were administered either XP19986 or placebo. Following an up-titration period, the first cohort received placebo or 30 mg once daily of XP19986 for seven days, followed by 30 mg twice daily for seven days and ending with a down-titration period. Subsequent cohorts received placebo or 60 mg and 90 mg once daily and twice daily following a similar protocol. The final group of subjects received placebo or 120 mg only once daily. |
14
Table of Contents
| Subjects were monitored for adverse events, and blood and urine were sampled to determine pharmacokinetic profiles and bioavailability. The preliminary results of this trial demonstrated that repeated once daily dosing of XP19986 resulted in sustained levels of R-baclofen in blood over24-hours, which reachedsteady-state within three days. Repeated twice-daily dosing reduced the steady-statepeak-to-trough ratio ofR-baclofen by approximately 50% compared to once-daily dosing. Exposure to R-baclofen and XP19986 increased linearly with dose. All reported adverse effects were consistent with those previously reported for racemic baclofen. In the 120 mg cohort, one subject experienced episodes of slurred speech and tremor, which are reported effects of baclofen. This subject received medical treatment, discontinued dosing and was reported as a serious adverse event. |
The results of these Phase 1 clinical trials indicated that XP19986 was well absorbed and rapidly converted to the R isomer of baclofen. Exposure to the intact Transported Prodrug was low and transient. Comparison of these data with historical pharmacokinetic data for racemic baclofen suggests that XP19986 taken once a day or twice a day should be associated with a decreasedpeak-to-trough ratio of R-baclofen blood levels over 24 hours compared to racemic baclofen dosed three or four times a day.
Initial Target Indications
Gastroesophageal Reflux Disease
Background on GERD. GERD is a digestive system disorder caused primarily by transient relaxations of the lower esophageal sphincter, which is a combination of muscles that controls the junction between the esophagus and the stomach. GERD is characterized by the frequent, undesirable passage of stomach contents into the esophagus that results in discomfort and potential damage to the lining of the esophagus.
Potential Market. Approximately $10.0 billion is spent worldwide each year on GERD and heartburn medications, and approximately 6% of the global population experiences GERD symptoms daily.
Current Treatments. Conventional treatment for GERD encompasses medications that suppress stomach acid, including proton pump inhibitors, or PPIs, such as Nexium, Prilosec and Prevacid, H2 receptor antagonists such as Tagamet, Pepcid and Zantac, as well asover-the-counter antacids. However, these treatments are not effective in all patients, and there is a subset of patients who suffer from reflux of stomach contents that are not acidic, such as bile, who do not respond to these acid-suppression treatments.
Baclofen has recently been the subject of clinical trials indicating that it may also be effective in treating GERD. Unlike acid suppressing agents, baclofen exerts its effects on the function of the lower esophageal sphincter that controls passage of material between the esophagus and the stomach. Baclofen reduces the frequency of transient lower esophageal sphincter relaxations and, therefore, passage of gastric contents into the esophagus. Such a mechanism potentially may be effective alone or in combination with acid suppressants to increase the effectiveness of existing therapies. One study published in 2003 indicated that baclofen was effective when compared to placebo in reducing the number of reflux episodes and the percentage of time that the esophagus was acidic. Another study published in 2003 indicated that baclofen, when combined with a proton pump inhibitor, was more effective in reducing the number of reflux episodes as compared to the proton pump inhibitor alone. In these studies, baclofen was taken three or four times a day.
While these studies suggest a potential role for baclofen in the treatment of GERD, it is currently not approved for this indication, and we believe that it is unlikely that an approval of baclofen for this indication will be pursued because of the requirement for frequent dosing. We believe that providing a steady exposure of the R isomer of baclofen to patients with a once- or twice-daily dosage of XP19986 may result in reduced side effects compared to racemic baclofen and may demonstrate improved efficacy in the treatment of GERD.
Phase 2a Clinical Trial Results. XP19986 has generated positive data in a Phase 2a clinical trial that evaluated the reduction in the number of reflux episodes in patients with GERD. The single-dose, randomized, double-blind, placebo-controlled, crossover clinical trial enrolled 50 patients at three sites in the United States. Enrolled patients had a history of GERD symptoms at least three times per week and met a screening criterion of 20 or more reflux events in the two hours following a reflux-provoking meal. Reflux was monitored using apH/impedance probe placed in the esophagus. The pH/impedance probe allows the monitoring of both acid
15
Table of Contents
and non-acid reflux episodes. Each patient who met the entry criteria received single doses of XP19986 or placebo in separate test periods with four to seven days between testing periods. On the testing days, dosing occurred one hour after probe placement. Reflux-provoking meals were consumed at two hours and six hours after dosing, and patients were required to lie on their right side for two hours after each meal to further provoke lower esophageal sphincter relaxations. Reflux was monitored continually for 12 hours. Patients also recorded when they experienced heartburn or regurgitation symptoms. In addition, blood samples were taken at regular time intervals for the purpose of pharmacokinetic assessment. Separate cohorts of patients were administered 10, 20, 40 or 60 mg single doses of XP19986, which was formulated in a prototype controlled-release capsule that had been tested previously in healthy subjects.
The pre-specified primary endpoint for the clinical trial was the total number of reflux episodes over the12-hour monitoring period following the dose of XP19986 or placebo. Acid and non-acid reflux were analyzed as secondary endpoints. Reflux episodes by hour and the number of heartburn and regurgitation events were also analyzed. The median number of total reflux episodes over 12 hours after placebo treatment for the combined dose groups was 50.5 (N=44). The median change in total reflux episodes after XP19986 treatment compared to placebo treatment was −9.5 (p=0.005).
XP19986 treatment, compared to placebo, was also associated with a statistically significant reduction in the number of acid reflux episodes during the12-hour monitoring period. The median number of acid reflux episodes during placebo treatment for the combined dose groups was 39.0, with a median reduction of −9.5 (p=0.0027) following XP19986 treatment. Further evaluation of individual dose groups showed that XP19986 dosing was associated with statistically significant reductions in acid reflux episodes in both the 40 mg (p=0.0498) and 60 mg (p=0.0039) dose groups, with 18 of 20 patients in these two dose groups having fewer acid reflux episodes in the 12 hours after XP19986 treatment compared to placebo treatment. In addition, analysis of the combined doses for reflux occurring during each hour interval after dosing indicated that the number of reflux episodes increased after each meal, as expected. XP19986 treatment resulted in a reduction, compared to placebo, of reflux episodes at all periods beyond the third hour, with reductions reaching statistical significance in the fourth, eighth, ninth and tenth hours.
Single-dose treatment with XP19986 resulted in a statistically significant reduction, compared with placebo, in the number of heartburn events that were associated with a reflux episode over the12-hour monitoring period (p=0.0294 for the combined dose groups). XP19986 was well tolerated at all dose levels with few reported adverse events. Pharmacokinetic results indicated that exposure to R-baclofen was proportional to dose with an extended length of exposure, similar to that observed previously in Phase 1 clinical trials in healthy subjects.
Clinical Development of XP19986 in GERD. We have initiated a randomized, parallel-group, double-blind, placebo-controlled Phase 2 clinical trial of XP19986 that is designed to evaluate the efficacy, safety and tolerability of a sustained-release formulation of XP19986 in patients with symptomatic GERD. The clinical trial is being conducted in approximately 150 patients at multiple study centers in the United States. Eligible subjects must be diagnosed by a gastroenterologist as suffering from GERD and have symptoms (heartburnand/or regurgitation) at least three days a week and have either no history of taking PPIs or a history of at least a partial symptom response to PPI therapy. Enrolled subjects must discontinue any prior therapy for GERD other than rescue antacids during a two-week washout period. During the second week of the washout period, baseline data regarding frequency and severity of GERD symptoms are assessed. Subjects are then randomized to one of five treatment arms: placebo; three dose levels of XP19986 (20 mg, 40 mg or 60 mg) administered once a day in the morning; or a fifth arm of XP19986 (30 mg) administered twice daily. The treatment period is four weeks. The primary endpoint of the GERD Phase 2 clinical trial is the difference in the total number of episodes of heartburn experienced by each subject over the entire treatment period for the combined XP19986 dose groups versus the placebo group.
Spasticity
Background on Spasticity. Spasticity is a widespread and debilitating condition that is associated with some common neurological disorders, such as multiple sclerosis, stroke and cerebral palsy as well as spinal cord injury. Spasticity is a condition in which certain muscles are continuously contracted, causing stiffness or tightness of muscles that interfere with movement or speech.
16
Table of Contents
Potential Market. Reports indicate that the prevalence of spasticity due to multiple sclerosis, stroke and cerebral palsy in 2002 was approximately 5.2 million patients in the United States and six other major pharmaceutical markets, collectively. According to the IMS National Prescription Audit Report, for the 12 months ended December 31, 2007, there were approximately 3.7 million prescriptions written for baclofen in the United States. According to data on baclofen prescriptions, multiple sclerosis, spinal disease/injury, pain conditions and spasm conditions accounted for 80% of baclofen use. Besides baclofen, treatments for spasticity include diazepam, tizanidine and dantrolene sodium. Although these medications may provide symptom relief in some people, they are often only partially effective and generally require dosing three or more times a day. In addition, these medications are often associated with unwanted side effects such as sedation and weakness, as well as issues with bladder, bowel and sexual function. We believe that a Transported Prodrug of R-baclofen that can be taken twice each day to provide a steady exposure of R-baclofen to patients may more adequately address the needs of spasticity patients than current therapies, including racemic baclofen.
Clinical Development of XP19986 in Spasticity. We have initiated a multiple-dose, randomized, placebo-controlled, crossover Phase 2 clinical trial of XP19986 to evaluate the efficacy, safety and tolerability of atwice-a-day sustained-release formulation of XP19986 in approximately 36 patients with spasticity due to spinal cord injury. The clinical trial is being conducted at multiple study centers in the United States. Three doses of XP19986 are being assessed in a randomized crossover comparison versus placebo. Twelve subjects will be enrolled in each dose level. Eligible subjects undergo a washout and baseline period, followed by XP19986 (10 mg, 20 mg or 30 mg) or placebo, administered twice a day in the first treatment segment. After a washout period, each subject receives the other treatment in the second treatment segment. The primary outcome measure in this study is the Ashworth Scale assessment of muscle tone.
Development, Commercialization and Partnering Strategy
Due to the likely need for a primary care physician sales force to address the GERD market, we may seek a development and commercialization partner for the development and commercialization of XP19986 for the potential treatment of GERD. Since the spasticity market could be served through a smaller, focused sales force, we may seek to retain promotional rights to XP19986 in the United States for spasticity indications.
XP21279 — A Transported Prodrug of L-Dopa
We are developing our product candidate, XP21279, a Transported Prodrug of L-Dopa, for the treatment of Parkinson’s disease. We have filed patent applications directed to the XP21279 composition of matter, methods of synthesis and use in the United States and other jurisdictions.
Parent Drug Background
Patients with Parkinson’s disease have a deficiency of the neurotransmitter dopamine resulting from neuronal degeneration within certain nerve cells in an area of the brain collectively known as the substantia nigra. L-Dopa is an immediate precursor of dopamine that, unlike dopamine, readily crosses the blood brain barrier. When administered in conjunction with carbidopa (and, in some cases, with benzerazide or carbidopa and entacapone), L-Dopa is protected from rapid degradation by peripheral enzymes, or enzymes that are outside of the brain, and able to convert to dopamine at its desired site of action in the brain.
L-Dopa is widely viewed as one of the most effective treatments of Parkinson’s disease, and virtually all patients with Parkinson’s disease ultimately require it. However, L-Dopa has many undesirable pharmacokinetic characteristics, including its rapid breakdown by gastric and other peripheral enzymes, a short duration in blood after oral dosing that leads to the fluctuation of drug plasma concentrations upon frequent dosing and a narrow absorption window within the GI tract. The poor colonic absorption of L-Dopa has precluded the development of a satisfactory sustained-release formulation of L-Dopa that would prolong absorption beyond the small intestine.
Our Transported Prodrug
We believe that XP21279 has the potential to improve upon the deficiencies of L-Dopa. XP21279 is designed to engage natural nutrient transport mechanisms located throughout the length of the GI tract and then be rapidly
17
Table of Contents
converted to L-Dopa by the body’s naturally occurring endogenous enzymes. In addition to L-Dopa, the metabolic breakdown products of XP21279 are substances with favorable safety characteristics. Because XP21279 is designed to be well absorbed from the lower GI tract, we believe that it can be formulated for sustained release, thus reducing fluctuations of L-Dopa levels in the bloodstream. From December 2002 to December 2004, we were engaged in a collaboration with the ALZA division of Johnson & Johnson to jointly develop Transported Prodrugs of L-Dopa. In March 2005, ALZA relinquished all rights to such Transported Prodrugs, subject to a royalty upon sales of certain product candidates if they are ultimately commercialized.
We are conducting a Phase 1 clinical trial of XP21279 that includes a total of 12 healthy volunteers. We expect to announce the results of this clinical trial in the first quarter of this year.
Initial Target Indication
Parkinson’s Disease
Background on Parkinson’s Disease. Parkinson’s disease is a motor system disorder that results from the loss of dopamine-producing nerve cells in the brain. Dopamine is a chemical that is naturally produced by the body. It is responsible for smooth, coordinated function of the body’s muscles and movement. When approximately 80% of dopamine-producing cells are damaged, the symptoms of Parkinson’s disease appear. The primary symptoms of Parkinson’s disease are tremor or shaking, slowness of movement, rigidity or stiffness and difficulty with balance.
Potential Market. According to Datamonitor, Parkinson’s disease is primarily a disease of elderly individuals with a peak age at onset of 55 to 66 years. Approximately 1% of the U.S. population over 65 years old has been diagnosed with Parkinson’s disease. The Parkinson’s Disease Foundation estimates that there are about 60,000 new cases of Parkinson’s disease diagnosed in the United States each year. According to the IMS National Prescription Audit Report and the IMS National Disease and Therapeutic Index Report, there were approximately 6.5 million prescriptions written in the United States in 2005 for treating the symptoms of Parkinson’s disease.
Current Treatments. At present, there is no cure for Parkinson’s disease, but a variety of medications provide relief from the symptoms. L-Dopa acts to replenish dopamine in the brain. It is usually administered with benzerazide or carbidopa, or a combination of carbidopa and entacapone, which delays the premature conversion of L-Dopa to dopamine in peripheral tissues. According to the National Institute of Neurological Disorders and Stroke, treatment with L-Dopa helps patients in at least three-quarters of Parkinson’s disease cases.
Another class of drugs, called dopamine agonists, is also commonly used to treat Parkinson’s disease. Dopamine agonists, which include bromocriptine, pergolide, pramipexole and ropinirole, mimic the role of dopamine in the brain, which causes neurons to react as they would to dopamine. In spite of their wide use, both L-Dopa and dopamine agonists remain suboptimal in treating the symptoms of Parkinson’s disease. L-Dopa therapy has been associated with “wearing-off,” a condition where treatment effects diminish over time as the disease progresses, and “on-off” dyskinesias, or impairment of movement, due to changes in L-Dopa plasma concentrations. Dopamine agonists are generally considered the next most powerful drug class in treating the symptoms of Parkinson’s disease, but are more likely to cause hallucinations, confusion and psychosis, especially in the elderly.
Development, Commercialization and Partnering Strategy
We plan to continue development of XP21279 and potentially retain rights to this product candidate in the United States and to seek a partner for the development and commercialization of XP21279 as a treatment for Parkinson’s disease outside the United States.
XP20925 — A Transported Prodrug of Propofol
Our fourth product candidate is XP20925, a Transported Prodrug of propofol, for the treatment of migraine. We have filed patent applications directed to the XP20925 composition of matter, methods of synthesis and use in the United States and other jurisdictions.
18
Table of Contents
Parent Drug Background
Propofol is a rapid-onset, short-acting intravenous anesthetic that is widely used in hospitals and outpatient settings to induce and maintain anesthesia during surgery or to sedate patients undergoing diagnostic or medical procedures. Diprivan, the brand name of propofol, has been administered to more than 330 million people worldwide since its launch in 1986. Propofol has very poor oral absorption due primarily to extensive metabolism in the GI tract.
A number of clinical investigators have demonstrated that intravenously infused, non-sedative doses of propofol are effective in treating disorders such as migraine. While there are approved drugs for this disorder, these approved drugs do not work optimally in all patients. We believe that propofol’s poor oral absorption, which necessitates intravenous administration, has precluded the development of propofol for this indication.
Our Transported Prodrug
XP20925 was designed to target a high-capacity intestinal transporter mechanism in order to overcome the rapid intestinal metabolism of propofol and enable the oral delivery of the active ingredient. We have conducted animal studies in which the bioavailability was increased from less than 2%, when dosed orally as propofol, to greater than 50% when dosed orally as XP20925. We have conducted various preclinical pharmacokinetic and safety studies in animals.
Planned Clinical Development
We have initiated preclinical development activities for this compound.
Initial Target Indications
Migraine. Migraine is a neurological disorder characterized by recurrent headache attacks that are usually accompanied by various combinations of symptoms, including nausea and vomiting, as well as distorted vision and sensitivity to light and sound. Migraine is a common neurological disorder in the developed world. According to the American Migraine Prevalence and Prevention Study, migraine affects approximately 30 million individuals in the United States. A Datamonitor Commercial Insight: Migraine Report, published in 2007, indicates that the migraine market in the U.S. is approximately $3.0 billion. There are a variety of drugs used in the treatment of migraine. However, a class of drugs known as triptans represents a significant proportion of the overall market. While the treatment of migraine was significantly improved with the introduction of the triptans, there continues to be an unmet need for patients who suffer from migraines that do not respond adequately to current treatments. Up to 40% of patients who suffer from migraines do not respond to oral triptans. In a study published in 2000, a low-dose infusion of propofol was shown to be effective in treating patients with migraine that was resistant to standard therapy, including triptans. We believe that an oral Transported Prodrug of propofol that is able to deliver non-sedating levels of propofol may provide a new method for the treatment of migraine.
XP21510 — A Transported Prodrug of Tranexamic Acid
Our fifth product candidate is XP21510, a Transported Prodrug of tranexamic acid, for the treatment of menorrhagia, or heavy menstrual bleeding. We have an allowed patent directed to the XP21510 composition of matter, and patent applications directed to the methods of synthesis and use in the United States and other jurisdictions.
Parent Drug Background
Tranexamic acid is a man-made derivative of the naturally occurring amino acid lysine and works to inhibit, on a molecular basis, the break down of blood clots. It is approved in many countries in Europe and Asia for the treatment of women with menorrhagia.
19
Table of Contents
Our Transported Prodrug
We believe that XP21510 has the potential to improve upon the deficiencies of tranexamic acid. XP21510 is designed to engage natural nutrient transport mechanisms located throughout the length of the GI tract and then be rapidly converted to tranexamic acid by the body’s endogenous enzymes. In addition to tranexamic acid, the metabolic breakdown products of XP21510 are substances with favorable safety characteristics.
Planned Clinical Development
In October 2007, we announced an exclusive license agreement for the development and commercialization in the United States by Xanodyne of XP21510 for the potential treatment of women diagnosed with menorrhagia. In exchange for these rights, we are entitled to receive non-refundable cash payments totaling $12.0 million, of which $6.0 million was paid to us upon execution of the agreement and the remaining $6.0 million is due on the12-month anniversary of the execution date. We are eligible to receive aggregate cash payments of up to $130.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to XP21510, as well as aggregate cash payments of up to $5.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to Xanodyne’s tranexamic acid product candidate, known as XP12B, that is in Phase 3 clinical development. In addition, we are entitled to receive tiered, double-digit royalty payments on potential future sales of XP21510, as well as escalating single-digit royalties on potential future sales of XP12B. Xanodyne may terminate the agreement at its discretion upon120-days’ prior written notice. In such event, all XP21510 rights would revert to us, and we would be entitled to specified transition assistance from Xanodyne. Xanodyne shall not issue any notice of termination before October 2008 unless Xanodyne first accelerates and pays to us the remaining $6.0 million initial license fee installment. Xanodyne is currently conducting preclinical development of XP21510.
Initial Target Indications
Menorrhagia. Menorrhagia is abnormally heavy and prolonged menstrual periods at regular intervals. While a normal menses cycle lasts 21 to 35 days with an average of five days of bleeding and total blood flow between 25 and 80 milliliters, women with menorrhagia can have seven or more days of bleeding and lose more than 80 milliliters of blood per menses. It is estimated that nine to 14 percent of healthy women suffer from menorrhagia. Because quantitative means of diagnosing menorrhagia are generally impractical, healthcare professionals often diagnose menorrhagia symptomatically by considering frequency of tampon or sanitary napkin change, spotting and staining events, presence of constant pain in the lower abdomen, interference with regular work and social routines and measurements of anemia. We believe that an oral Transported Prodrug of tranexamic acid may provide more optimal delivery of tranexamic acid and thereby improve the efficacy and safety profile of this product.
Future Applications for Our Transported Prodrugs
We believe that there are a number of other generic parent drugs that could be candidates for our Transported Prodrug technology. We will apply our proprietary technology to selected parent drugs that have low or regionally restricted absorption in the GI tract that results in suboptimal therapy, have a chemical structure that is amenable to prodrug manipulation and are economical to manufacture.
Additionally, we believe that our proprietary technology has broad applicability beyond improving absorption from the GI tract, such as improving the penetration of drugs into the CNS. We also believe that there is a significant opportunity to use our proprietary technology to improve drug candidates that otherwise would not be successfully developed due to poor oral absorption, distributionand/or metabolism.
Blood Brain Barrier
We have efforts underway to further extend our proprietary technology to transporters found in the blood brain barrier with a goal of improving CNS penetration. The blood brain barrier is an important obstacle to the effectiveness of compounds acting on CNS targets. The highly restrictive endothelium of the brain capillary bed and the protective epithelial layer of a part of the brain known as the choroid plexus comprise a formidable barrier of cells through which drugs must pass from the blood to enter the brain. However, many natural compounds needed to
20
Table of Contents
feed the high metabolic activity of the brain are selectively absorbed into the CNS, particularly through the extensive capillary beds in the brain. In some cases, large amounts of these compounds are actively pumped from the blood to the brain by transporter proteins. From November 2003 to November 2005, we were engaged in a collaboration with Pfizer to jointly develop transporter technology to enhance the delivery of drugs to the brain. The program was exclusive during the term of the collaboration and provided Pfizer with non-exclusive rights to resulting technologies.
Third-Party Compounds
We believe that our proprietary technology can be utilized to rehabilitate those product candidates of third parties that initially demonstrated potential therapeutic benefits but whose limitations in absorption, distribution and pharmacokinetics have prevented successful drug development or commercialization. We will select other drug molecules for this approach based on our ability to license from third parties these product candidates, the medical need for an improved version of the third party’s drug, the size of the commercial opportunity and the amenability of our chemistry to the drug’s particular structure.
Our Strategic Alliances
Astellas Pharma Inc.
In December 2005, we entered into an agreement in which we licensed to Astellas exclusive rights to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan. Under the terms of this agreement, we received an initial license payment of $25.0 million and have subsequently received $15.0 million in milestone payments. In addition, we are eligible to receive clinical and regulatory milestone payments totaling up to an additional $45.0 million. We will provide Astellas both clinical and commercial supplies of XP13512 and will receive royalties on any sales of XP13512 in the Astellas territory at a royalty rate in the mid-teens on a percentage basis. Astellas may terminate the collaboration at its discretion. In such event, all XP13512 product rights would revert to us and we would be entitled to specified transition assistance from Astellas.
Glaxo Group Limited
In February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 worldwide, excluding the Astellas territory. GSK made an up-front payment to us of $75.0 million, has paid additional milestones of $32.0 million and may make additional payments of up to $243.0 million upon the achievement of clinical and regulatory milestones and up to $290.0 million upon the achievement of specified sales levels. In addition, GSK is responsible for all future development costs, with the exception of specified development costs that we will assume in connection with the development of XP13512 for RLS in the United States. Subject to further positive Phase 3 clinical data, GSK will be responsible for filing an NDA for RLS with the FDA. GSK would lead the development and registration of XP13512 for all other indications, including neuropathic pain and migraine prophylaxis. GSK is solely responsible for the manufacture of XP13512 to support its development and commercialization within the licensed territories. We would be entitled to receive royalties based upon a percentage of sales of XP13512 in the GSK territory for a specified period of time, unless we elect the option to co-promote XP13512 in the United States. In the event that we elect the co-promotion option for XP13512, we would share marketing and commercialization costs and would be entitled to a share of operating profits from sales of XP13512 in the United States for so long as XP13512 is sold, as well as receive payments on details we perform in the United States on Requip XL, GSK’s development-stage product candidate for Parkinson’s disease. Upon FDA approval of the NDA for XP13512, we would co-promote XP13512 in the United States to those same prescribers. GSK may terminate our collaboration agreement in its entirety for any reason.
Xanodyne Pharmaceuticals, Inc.
In October 2007, we announced an exclusive license agreement for the development and commercialization in the United States by Xanodyne of XP21510 for the potential treatment of women diagnosed with menorrhagia. In exchange for these rights, we are entitled to receive non-refundable cash payments totaling $12.0 million, of which $6.0 million was paid to us upon execution of the agreement and the remaining $6.0 million is due on the12-month
21
Table of Contents
anniversary of the execution date. We are eligible to receive aggregate cash payments of up to $130.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to XP21510, as well as aggregate cash payments of up to $5.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to Xanodyne’s tranexamic acid product candidate, known as XP12B, that is in Phase 3 clinical development. In addition, we are entitled to receive tiered, double-digit royalty payments on potential future sales of XP21510, as well as escalating single-digit royalties on potential future sales of XP12B. Xanodyne may terminate the agreement at its discretion upon120-days’ prior written notice. In such event, all XP21510 rights would revert to us and we would be entitled to specified transition assistance from Xanodyne. Xanodyne shall not issue any notice of termination before October 2008 unless Xanodyne first accelerates and pays to us the remaining $6.0 million initial license fee installment.
Patents and Proprietary Rights
We will be able to protect our technology from unauthorized use by third parties only to the extent that our technology is covered by valid and enforceable patents or effectively maintained as trade secrets and able to be utilized without infringing the proprietary rights of others. Our success in the future will depend in part on obtaining patent protection for our technologies and product candidates. Accordingly, patents and other proprietary rights are essential elements of our business. Our policy is to actively seek in the United States and selected foreign countries patent protection for novel technologies and compositions of matter that are commercially important to the development of our business.
Issued U.S. and foreign patents generally expire 20 years after filing. As of February 1, 2008, we held 30 issued U.S. patents, includingcomposition-of-matter patents on XP13512 and XP19986. As of that date, we had 94 pending patent applications in the United States, includingcomposition-of-matter patent applications on XP19986, XP21279 and XP20925. Of the 30 U.S. patents that we hold, 22 patents are compound- and composition-related, having expiration dates from 2021 to 2026; three patents are synthesis-method related, having expiration dates from 2022 to 2025; one patent is proteomics methodology-related, having an expiration date in 2022; and four patents are screening methodology-related, having expiration dates from 2022 to 2025. We hold 31 issued foreign patents. We have 20 pending Patent Cooperation Treaty, known as PCT, regional applications that permit us to pursue patents outside of the United States, 27 pending European regional patent applications that permit us to pursue patents in various European countries and 204 foreign national patent applications. The claims in these various patents and patent applications are directed to compositions of matter, including claims covering product candidates, lead compounds and key intermediates, pharmaceutical compositions, methods of use and processes for making our compounds, along with methods of design, synthesis, selection and use of Transported Prodrugs in general and to our research and development programs in particular.
The patent rights relating to XP13512, its synthesis, formulations and methods of use are owned by us and consist of six issued U.S. patents that expire from 2022 to 2025 and 19 pending U.S. patent applications. We also own four pending counterpart PCT regional patent applications, 12 issued foreign patents and 135 foreign national applications in a number of jurisdictions, including Asia and Europe. Rights under these patents and applications have been exclusively licensed to GSK and Astellas within their respective licensed territories. The patent rights relating to XP19986 and its synthesis, formulations and methods of use are owned by us and consist of four issued U.S. patents that expire from 2023 to 2025, four pending U.S. patent applications, one issued foreign patent and 35 foreign national applications. The patent rights relating to XP21279 and its synthesis, formulations and methods of use are owned by us and consist of four pending U.S. patent applications and two counterpart PCT applications designating an extensive number of jurisdictions, including Asia, Europe and 16 foreign national applications. The patent rights relating to XP20925 and its synthesis and use are owned by us and consist of one issued U.S. patent expiring in 2025, three pending U.S. patent applications, one counterpart PCT application designating an extensive number of jurisdictions, including Asia and Europe, two issued foreign patents and 13 foreign national applications. The patent rights relating to XP21510, its synthesis and methods of use are owned by us and consist of two pending U.S. patent applications and 14 pending foreign patent applications, including a European patent application designating a number of European countries.
Thecomposition-of-matter patent on gabapentin, the parent drug of XP13512, expired in 2000, but Pfizer sold gabapentin exclusively based on a formulation patent until September 2004. This formulation patent is the subject
22
Table of Contents
of ongoing litigation between Pfizer and several generic manufacturers, including Alpharma, Inc. and Teva Pharmaceutical Industries, Ltd. Pfizer currently markets generic gabapentin through its Greenstone Ltd. subsidiary. Alpharma and Teva, along with many others, currently market gabapentin as a generic drug. In July 2006, the United States District Court for the District of New Jersey ruled in favor of the generic gabapentin makers, including Teva, and Pfizer appealed that ruling. In September 2007, the Court of Appeals for the Federal Circuit overturned the July 2006 District Court ruling that was in favor of the generic gabapentin makers, including Teva, and the suit has been remanded to the District Court to continue with the trial. We are not a party to this litigation, and we believe that our manufacturing process for XP13512 does not infringe the patent that is the subject of this litigation. However, in case of an adverse event in this litigation, such as the enjoining or limiting of Teva’s ability to sell generic gabapentin to us, we would not be able to manufacture XP13512 until a qualified alternative supplier is identified. This could delay the development of, and impair our or our collaborative partners’ ability to commercialize, this product candidate.
We also rely on trade secret protection and confidentiality agreements to protect our proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery process that involve proprietary know-how and technology that is not covered by patent applications, especially where patent protection is not believed to be appropriate or obtainable. We require all of our employees, consultants and advisors to enter into confidentiality agreements. Where it is necessary to share our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties.
Manufacturing
We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of any of our product candidates. To date, we have relied on a small number of third-party manufacturers to produce our compounds. Under the terms of our collaboration with GSK, GSK is solely responsible for the manufacture of XP13512 to support its development and commercialization within its licensed territory. However, we will continue to be responsible for providing Astellas both clinical and commercial supplies of XP13512. Thus, we expect to continue to rely on a small number of third-party manufacturers to meet our clinical and commercial supply obligations to Astellas for XP13512 and to meet our preclinical and clinical requirements of our other product candidates and for any related commercial needs. We do not have long-term agreements with any of these other third parties.
We have purchased substantial amounts of gabapentin, which is the active agent used to make XP13512, from Teva pursuant to purchase orders issued from time to time. Currently, we believe that there are at least five alternative manufacturers that could supply our requirements of gabapentin in the event that Teva determines to not sell gabapentin to us at a price that is commercially attractive. In addition, we believe that there will be an increasing number of qualified alternative suppliers of gabapentin in the future. We are currently in the process of qualifying alternative sources of gabapentin for use in the manufacture of XP13512.
In support of our supply obligations under the Astellas collaboration, we purchase XP13512 from Lonza Ltd. in active pharmaceutical ingredient form, known as API, under a manufacturing services and product supply agreement. The parties have agreed to specific transfer prices for this API under a quotation that forms a part of the agreement. We believe that the quantities of API that we have on hand, will be sufficient to complete our RLS clinical trials required for regulatory approval. Our current agreement with Lonza does not provide for the entire supply of API necessary to support ongoing development and full-scale commercialization in the Astellas territory. However, the manufacturing services and product supply agreement obligates the parties to negotiate in good faith on the terms and conditions for Lonza to supply some or all of our total requirements for the commercial supply of API for XP13512. The API is manufactured using a four-step synthetic process that uses commercially available starting materials for each step. There are no complicated chemistries or unusual equipment required in the manufacturing process. We may terminate this agreement upon 30 days’ notice. Either party may terminate this agreement for cause upon notice and a failure to cure by the other party. Unless earlier terminated for the reasons stated above, this agreement terminates in July 2008, unless extended by the mutual agreement of the parties. In the event that Lonza terminates the agreement following a breach by us, we would not be able to manufacture the API until a qualified alternative supplier is identified.
23
Table of Contents
We rely on Patheon as a single source supplier for XP13512 formulated in sustained-release tablets for clinical trials at specified transfer prices under a quotation agreed upon by the parties as a part of a master services agreement. We may terminate this agreement at any time. Patheon may terminate this agreement if we do not cure a breach within 30 days of receiving notice from Patheon. In the event that Patheon terminates the agreement under the specified circumstances, we would not be able to manufacture XP13512 sustained-release tablets until a qualified alternative supplier is selected.
If either of these agreements is terminated by us, we are contractually obligated to reimburse Lonza or Patheon for costs incurred up to the termination date, as well as any specific costs incurred by either party in connection with the termination.
We currently rely on Heumann Pharma GmbH as our single source supplier of R-baclofen, the active agent used to make XP19986, under purchase orders issued from time to time. We are aware of two alternative suppliers of R-baclofen, and we believe at least one alternative manufacturer could potentially supply R-baclofen in the event that Heumann determines to not sell R-baclofen to us at a price that is commercially attractive. We are currently in the process of qualifying alternative sources of R-baclofen for use in the manufacture of XP19986.
We currently rely on Lonza as the single source supplier of our current worldwide requirements of XP19986 in API form under a manufacturing services and product supply agreement. Our current agreement with Lonza does not provide for the entire supply of the API necessary for additional Phase 2 and Phase 3 clinical trials nor for full-scale commercialization. In the event that the parties cannot agree to the terms and conditions for Lonza to provide some or all of our API clinical and commercial supply needs, we would not be able to manufacture API until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, this product candidate. The API is currently manufactured using a four-step synthetic process that uses commercially available starting materials for each step. There are no complicated chemistries or unusual equipment required in the manufacturing process.
Prior to December 2005, we obtained from Cardinal Health PTS, LLC a prototype controlled-release formulation of XP19986 for clinical trials in the form of capsules containing controlled-release beads. In 2006, we began working with Xcelience, LLC to produce new sustained-release tablet formulations that provide the potential forscale-up to commercial manufacturing-scale quantities.
Xcelience provides our requirements of XP19986 for clinical trials in the form of sustained-release tablets at specified transfer prices under a quotation agreed upon by the parties as a part of a master services agreement. We rely on Xcelience as a single source supplier for tablets of XP19986. In the event that Xcelience terminates the agreement under specified circumstances, we would not be able to manufacture XP19986 until a qualified alternative supplier is identified.
We currently rely on Ajinomoto Company as our single source supplier of L-Dopa, the active pharmaceutical ingredient used to make XP21279, under purchase orders issued from time to time. We are aware of several alternative suppliers of L-Dopa, and we believe at least one alternative manufacturer could potentially supplyL-Dopa in the event that Ajinomoto determines to not sell L-Dopa to us at a price that is commercially attractive.
We have purchased from Raylo Chemicals, Inc., a subsidiary of Gilead Sciences, Inc., all of our current worldwide requirements of XP21279 in API form through our initial Phase 1 clinical trial under a manufacturing services and product supply agreement. We are currently in the process of identifying a qualified alternative supplier for manufacture of XP21279 in API form. The API is currently manufactured by a four-step synthetic process that uses commercially available starting materials. There are no complicated chemistries or unusual equipment required in the manufacturing process.
UPM Pharmaceuticals, Inc. provides our requirements of XP21279 for clinical trials in the form of sustained-release tablets at specified transfer prices under a quotation agreed upon by the parties as a part of a master services agreement. We rely on UPM as a single source supplier for tablets of XP21279. In the event that UPM terminates the agreement under specified circumstances, we would not be able to manufacture XP21279 until a qualified alternative supplier is identified.
24
Table of Contents
Our contract manufacturers may own process technology related to the manufacture of our compounds. This would increase our reliance on this manufacturer. Each of Lonza, Patheon, Raylo, UPM Pharmaceuticals and Xcelience has informed us that they are not using any proprietary technology in their work for us on XP13512, XP19986 or XP21279. Moreover, we have been successful in negotiating agreements with our contract manufacturers that include licenses, with the right to grant sublicenses, to any technology incorporated into the manufacture of our compounds or that is invented by employees of the contract manufacturers during the course of work conducted on our product candidates.
Research and Development
Since inception, we have devoted a significant amount of resources to develop our product candidates. For the years ended December 31, 2007, 2006 and 2005, we recorded $74.4 million, $65.4 million and $38.7 million, respectively, in research and development expenses.
Marketing and Sales
In order for us to commercialize any of our product candidates, we must either make arrangements with third parties to perform sales, marketing or distribution services for us or acquire or develop internal sales, marketing and distribution capabilities, or both. In December 2005, we entered into a collaboration with Astellas to develop and commercialize XP13512 in Japan and five other Asian markets. Under the terms of our agreement, we will receive royalties on any sales of XP13512 in the Astellas territory. In February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 worldwide, excluding the Astellas territory. Under the terms of the agreement, we have the option, pending regulatory approval, to co-promote XP13512 in the United States. In the event we elect the co-promotion option for XP13512, we will share marketing and commercialization costs and will be entitled to a share of operating profits from sales of XP13512 in the United States. We will also have the right, for a period of time, to detail Requip XL, GSK’s development-stage product candidate for Parkinson’s disease in the United States. If we elect the co-promotion option under our GSK collaboration, we plan to establish a focused sales and marketing organization in North America to market and sell product candidates, for which marketing approval is ultimately received, to specialty physicians, including neurologists, psychiatrists and sleep specialists, for target indications in which specialists significantly influence the market and to selectively co-promote to primary care physicians.
We plan to establish additional development and commercialization partnerships with pharmaceutical and biotechnology companies to accelerate the completion of regulatory approval and product introduction and to maximize the breadth of the commercial opportunity of our other product candidates.
We also plan to license to third parties for development, marketing and sales other potential drug candidates that are discovered by XenoPort but do not fall within our primary therapeutic area of interest of CNS disorders. For example, in October 2007, we entered into an exclusive license agreement for the development and commercialization in the United States by Xanodyne of XP21510 for the potential treatment of women diagnosed with menorrhagia. We are entitled to receive tiered, double-digit royalty payments on potential future sales of XP21510, as well as escalating single-digit royalties on potential future sales of Xanodyne’s product candidate, XP12B.
Competition
The pharmaceutical and biotechnology industries are intensely competitive. Any product candidate developed by us would compete with existing drugs and therapies. There are many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations actively engaged in research and development of products targeting the same markets as our product candidates. Many of these organizations have substantially greater financial, technical, manufacturing and marketing resources than we have. Several of them have developed or are developing therapies that could be used for treatment of the same diseases that we are targeting. In addition, many of these competitors have significantly greater commercial infrastructures than we have. Our ability to compete successfully will depend largely on our ability to leverage our experience in drug discovery and development to:
| • | discover and develop products that are superior to other products in the market; |
25
Table of Contents
| • | attract and retain qualified scientific, product development and commercial personnel; | |
| • | obtain patentand/or other proprietary protection for our products and technologies; | |
| • | obtain required regulatory approvals; and | |
| • | successfully collaborate with pharmaceutical companies in the discovery, development and commercialization of new products. |
We expect to compete on, among other things, product efficacy and safety, time to market, price, extent of adverse side effects experienced and convenience of treatment procedures. In order to compete successfully, we will need to identify, secure the rights to and develop pharmaceutical products and exploit these products commercially before others are able to develop competitive products.
In addition, our ability to compete may be affected if insurers and other third-party payors seek to encourage the use of generic products, making branded products less attractive to buyers from a cost perspective.
We believe that our product development programs will be subject to significant competition from companies utilizing alternative technologies. In addition, as the principles of active transport become more widely known and appreciated based on patent and scientific publications and regulatory filings, we expect the field to become highly competitive. Pharmaceutical companies, biotechnology companies and academic and research institutions may succeed in developing products based upon the principles underlying our proprietary technologies earlier than us, obtaining approvals for such products from the FDA more rapidly than us or developing products that are safer, more effectiveand/or more cost effective than those under development or proposed to be developed by us.
Except for XP13512, our research and development efforts are at an early stage. Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerabilityand/or safety. To the extent that we are able to develop medicines, they are likely to compete with existing drugs that have long histories of effective and safe use and with new therapeutic agents. We expect that any medicines that we commercialize with our collaborative partners or on our own will compete with existing, market-leading medicines.
XP13512. We anticipate that, if approved, XP13512 would compete with generic gabapentin. We believe that it is unlikely that a healthcare provider would require the use of gabapentin in preference to XP13512 in an indication for which XP13512 is approved and gabapentin is not labeled. Other drugs targeting RLSand/or neuropathic pain will represent substantial competition. These include duloxetine (marketed by Lilly as Cymbalta), pramipexole (marketed by Boehringer Ingelheim as Mirapex), pregabalin (marketed by Pfizer as Lyrica) and ropinirole (marketed by GSK as Requip). In addition, transdermal patches containing the anesthetic known as lidocaine are sometimes used for the management of PHN. We anticipate that, if approved for migraine prophylaxis, XP13512 would compete with existing products on the market, including topiramate (marketed by Johnson & Johnson as Topamax) and divalproex sodium (marketed by Abbott Laboratories as Depakote).
Other products that may achieve FDA approval could pose additional competitive threats to XP13512. These products include: a controlled-release form of gabapentin (known as Gabapentin GR from Depomed, Inc.), which is currently being evaluated for hot flashes; and the rotigotine transdermal system (being developed by Schwarz Pharma AG, a member of the UCB group), which filed an NDA with the FDA in late 2007 for the treatment ofmoderate-to-severe RLS.
XP19986. We anticipate that, if approved, XP19986 would compete with generic baclofen and other drugs for the alleviation of symptoms of spasticity, as well as other drugs targeted at GERD. These include approved treatments for spasticity, such as diazepam, dantrolene sodium and tizanidine, and many therapies in development, such as tolperisone from Avigen, Inc. and Fampridine-SR from Acorda Therapeutics, Inc. These also include GERD treatments, such as esomeprazole and omeprazole (marketed by AstraZeneca as Nexium and Prilosec, respectively), lansoprazole (marketed by TAP Pharmaceutical Products Inc. as Prevacid) and pantoprazole sodium (marketed by Wyeth as Protonix). In addition, tenatoprazole (being developed by Abbott Laboratories), soraprazan (being developed by ALTANA Pharma AG), AFQ056 (being developed by Novartis), ADX10059 (being developed by Addex Pharmaceuticals) and AZ3355 (being developed by AstraZeneca) are among multiple product candidates in late-stage clinical trials and represent potential competition for XP19986.
26
Table of Contents
XP21279. We anticipate that, if approved, XP21279 would compete with generic L-Dopa/carbidopa drugs and other drugs for the treatment of Parkinson’s disease. These include a combination therapy of L-Dopa/carbidopa/entecapone (marketed in the United States by Novartis as Stalevo) and dopamine agonists (marketed by Boehringer-Ingelheim, GSK and UCB as Mirapex, Requip and Neupro, respectively).
Government Regulation
The testing, manufacturing, labeling, advertising, promotion, export and marketing of our product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The FDA, under the Federal Food, Drug and Cosmetic Act, or FFDCA, regulates pharmaceutical products in the United States. The steps required before a drug may be approved for marketing in the United States generally include:
| • | preclinical laboratory tests and animal tests; | |
| • | the submission to the FDA of an investigational new drug application, or IND, for human clinical testing, which must become effective before human clinical trials commence; | |
| • | adequate and well-controlled human clinical trials to establish the safety and efficacy of the product; | |
| • | the submission to the FDA of a new drug application, or NDA; | |
| • | FDA review and approval of the NDA; and | |
| • | satisfactory completion of an FDA inspection of the manufacturing facilities at which the product is made to assess compliance with current Good Manufacturing Practices, or cGMPs. |
The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain. The FDA may suspend clinical trials at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk.
Preclinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential safety and efficacy of the product candidate. The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of the IND, which must become effective before clinical trials may be commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the trials as outlined in the IND prior to that time. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can proceed.
Clinical trials involve the administration of the product candidates to healthy volunteers or patients under the supervision of a qualified principal investigator. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution.
Clinical trials typically are conducted in three sequential phases prior to approval, but the phases may overlap. These phases generally include the following:
Phase 1. Represents the initial introduction of the drug into human subjects, frequently healthy volunteers. In Phase 1, the drug is usually tested for safety, including adverse effects, dosage tolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.
Phase 2. Phase 2 clinical trials usually involve studies in a limited patient population to (1) evaluate the efficacy of the drug for specific indications, (2) determine dosage tolerance and optimal dosage and (3) identify possible adverse effects and safety risks. Although there are no statutory definitions for Phase 2a and Phase 2b, Phase 2a is commonly used to describe a Phase 2 clinical trial evaluating efficacy, adverse effects and safety risks, and Phase 2b is commonly used to describe a subsequent Phase 2 clinical trial that also evaluates dosage tolerance and optimal dosage.
27
Table of Contents
Phase 3. If a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 studies, the clinical trial program will be expanded to further demonstrate clinical efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical study sites.
Phase 4 clinical trials are conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. These clinical trials are often referred to as Phase 3/4 post-approval clinical trials. Failure to promptly conduct Phase 4 clinical trials could result in withdrawal of approval for products approved under accelerated approval regulations.
The results of preclinical studies and clinical trials, together with detailed information on the manufacture and composition of the product, are submitted to the FDA in the form of an NDA requesting approval to market the product. Generally, regulatory approval of a new drug by the FDA may follow one of three routes. The most traditional of these routes is the submission of a full NDA under Section 505(b)(1) of the FFDCA. A second route, which is possible where an applicant chooses to rely in part on data generated or approvals obtained previously by other parties, is to submit a more limited NDA described in Section 505(b)(2) of the FFDCA. The final route is the submission of an Abbreviated New Drug Application for products that are shown to be pharmaceutically and therapeutically equivalent to previously approved drug products as permitted under Section 505(j) of the FFDCA.
Both Section 505(b)(1) and Section 505(b)(2) applications are required by the FDA to contain full reports of investigations of safety and effectiveness. However, in contrast to a traditional NDA submitted pursuant to Section 505(b)(1) in which the applicant submits all of the data demonstrating safety and effectiveness, we believe an application submitted pursuant to Section 505(b)(2) can rely upon findings by the FDA that the parent drug is safe and effective in that indication. As a consequence, the preclinical and clinical development programs leading to the submission of an NDA under Section 505(b)(2) may be less expensive to carry out and can be concluded in a shorter period of time than programs required for a Section 505(b)(1) application. In its review of any NDA submissions, however, the FDA has broad discretion to require an applicant to generate additional data related to safety and efficacy, and it is impossible to predict the number or nature of the studies that may be required before the FDA will grant approval.
Subject to further positive Phase 3 clinical data, pursuant to the terms of our collaboration with GSK, GSK will be responsible for filing an NDA for XP13512 for RLS with the FDA, and GSK would lead the development and registration of XP13512 for all other indications, including neuropathic pain and migraine prophylaxis. In the NDA submissions for our other product candidates that are currently undergoing clinical trials, we intend to follow the development pathway permitted under the FFDCA that will maximize the commercial opportunities for these Transported Prodrugs. We are currently pursuing the traditional NDA route for our Transported Prodrugs under Section 505(b)(1) of the FFDCA. In the event that we decide to utilize Section 505(b)(2) of the FFDCA to pursue an approval of our Transported Prodrugs in indications for which the relevant parent drug has previously been approved, we will engage in discussions with the FDA to determine which, if any, portions of our development program can be modified.
Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facility complies with cGMPs. Once the NDA submission has been accepted for filing, the FDA typically takes one year to review the application and respond to the applicant. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may delay approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or informationand/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. FDA approval of any NDA submitted by us will be at a time the FDA chooses. Also, if regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies.
28
Table of Contents
If we or our collaborative partners obtain regulatory approval for a product, this clearance will be limited to those diseases and conditions for which the product is effective, as demonstrated through clinical trials. Even if this regulatory approval is obtained, a marketed product, its manufacturer and its manufacturing facilities are subject to continual review and periodic inspections by the FDA. Discovery of previously unknown problems with a medicine, manufacturer or facility may result in restrictions on the marketing or manufacturing of an approved product, including costly recalls or withdrawal of the product from the market. The FDA has broad post-market regulatory and enforcement powers, including the ability to suspend or delay issuance of approvals, seize or recall products, withdraw approvals, enjoin violations and institute criminal prosecution.
The Controlled Substances Act imposes various registration, record-keeping and reporting requirements, procurement and manufacturing quotas, labeling and packaging requirements, security controls and a restriction on prescription refills on certain pharmaceutical products. A principal factor in determining the particular requirements, if any, applicable to a product is its actual or potential abuse profile. The U.S. Drug Enforcement Agency, or DEA, regulates chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the lowest risk. Pregabalin is classified as a controlled substance (Schedule V), which could increase the possibility that XP13512 would be classified as a controlled substance since they are believed to act on the same therapeutic target. If any of our product candidates contains a scheduled substance, it would be subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures, and the DEA would regulate the amount of the scheduled substance that would be available for clinical trials and commercial distribution.
We and our collaborative partners also will be subject to a variety of foreign regulations governing clinical trials and the marketing of our products. Outside the United States, our ability to market a product depends upon receiving a marketing authorization from the appropriate regulatory authorities. The requirements governing the conduct of clinical trials, marketing authorization, pricing and reimbursement vary widely from country to country. In any country, however, we and our collaborative partners will only be permitted to commercialize our products if the appropriate regulatory authority is satisfied that we have presented adequate evidence of safety, quality and efficacy. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing of the product in those countries. The time needed to secure approval may be longer or shorter than that required for FDA approval. The regulatory approval and oversight process in other countries includes all of the risks associated with the FDA process described above.
Pharmaceutical Pricing and Reimbursement
Political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental change. Initiatives to reduce the federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability. Legislative debate is expected to continue in the future, and market forces are expected to drive reductions of healthcare costs. The adoption of any federal or state healthcare reform measures or future private sector reforms could further limit reimbursement for medical products.
In both domestic and foreign markets, sales of any products for which we or our collaborative partners receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare product candidates. We or our collaborative partners may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective.
29
Table of Contents
In December 2003, the Medicare Prescription Drug Improvement and Modernization Act of 2003, or the 2003 Medicare Act, was enacted. Under this legislation, Medicare beneficiaries are now eligible to obtain a Medicare-endorsed, drug-discount card from a choice of private sector providers. It remains difficult to predict the long-term impact of the 2003 Medicare Act on pharmaceutical companies. Usage of pharmaceuticals is likely to increase as the result of the expanded access to medicines afforded by the coverage under Medicare. Such expanded utilization, however, may be offset by the increased pricing pressure and competition due to the enhanced purchasing power of the private sector providers that negotiate on behalf of Medicare beneficiaries.
Facilities
We lease approximately 103,000 square feet of office and laboratory space in one building in Santa Clara, California, where we conduct our operations. The lease expires in September 2011, although we have the option to extend the lease for two additional terms of five years each. The 2007 annual rental amount payable under this lease was approximately $3.8 million, subject to periodic increases. Although our facilities are adequate for our existing needs, we will require additional space as our business expands in 2008.
Employees
As of December 31, 2007, we had 181 full-time employees, 138 of whom were engaged in research and product development activities. One hundred and six employees hold post-graduate degrees, including three with M.D. degrees and 46 with Ph.D. degrees. Our employees are not represented by a collective bargaining agreement. We believe our relations with our employees are good.
Executive Officers of the Registrant
The following sets forth certain information regarding our executive officers as of February 1, 2008:
Name | Age | Position | ||||
| Ronald W. Barrett, Ph.D. | 52 | Chief Executive Officer and Director | ||||
| William J. Rieflin | 47 | President | ||||
| Kenneth C. Cundy, Ph.D. | 48 | Senior Vice President of Preclinical Development | ||||
| Mark A. Gallop, Ph.D. | 45 | Senior Vice President of Research | ||||
| William G. Harris | 49 | Senior Vice President of Finance and Chief Financial Officer | ||||
| David R. Savello, Ph.D. | 62 | Senior Vice President of Development | ||||
Ronald W. Barrett is one of our founders and has served as our chief executive officer since September 2001. He served as our chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, a company employing combinatorial chemistry and high-throughput target screening for drug discovery, the most recent of which was senior vice president of research. Glaxo Wellcome plc, a pharmaceutical company, acquired Affymax Research Institute in 1995. Glaxo Wellcome subsequently merged with SmithKline Beecham plc, a pharmaceutical company, in 2000 to form GlaxoSmithKline plc, a pharmaceutical company. Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories, a healthcare company, from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.
William J. Rieflin has been our president since September 2004. From 1996 to 2004, he held various positions with Tularik Inc., a biotechnology company focused on the discovery and development of product candidates based on the regulation of gene expression, the most recent of which was executive vice president, administration, chief financial officer, general counsel and secretary. Amgen Inc., a biotechnology company, acquired Tularik in 2004. Mr. Rieflin received a B.S. from Cornell University, an M.B.A. from the University of Chicago Graduate School of Business and a J.D. from Stanford Law School.
Kenneth C. Cundy has been our senior vice president of preclinical development since January 2004. He was previously our vice president of biopharmaceutics from 2000 to 2004. From 1992 to 2000, he was senior director of biopharmaceutics at Gilead Sciences, Inc., a biopharmaceutical company. Prior to Gilead Sciences, Dr. Cundy was
30
Table of Contents
principal research investigator at Sterling Drug, a pharmaceutical division of Eastman Kodak Company, an imaging and photographic equipment company, from 1988 to 1992. He received a B.S. from the University of Manchester and a Ph.D. in pharmaceutical sciences from the University of Kentucky.
Mark A. Gallop is one of our founders and has been our senior vice president of research since January 2004. He was previously our vice president of chemistry since 1999. From 1990 to 1999, Dr. Gallop held several positions at Affymax Research Institute, the most recent of which was senior director of combinatorial chemistry. Dr. Gallop received a B.Sc. from the University of Auckland and a Ph.D. in inorganic chemistry from the University of Cambridge.
William G. Harris has been our senior vice president of finance and chief financial officer since November 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., a biotechnology company engaged in the development of novel therapies for the treatment of cancer and autoimmune diseases, the most recent of which was senior vice president and chief financial officer. Corixa Corp., a developer of immunotherapeutic products, acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, the most recent of which was director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.
David R. Savello has been our senior vice president of development since February 2007. He was previously responsible for our regulatory affairs, quality and project management from 2005 to 2007. From 1999 to 2005, Dr. Savello was executive vice president and chief scientific officer for the Pharmaceutical Technology and Services Sector of Cardinal Health, Inc., a pharmaceutical services company. Prior to joining Cardinal Health, from 1997 to 1999, he was senior vice president for drug development at Guilford Pharmaceuticals Inc., a biotechnology company. From 1985 to 1997, Dr. Savello held several positions at Glaxo and Glaxo Wellcome including both vice president of drug development and vice president of regulatory affairs and compliance. Prior to that, he held R&D management and executive management positions at Boehringer Ingelheim GmbH, a pharmaceutical company, and 3M Company, a pharmaceutical company. Dr. Savello received his B.S. degree from the Massachusetts College of Pharmacy and an M.S. and Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.
About XenoPort
We were incorporated in Delaware in May 1999. Our principal offices are located at 3410 Central Expressway, Santa Clara, California 95051, and our telephone number is(408) 616-7200. Our Web site address is www.XenoPort.com. Information found on, or accessible through, our Web site is not a part of, and is not incorporated into, this Annual Report onForm 10-K. XENOPORT, the XenoPort logo and Transported Prodrug are our trademarks. Service marks, trademarks and trade names appearing in this Annual Report onForm 10-K are the property of their respective owners. Unless the context requires otherwise, references in this Annual Report onForm 10-K to “the company,” “we,” “us” and “our” refer to XenoPort, Inc.
Available Information
We file electronically with the U.S. Securities and Exchange Commission our annual reports onForm 10-K, quarterly reports onForm 10-Q, current reports onForm 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934. We make available on our Web site at www.XenoPort.com, free of charge, copies of these reports as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Further, copies of these reports are located at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at1-800-SEC-0330. The SEC maintains a Web site that contains reports, proxy and information statements, and other information regarding our filings, at www.sec.gov.
| Item 1A. | Risk Factors. |
The following risks and uncertainties may have a material adverse effect on our business, financial condition or results of operations. Investors should carefully consider the risks described below before making an investment decision. The risks described below are not the only ones we face. Additional risks not presently known to us or that
31
Table of Contents
we currently believe are immaterial may also significantly impair our business operations. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and investors may lose all or part of their investment.
Risks Related to Our Business and Industry
We have incurred cumulative operating losses since inception. Although we may achieve quarterly and annual profitability from time to time, we expect to continue to incur losses for the foreseeable future and we may never sustain profitability.
We have a limited operating history and have incurred cumulative losses of $176.1 million since our inception in May 1999. Due to the recognition of revenues from up-front and milestone payments from our collaborations with Glaxo Group Limited, or GSK, Astellas Pharma Inc. and Xanodyne Pharmaceuticals, Inc., we were profitable in the three-month periods ended June 30, September 30 and December 31, 2007, and may have profitable quarters from time to time. However, while recognition of these revenues resulted in a profitable year for 2007, we continue to expect to incur losses for the next several years. We expect our research and development expenses to increase in the foreseeable future due to increasing headcount, investment in our preclinical development programs and XP19986 development costs, partially offset by decreasing expenses for our Phase 3 clinical program evaluating XP13512 for the treatment of restless legs syndrome, or RLS. Subject to regulatory approval of any of our product candidates, we expect to incur significant expenses associated with the establishment of a North American specialty sales force. Annual losses have had, and will continue to have, an adverse effect on our stockholders’ equity.
Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or sustain profitability. Currently, we have no products approved for commercial sale and, to date, we have not generated any product revenues. We have financed our operations primarily through the sale of equity securities, non-equity payments from collaborative partners, capital lease and equipment financings and government grants. We have devoted substantially all of our efforts to research and development, including clinical trials. If we or our collaborative partners are unable to develop and commercialize any of our product candidates, if development is delayed or if sales revenue from any product candidate that receives marketing approval is insufficient, we may never become profitable. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.
Our success depends substantially on our most advanced product candidates, which are still under development. If we or our collaborative partners are unable to bring any or all of these product candidates to market, or experience significant delays in doing so, our ability to generate product revenue and our likelihood of success will be harmed.
Our ability to generate product revenue in the future will depend heavily on the successful development and commercialization of our product candidates. Our most advanced product candidate is currently being evaluated in a Phase 3 clinical program in the United States, by Astellas in Phase 2 clinical trials in Japan and by GSK in a Phase 2 neuropathic pain program. Our other product candidates are either in Phase 1 or Phase 2 clinical development or in various stages of preclinical development. Any of our product candidates could be unsuccessful if it:
| • | does not demonstrate acceptable safety and efficacy in preclinical studies or clinical trials or otherwise does not meet applicable regulatory standards for approval; | |
| • | does not offer therapeutic or other improvements over existing or future drugs used to treat the same conditions; | |
| • | is not capable of being produced in commercial quantities at acceptable costs; or | |
| • | is not accepted in the medical community or by third-party payors. |
We do not expect any of our current product candidates to be commercially available before 2009, if at all. If we or our collaborative partners are unable to make our product candidates commercially available, we will not generate substantial product revenue and we will not be successful. The results of our clinical trials to date do not provide assurance that acceptable efficacy or safety will be shown upon completion of future Phase 3 clinical trials.
32
Table of Contents
If we or our partners are not able to obtain required regulatory approvals, we or our partners will not be able to commercialize our product candidates, our ability to generate revenue will be materially impaired and our business will not be successful.
Our product candidates and the activities associated with their development and commercialization are subject to comprehensive regulation by the U.S. Food and Drug Administration, or FDA, and other regulatory agencies in the United States and by comparable authorities in other countries. In February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 in all countries of the world other than the six countries that comprise the territory under our collaboration with Astellas. Under the terms of our agreement, subject to further positive Phase 3 clinical data, GSK will file the new drug application, or NDA, for restless legs syndrome, or RLS, for FDA approval, and GSK will lead the development and registration of XP13512 for all indications other than RLS in the United States and all indications in the remainder of GSK’s licensed territory. The inability to obtain FDA approval or approval from comparable authorities in other countries would prevent us and our collaborative partners from commercializing our product candidates in the United States or other countries. We or our collaborative partners may never receive regulatory approval for the commercial sale of any of our product candidates. Moreover, if the FDA requires that any of our product candidates be scheduled by the U.S. Drug Enforcement Agency, or DEA, we or our collaborative partners will be unable to begin commercial sale of that product until the DEA completes scheduling proceedings. If any of our product candidates is classified as a controlled substance by the DEA, we or our collaborative partners would have to register annually with the DEA and those product candidates would be subject to additional regulation.
Neither we nor our collaborative partners have received regulatory approval to market any of our product candidates in any jurisdiction. We have only limited experience in preparing and filing the applications necessary to gain regulatory approvals. The process of applying for regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the product candidates involved.
Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional, regulations or statutes or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. Even if the FDA or other regulatory agency approves a product candidate, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketingand/or production of such product and may impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.
The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that our or our collaborative partners’ data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of any of our product candidates.
We and our collaborative partners will need to obtain regulatory approval from authorities in foreign countries to market our product candidates in those countries. Neither we nor our collaborative partners have filed for final regulatory approval in any foreign jurisdictions. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we or our collaborative partners fail to obtain approvals from foreign jurisdictions, the geographic market for our product candidates would be limited.
We depend on collaborations to complete the development and commercialization of some of our product candidates. These collaborations may place the development of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us.
In December 2005, we entered into a collaboration with Astellas for the development and commercialization of XP13512 in Japan and five other Asian countries. In February 2007, we entered into an exclusive collaboration with GSK to develop and commercialize XP13512 worldwide, excluding the Astellas territory. In October 2007, we entered into a collaboration with Xanodyne for the development and commercialization of XP21510 in the United States. We may enter into additional collaborations with third parties to develop and commercialize some of our other product candidates. Our dependence on Astellas and GSK for the development and commercialization of
33
Table of Contents
XP13512 and Xanodyne for the development and commercialization of XP21510 subjects us to, and dependence on future collaborators for development and commercialization of additional product candidates will subject us to, a number of risks, including:
| • | we may not be able to control the amount and timing of resources that our collaborators may devote to the development or commercialization of product candidates or to their marketing and distribution; | |
| • | collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; | |
| • | disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and resources; | |
| • | collaborators may experience financial difficulties; | |
| • | collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; | |
| • | business combinations or significant changes in a collaborator’s business strategy may also adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement; | |
| • | a collaborator could independently move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and | |
| • | the collaborations may be terminated or allowed to expire, which would delay the development and may increase the cost of developing our product candidates. |
For example, pursuant to the terms of our agreement, GSK is responsible for all future development costs of XP13512, with the exception of specified development costs that we will assume in connection with the development of XP13512 for RLS in the United States. In addition, subject to additional positive Phase 3 clinical data, GSK will be responsible for filing an NDA for FDA approval of XP13512 for RLS, and GSK would lead the development and registration of XP13512 for all indications other than RLS in the United States and all indications in the remainder of GSK’s licensed territory. We cannot control the amount and timing of resources that GSK or Astellas may devote to the development or commercialization of XP13512, or that Xanodyne may devote to the development and commercialization of XP21510, or to their respective marketing and distribution. In addition, GSK, Astellas or Xanodyne could independently direct their respective development and marketing resources to the development or commercialization of competitive products, which could delay or impair the commercialization of XP13512 or XP21510, as the case may be, and harm our business.
If we do not establish collaborations for XP19986 or our product candidates other than XP13512 and XP21510, we will have to alter our development and commercialization plans.
Our strategy includes selectively collaborating with leading pharmaceutical and biotechnology companies to assist us in furthering development and potential commercialization of some of our product candidates, including XP19986. We intend to do so especially for indications that involve a large, primary care market that must be served by large sales and marketing organizations. We face significant competition in seeking appropriate collaborators, and these collaborations are complex and time consuming to negotiate and document. We may not be able to negotiate additional collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional collaborations because of the numerous risks and uncertainties associated with establishing additional collaborations. If we are unable to negotiate additional collaborations, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own,
34
Table of Contents
we may need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and generate product revenues.
We will need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts.
We will need to raise additional capital to fund our operations and complete the development of our product candidates. If any product candidates receive regulatory approval for commercial sale, we may need to raise additional capital to fund our commercialization efforts. Our future funding requirements will depend on many factors, including:
| • | the scope, rate of progress, results and cost of our preclinical testing, clinical trials and other research and development activities; | |
| • | the cost of manufacturing clinical and establishing commercial supplies of our product candidates and any products that we may develop; | |
| • | the timing of any milestone payments under our collaborative arrangements; | |
| • | the number and characteristics of product candidates that we pursue; | |
| • | the cost, timing and outcomes of regulatory approvals; | |
| • | the cost and timing of establishing sales, marketing and distribution capabilities; | |
| • | the terms and timing of any collaborative, licensing and other arrangements that we may establish; | |
| • | the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products; | |
| • | the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and | |
| • | the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions. |
Until we can generate a sufficient amount of product revenues, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, as well as through interest income earned on cash balances.
If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any debt financing or additional equity that we raise may contain terms that are not favorable to our stockholders or us. To the extent that we raise additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize ourselves.
We believe that our existing capital resources and expected milestone payments, together with interest thereon, will be sufficient to meet our projected operating requirements through the end of 2009. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently have no credit facility or committed sources of capital other than potential milestones receivable under our collaborations.
Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available on a timely basis, we may:
| • | terminate or delay clinical trials for one or more of our product candidates; | |
| • | delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates; or | |
| • | curtail significant drug development programs that are designed to identify new product candidates. |
35
Table of Contents
If our preclinical studies do not produce successful results or our clinical trials do not demonstrate safety and efficacy in humans, we will not be able to commercialize our product candidates.
To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate, through extensive preclinical studies and clinical trials, that the product candidate is safe and effective in humans. Preclinical and clinical testing is expensive, can take many years and has an uncertain outcome. A failure of one or more of our clinical trials could occur at any stage of testing. In addition, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results. We may experience numerous unforeseen events during, or as a result of, preclinical testing and the clinical trial process, which could delay or prevent our or our collaborative partners’ ability to commercialize our product candidates, including:
| • | regulators or institutional review boards may not authorize us to commence a clinical trial at a prospective trial site; | |
| • | our preclinical testing or clinical trials may produce negative or inconclusive results, which may require us to conduct additional preclinical or clinical testing or to abandon projects that we expect to be promising; | |
| • | we may suspend or terminate our clinical trials if the participating patients are being exposed to unacceptable health risks; | |
| • | regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; and | |
| • | the effects of our product candidates may not be the desired effects or may include undesirable side effects. |
As an example of an unforeseen event, after having been discharged from a Phase 1 clinical trial in which a single dose of XP13512 was administered almost two days earlier, a volunteer died of a self-inflicted gunshot wound following a domestic dispute. We do not believe that this incident was related to XP13512. However, any unforeseen event could cause us to experience significant delays in, or the termination of, clinical trials. Any such events would increase our costs and could delay or prevent our ability to commercialize our product candidates, which would adversely impact our financial results.
Any failure or delay in commencing or completing clinical trials for our product candidates could severely harm our business.
To date, we have not completed all of the clinical trials required for regulatory approval of any product candidate. The commencement and completion of clinical trials for our product candidates may be delayed or terminated as a result of many factors, including:
| • | our inability or the inability of our collaborators or licensees to manufacture or obtain from third parties materials sufficient for use in preclinical studies and clinical trials; | |
| • | delays in patient enrollment, which we have experienced in the past, and variability in the number and types of patients available for clinical trials; | |
| • | difficulty in maintaining contact with patients after treatment, resulting in incomplete data; | |
| • | poor effectiveness of product candidates during clinical trials; | |
| • | unforeseen safety issues or side effects; and | |
| • | governmental or regulatory delays and changes in regulatory requirements, policy and guidelines. |
Any delay in commencing or completing clinical trials for our product candidates would delay commercialization of our product candidates and severely harm our business and financial condition. It is also possible that none of our product candidates will complete clinical trials in any of the markets in which we or our collaborators intend to sell those product candidates. Accordingly, we or our collaborators would not receive the regulatory approvals needed to market our product candidates, which would severely harm our business and financial condition.
36
Table of Contents
We rely on third parties to conduct our clinical trials. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for, or commercialize, our product candidates.
We do not have the ability to independently conduct clinical trials for our product candidates, and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators, collaborative partners and contract laboratories, to conduct our clinical trials. We have, in the ordinary course of business, entered into agreements with these third parties. Nonetheless, with the exception of XP21510 in the United States and XP13512 outside the United States for RLS and all other indications around the world, we are responsible for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol. Moreover, the FDA requires us to comply with regulations and standards, commonly referred to as good clinical practices, for conducting and recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trial participants are adequately protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. For example, we need to prepare, and ensure our compliance with, various procedures required under good clinical practices, even though third-party contract research organizations have prepared and are complying with their own, comparable procedures. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates. For example, one of our third-party contract research organizations was acquired by another company, and if such acquisition delays or prevents them from successfully carrying out their contractual duties to us, there could be a delay in commencing or completing clinical trials for our product candidates that could delay commercialization of our product candidates.
If some or all of our patents expire, are invalidated or are unenforceable, or if some or all of our patent applications do not yield issued patents or yield patents with narrow claims, competitors may develop competing products using our intellectual property and our business will suffer.
Our success will depend in part on our ability to obtain and maintain patent and trade secret protection for our technologies and product candidates both in the United States and other countries. We cannot guarantee that any patents will issue from any of our pending or future patent applications. Alternatively, a third party may successfully circumvent our patents. Our rights under any issued patents may not provide us with sufficient protection against competitive products or otherwise cover commercially valuable products or processes.
The degree of future protection for our proprietary technologies and product candidates is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:
| • | we might not have been the first to make the inventions covered by each of our pending patent applications and issued patents; | |
| • | we might not have been the first to file patent applications for these inventions; | |
| • | others may independently develop similar or alternative technologies or duplicate any of our technologies; | |
| • | it is possible that none of our pending patent applications will result in issued patents; | |
| • | any patents issued to us or our collaborators may not provide a basis for commercially viable products or may be challenged by third parties; or | |
| • | the patents of others may have an adverse effect on our ability to do business. |
Even if valid and enforceable patents cover our product candidates and technologies, the patents will provide protection only for a limited amount of time.
Our and our collaborators’ ability to obtain patents is highly uncertain because, to date, some legal principles remain unresolved, there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States and the specific content of patents and patent applications that are necessary to
37
Table of Contents
support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues. Furthermore, the policies governing biotechnology patents outside the United States are even more uncertain. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection.
Even if patents are issued regarding our product candidates or methods of using them, those patents can be challenged by our competitors who can argue such patents are invalidand/or unenforceable. Patents also may not protect our product candidates if competitors devise ways of making these or similar product candidates without legally infringing our patents. The Federal Food, Drug and Cosmetic Act and FDA regulations and policies provide incentives to manufacturers to challenge patent validity and these same types of incentives encourage manufacturers to submit new drug applications that rely on literature and clinical data not prepared for or by the drug sponsor.
As of February 1, 2008, we held 30 U.S. patents and had 94 patent applications pending before the U.S. Patent and Trademark Office, or PTO. For some of our inventions, correspondingnon-U.S. patent protection is pending. Of the 30 U.S. patents that we hold, 22 patents are compound- and composition-related, having expiration dates from 2021 to 2026; three patents are synthesis-method related, having expiration dates from 2022 to 2025; one patent is proteomics methodology-related having an expiration date in 2022; and four patents are screening methodology-related, having expiration dates from 2022 to 2025. Subject to possible patent term extension, the entitlement for which and the term of which we cannot predict, patent protection in the United States covering XP13512, our product candidate that is a Transported Prodrug of gabapentin, will expire no earlier than 2023. We believe that in all countries in which we hold or have licensed rights to patents or patent applications related to XP13512, the composition-of-matter patents relating to gabapentin have expired. For XP19986, our product candidate that is a Transported Prodrug of R-baclofen, two U.S. composition-of-matter patents have issued that will expire no earlier than 2025 and two synthesis method/chemical intermediate U.S. patents have issued that will expire no earlier than 2025. For XP21279, no U.S. or foreign composition-of-matter patents have yet issued. For XP21510, no U.S. or foreign composition-of-matter patents have yet issued. Although third parties may challenge our rights to, or the scope or validity of, our patents, to date, we have not received any communications from third parties challenging our patents or patent applications covering our product candidates.
We also rely on trade secrets to protect our technology, especially where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our confidential information to competitors. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time-consuming, and the outcome is unpredictable. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
Our research and development collaborators may have rights to publish data and other information in which we have rights. In addition, we sometimes engage individuals or entities to conduct research that may be relevant to our business. The ability of these individuals or entities to publish or otherwise publicly disclose data and other information generated during the course of their research is subject to certain contractual limitations. In most cases, these individuals or entities are, at the least, precluded from publicly disclosing our confidential information and are only allowed to disclose other data or information generated during the course of the research after we have been afforded an opportunity to consider whether patentand/or other proprietary protection should be sought. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our technology and other confidential information, then our ability to receive patent protection or protect our proprietary information may be jeopardized.
38
Table of Contents
Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.
Our commercial success depends in part on not infringing the patents and proprietary rights of other parties and not breaching any licenses that we have entered into with regard to our technologies and products. Because others may have filed, and in the future are likely to file, patent applications covering products or other technologies of interest to us that are similar or identical to ours, patent applications or issued patents of others may have priority over our patent applications or issued patents. For example, we are aware of a third party patent application relating to prodrugs of gabapentin that has been abandoned. However, if it is reopened, if it issues, if it is determined to be valid and if it is construed to cover XP13512, this patent application could affect the development and commercialization of XP13512. Additionally, we are aware of third-party patents relating to the use of baclofen in the treatment of gastroesophageal reflux disease, or GERD. If the patents are determined to be valid and construed to cover XP19986, the development and commercialization of XP19986 could be affected. With respect to the claims contained in these patent applications and patents, we believe that our activities do not infringe the patents at issueand/or that the third-party patent or patent applications are invalid. However, it is possible that a judge or jury will disagree with our conclusions regarding non-infringementand/or invalidity, and we could incur substantial costs in litigation if we are required to defend against patent suits brought by third parties or if we initiate these suits. Any legal action against our collaborators or us claiming damages and seeking to enjoin commercial activities relating to the affected products and processes could, in addition to subjecting us to potential liability for damages, require our collaborators or us to obtain a license to continue to manufacture or market the affected products and processes. Licenses required under any of these patents may not be available on commercially acceptable terms, if at all. Failure to obtain such licenses could materially and adversely affect our ability to develop, commercialize and sell our product candidates. We believe that there may continue to be significant litigation in the biotechnology and pharmaceutical industry regarding patent and other intellectual property rights. If we become involved in litigation, it could consume a substantial portion of our management and financial resources and we may not prevail in any such litigation.
Furthermore, our commercial success will depend, in part, on our ability to continue to conduct research to identify additional product candidates in current indications of interest or opportunities in other indications. Some of these activities may involve the use of genes, gene products, screening technologies and other research tools that are covered by third-party patents. Court decisions have indicated that the exemption from patent infringement afforded by 35 U.S.C. § 271(e)(1) does not encompass all research and development activities associated with product development. In some instances, we may be required to obtain licenses to such third-party patents to conduct our research and development activities, including activities that may have already occurred. It is not known whether any license required under any of these patents would be made available on commercially acceptable terms, if at all. Failure to obtain such licenses could materially and adversely affect our ability to maintain a pipeline of potential product candidates and to bring new products to market. If we are required to defend against patent suits brought by third parties relating to third-party patents that may be relevant to our research activities, or if we initiate such suits, we could incur substantial costs in litigation. Moreover, an adverse result from any legal action in which we are involved could subject us to damagesand/or prevent us from conducting some of our research and development activities.
If third parties do not manufacture our product candidates in sufficient quantities or at an acceptable cost, clinical development and commercialization of our product candidates would be delayed.
We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of any of our product candidates. To date, we have relied on a small number of third-party compound manufacturers and active pharmaceutical ingredient, or API, formulators for the production of clinical and commercial quantities of our product candidates.
Under the terms of our collaboration with GSK, GSK is solely responsible for the manufacture of XP13512 to support its development and commercialization within its licensed territory. However, we will continue to be responsible for providing Astellas both clinical and commercial supplies of XP13512. Thus, we expect to continue to rely on a small number of third-party manufacturers to meet our clinical and commercial supply obligations to Astellas for XP13512 and to meet our preclinical and clinical requirements of our other potential products and for
39
Table of Contents
any related commercial needs. We do not have commercial supply agreements with any of these third parties, and our agreements with these parties are generally terminable at will by either party at any time. If, for any reason, these third parties are unable or unwilling to perform under our agreements or enter into new agreements, we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities of our product candidates in a timely manner from these third parties could delay clinical trials and prevent us or our partners from developing and commercializing our product candidates in a cost-effective manner or on a timely basis. We purchase substantial amounts of gabapentin, which is used to make XP13512, from Teva Pharmaceutical Industries, Ltd. pursuant to purchase orders issued from time to time. Teva’s sale of gabapentin is the subject of ongoing litigation brought by Pfizer Inc alleging infringement of a patent held by Pfizer. In September 2007, the Court of Appeals for the Federal Circuit overturned a July 2006 District Court ruling that was in favor of the generic gabapentin makers, including Teva, and the suit has been remanded to the District Court to continue with the trial. In the event that Teva decides not to sell gabapentin to us, or decides to sell gabapentin to us at a price that is not commercially attractive, or, as a result of this litigation, ceases producing gabapentin, we would not be able to manufacture XP13512 until a qualified alternative supplier is identified. This could delay the development of, and impair our or our collaborative partners’ ability to commercialize, this product candidate.
We currently rely on Lonza Ltd. as the single source supplier of our current requirements of XP13512 API. We have agreed to purchase XP13512 API from Lonza under a manufacturing services and product supply agreement. In the event that Lonza terminates the agreement in response to a breach by us, we would not be able to manufacture the API until a qualified alternative supplier is identified. This could delay the development of, and impair the ability of us or Astellas to commercialize, this product candidate. In addition, our current agreement with Lonza does not provide for the entire supply of API that we require to support Astellas’ planned clinical trials or full-scale commercialization. However, the manufacturing services and product supply agreement obligates the parties to negotiate in good faith on the terms and conditions for Lonza to supply some or all of our total requirements for the commercial supply of XP13512 API. In the event that the parties cannot agree to the terms and conditions for Lonza to provide some or all of our API commercial supply needs, we would not be able to manufacture API until a qualified alternative supplier is identified. This could impair our ability to satisfy our contractual obligations to Astellas and could also delay or impair Astellas’ ability to develop and commercialize XP13512. Unless earlier terminated, our current agreement with Lonza expires in July 2008.
In addition, we currently rely on Patheon Pharmaceuticals, Inc. as our single source supplier for XP13512 formulated in sustained-release tablets for clinical trials at specified transfer prices under a quotation agreed upon by the parties that forms a part of a master services agreement. In the event that Patheon terminates the agreement under specified circumstances, we would not be able to manufacture XP13512 sustained-release tablets until a qualified alternative supplier is identified. This could impair our ability to satisfy our contractual obligations to Astellas and could also delay or impair Astellas’ ability to develop and commercialize XP13512.
We currently rely on Heumann Pharma GmbH as our single source supplier of R-baclofen, the active agent used to make XP19986, under purchase orders issued from time to time. We are aware of two alternative suppliers of R-baclofen. If we were unable to qualify an alternative supplier of R-baclofen, this could delay the development of, and impair our ability to commercialize, this product candidate.
We currently rely on Lonza as the single source supplier of our current worldwide requirements of XP19986 in API form under a manufacturing services and product supply agreement. Our current agreement with Lonza does not provide for the entire supply of the API necessary for our Phase 2 and Phase 3 clinical trials or for full-scale commercialization. In the event that the parties cannot agree to the terms and conditions for Lonza to provide some or all of our API clinical and commercial supply needs, we would not be able to manufacture API until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, this product candidate.
We currently rely on Xcelience, LLC as our single source supplier for XP19986 formulated in sustained-release tablets for clinical trials at specified transfer prices under quotations agreed upon by the parties as a part of a master services agreement. In the event that Xcelience terminates the agreement under specified circumstances, we
40
Table of Contents
would not be able to manufacture XP19986 sustained-release tablets until a qualified alternative supplier is identified. This could delay the development of, and impair our ability to commercialize, XP19986.
We currently rely on Ajinomoto Company as our single source supplier of L-Dopa, the API used to make XP21279, under purchase orders issued from time to time. We are aware of several alternative suppliers of L-Dopa, and we believe at least one alternative manufacturer could potentially supply L-Dopa, in the event that Ajinomoto determines to not sell L-Dopa to us at a price that is commercially attractive. If we were unable to qualify an alternative supplier of L-Dopa, this could delay the development of, and impair our ability to commercialize, XP21279.
We have purchased from Raylo Chemicals, Inc., a subsidiary of Gilead Sciences, Inc., all of our current worldwide requirements of XP21279 in API form through our initial Phase 1 clinical trial under a manufacturing services and product supply agreement. We are currently in the process of identifying a qualified alternative supplier for manufacture of XP21279 in API form. If we were unable to qualify an alternative supplier of XP21279, this could delay the development of, and impair our ability to commercialize, this product candidate.
UPM Pharmaceuticals, Inc. provides our requirements of XP21279 for clinical trials in the form of sustained-release tablets at specified transfer prices under a quotation agreed upon by the parties as a part of a master services agreement. We rely on UPM as a single source supplier for tablets of XP21279. In the event that UPM terminates the agreement under specified circumstances, we would not be able to manufacture XP21279 sustained-release tablets until a qualified alternative supplier is identified. This could delay the development of, and impair our ability to commercialize, XP21279.
If we are required to obtain alternate third-party manufacturers, it could delay or prevent the clinical development and commercialization of our product candidates.
We may not be able to maintain or renew our existing or any other third-party manufacturing arrangements on acceptable terms, if at all. If we are unable to continue relationships with Teva, Lonza or Patheon for XP13512, Heumann, Lonza or Xcelience for XP19986 or Ajinomoto or UPM for XP21279, to do so at an acceptable cost, or if these suppliers fail to meet our requirements for these product candidates for any reason, we would be required to obtain alternative suppliers. Any inability to obtain qualified alternative suppliers, including an inability to obtain, or delay in obtaining, approval of an alternative supplier from the FDA, would delay or prevent the clinical development and commercialization of these product candidates, and could impact our ability to meet our supply obligations to Astellas.
Any failure or delay in developing or manufacturing, or obtaining a qualified commercial supplier of, a new sustained-release tablet formulation of XP19986 could delay the clinical development and commercialization of this product candidate.
Catalent Pharma Solutions, LLC (formerly Cardinal Health PTS, LLC) provided our requirements of XP19986 for our Phase 1 and Phase 2a clinical trials in the form of capsules containing controlled-release beads. However, we have developed new sustained-release tablet formulations of XP19986 to replace the Catalent capsules and have conducted clinical trials with these new tablet formulations. There can be no assurance that clinical trials with the sustained-release tablet formulations will replicate results from our earlier clinical trials with the capsule formulation. The failure to replicate these earlier clinical trials would delay our clinical development timelines. We have engaged Xcelience as a third-party manufacturer for the new sustained-release tablet formulations. Any inability to obtain a qualified commercial supplier, including an inability to obtain, or delay in obtaining, approval of a supplier from the FDA, would delay or prevent the clinical development and commercialization of this product candidate. We currently ship XP19986 using refrigerated containers. We anticipate that manufacturing improvements we will make will alleviate the need to ship this product candidate for commercial sale using refrigerated containers. If we are unable to achieve these manufacturing improvements, we may incur additional expenses and delays that could impair our ability to generate product revenue.
41
Table of Contents
Use of third-party manufacturers may increase the risk that we or our partners will not have adequate supplies of our product candidates.
Our current reliance, and our and our partners’ anticipated future reliance, on third-party manufacturers will expose us and our partners to risks that could delay or prevent the initiation or completion of clinical trials by us or our partners, the submission of applications for regulatory approvals, the approval of our products by the FDA or foreign regulatory authorities or the commercialization of our products or could result in higher costs or lost product revenues. In particular, our contract manufacturers:
| • | could encounter difficulties in achieving volume production, quality control and quality assurance or suffer shortages of qualified personnel, which could result in their inability to manufacture sufficient quantities of drugs to meet clinical schedules or to commercialize our product candidates; | |
| • | could terminate or choose not to renew manufacturing agreements, based on their own business priorities, at a time that is costly or inconvenient for us; | |
| • | could fail to establish and follow FDA-mandated current good manufacturing practices, or cGMPs, which are required for FDA approval of our product candidates, or fail to document their adherence to cGMPs, either of which could lead to significant delays in the availability of material for clinical study and delay or prevent marketing approval for our product candidates; | |
| • | could encounter financial difficulties that would interfere with their obligations to supply our product candidates; and | |
| • | could breach, or fail to perform as agreed under, manufacturing agreements. |
As an example, one of our third-party manufacturers previously released financial results indicating that its earnings were adversely affected due to certain circumstances at two of its manufacturing operations. If such financial difficulties interfere with its ability to satisfy its contractual obligations to supply our product candidates, there could be a delay in commencing or completing our or our collaborative partners’ clinical trials, which could also delay the development of, and impair our or our partners’ ability to commercialize, our product candidates.
We use Patheon to manufacture XP13512 sustained-release tablets that we utilize for our clinical trials and the clinical trials of Astellas. Patheon continues to perform formulation development work to achieve the commercial image for XP13512, including color coating and brand marking for the tablets that would be sold following launch, if obtained. Patheon may not be able to manufacture this product candidate using our desired commercial image, which would delay or prevent the commercialization of XP13512 by Astellas and could impact our ability to meet our supply obligations to Astellas.
If we are not able to obtain adequate supplies of our product candidates, it will be more difficult to develop our product candidates and compete effectively. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. For example, gabapentin is also marketed as generic gabapentin by Teva, one of our third-party manufacturers.
In addition, the manufacturing facilities of Heumann, Lonza, Teva and Ajinomoto are located outside of the United States. This may give rise to difficulties in importing our product candidates or their components into the United States or other countries as a result of, among other things, regulatory agency import inspections, incomplete or inaccurate import documentation or defective packaging.
Safety issues with the parent drugs or other components of our product candidates, or with approved products of third parties that are similar to our product candidates, could give rise to delays in the regulatory approval process, restrictions on labeling or product withdrawal.
Discovery of previously unknown problems with an approved product may result in restrictions on its permissible uses, including withdrawal of the medicine from the market. The FDA approved gabapentin, the parent drug for our XP13512 product candidate, in 1993, and, to date, it has been used in at least 12 million patients. Baclofen, the R-isomer of which is the parent drug for our XP19986 product candidate, has been used since 1977. The FDA has not approved the R-isomer of baclofen for use in humans. The FDA approved levadopa, or L-Dopa,
42
Table of Contents
the parent drug for our XP21279, in 1967. The FDA has not approved oral tranexamic acid, which is the parent drug for our XP21510 product candidate, although it has been used in European countries and other countries for many years and is approved in intravenous form in the United States for tooth extractions in hemophiliacs. Although gabapentin, baclofen, L-Dopa and tranexamic acid have been used successfully in patients for many years, newly observed toxicities, or worsening of known toxicities, in patients receiving gabapentin, baclofen, L-Dopa or tranexamic acid could result in increased regulatory scrutiny of XP13512, XP19986, XP21279 and XP21510, respectively.
Our product candidates are engineered to be broken down by the body’s natural metabolic processes and to release the parent drug and other metabolic substances. While these breakdown products are generally regarded as safe, it is possible that there could be unexpected toxicity associated with these breakdown products that will cause any or all of XP13512, XP19986, XP21279 and XP21510 to be poorly tolerated by, or toxic to, humans. Any unexpected toxicity of, or suboptimal tolerance to, our Transported Prodrugs would delay or prevent commercialization of these product candidates.
Additionally, problems with approved products marketed by third parties that utilize the same therapeutic target as the parent drug of our product candidates could adversely affect the development of our product candidates. For example, the product withdrawals of Vioxx by Merck & Co., Inc. and Bextra from Pfizer in 2005 due to safety issues has caused other drugs that have the same therapeutic target, such as Celebrex from Pfizer, to receive additional scrutiny from regulatory authorities. If either gabapentin or pregabalin, a drug from Pfizer that is marketed as Lyrica, encounters unexpected toxicity problems in humans, the FDA may delay or prevent the regulatory approval of XP13512 since it is a member of the same class of drugs and shares the same therapeutic target as gabapentin and pregabalin. In 2005, the FDA requested that all makers of epilepsy drugs, including Neurontin, analyze their clinical trial data to determine whether these drugs increase the risk of suicide in patients. In January 2008, the FDA warned doctors that 11 antiepileptic drugs, including gabapentin, increased suicide-related risk in patients, especially epileptics. Finally, if the FDA determines that a drug may present a risk of substance abuse, it can recommend to the DEA that the drug be scheduled under the Controlled Substances Act. While gabapentin is not a scheduled drug at the present time, pregabalin has been scheduled as a controlled substance. Since pregabalin is a scheduled drug, it is possible that the FDA may require additional testing of XP13512, the results of which could lead the FDA to conclude that XP13512 should be scheduled as well. Scheduled substances are subject to DEA regulations relating to manufacturing, storage, distribution and physician prescription procedures, and the DEA regulates the amount of a scheduled substance that is available for clinical trials and commercial distribution. Accordingly, any scheduling action that the FDA or DEA may take with respect to XP13512 may delay its clinical trial and approval process. Any failure or delay in commencing or completing clinical trials or obtaining regulatory approvals for our product candidates would delay commercialization of our product candidates and severely harm our business and financial condition.
We may not be successful in our efforts to identify or discover additional Transported Prodrug candidates.
An important element of our strategy is to identify, develop and commercialize Transported Prodrugs that improve upon the absorption, distributionand/or metabolism of drugs that have already received regulatory approval. Other than XP13512, XP19986 and XP21279, all of our research and development programs are at a preclinical stage. Research programs to identify new product candidates require substantial technical, financial and human resources. These research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:
| • | the research methodology used may not be successful in identifying potential product candidates; or | |
| • | potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profile or other characteristics suggesting that they are unlikely to be effective products. |
If we are unable to develop suitable product candidates through internal research programs or otherwise, we will not be able to increase our revenues in future periods, which could result in significant harm to our financial position and adversely impact our stock price.
43
Table of Contents
Our product candidates will remain subject to ongoing regulatory review, even if they receive marketing approval. If we or our collaborative partners fail to comply with continuing regulations, these approvals could be rescinded and the sale of our products could be suspended.
Even if we or our collaborative partners receive regulatory approval to market a particular product candidate, the approval could be conditioned on conducting additional, costly, post-approval studies or could limit the indicated uses included in the labeling. Moreover, the product may later cause adverse effects that limit or prevent its widespread use, force us or our collaborative partners to withdraw it from the market or impede or delay our or our collaborative partners’ ability to obtain regulatory approvals in additional countries. In addition, the manufacturer of the product and its facilities will continue to be subject to FDA review and periodic inspections to ensure adherence to applicable regulations. After receiving marketing approval, the manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion and record keeping related to the product will remain subject to extensive regulatory requirements.
If we or our collaborative partners fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory authorities or previously unknown problems with our products, manufacturers or manufacturing processes are discovered, we and our partners could be subject to administrative or judicially imposed sanctions, including:
| • | restrictions on the products, manufacturers or manufacturing processes; | |
| • | warning letters; | |
| • | civil or criminal penalties or fines; | |
| • | injunctions; | |
| • | product seizures, detentions or import bans; | |
| • | voluntary or mandatory product recalls and publicity requirements; | |
| • | suspension or withdrawal of regulatory approvals; | |
| • | total or partial suspension of production; and | |
| • | refusal to approve pending applications for marketing approval of new drugs or supplements to approved applications. |
Because we have a number of product candidates and are considering a variety of target indications, we may expend our limited resources to pursue a particular candidate or indication and fail to capitalize on candidates or indications that may be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we must focus on research programs and product candidates for the specific indications that we believe are the most promising. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. In addition, we may spend valuable time and managerial and financial resources on research programs and product candidates for specific indications that ultimately do not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in situations where it would have been more advantageous for us to retain sole rights to development and commercialization.
The commercial success of any products that we or our partners may develop will depend upon the degree of market acceptance among physicians, patients, healthcare payors and the medical community.
Any products that result from our product candidates may not gain market acceptance among physicians, patients, healthcare payors and the medical community. If these products do not achieve an adequate level of acceptance, we may not generate material product revenues and we may not become profitable. The degree of
44
Table of Contents
market acceptance of any products resulting from our product candidates will depend on a number of factors, including:
| • | demonstration of efficacy and safety in clinical trials; | |
| • | the prevalence and severity of any side effects; | |
| • | potential or perceived advantages over alternative treatments; | |
| • | perceptions about the relationship or similarity between our product candidates and the parent drug upon which each Transported Prodrug candidate was based; | |
| • | the timing of market entry relative to competitive treatments; | |
| • | the ability to offer product candidates for sale at competitive prices; | |
| • | relative convenience and ease of administration; | |
| • | the strength of marketing and distribution support; | |
| • | sufficient third-party coverage or reimbursement; and | |
| • | the product labeling or product insert required by the FDA or regulatory authorities in other countries. |
If we are unable to establish sales and marketing capabilities or enter into additional agreements with third parties to market and sell our product candidates, we may be unable to generate product revenues.
We do not have a sales and marketing organization and have no experience in the sales, marketing and distribution of pharmaceutical products. There are risks involved with establishing our own sales and marketing capabilities, as well as entering into arrangements with third parties to perform these services. Developing an internal sales force is expensive and time-consuming. On the other hand, if we enter into arrangements with third parties to perform sales, marketing and distribution services, as we have for XP13512 around the world and XP21510 in the United States, our product revenues will be lower than if we market and sell any products that we develop ourselves.
Under the terms of our collaboration with GSK, we are entitled to a percentage of sales of XP13512 in the GSK territory for a specified period of time, unless we elect the option to co-promote XP13512 in the United States. In the event that we elect the co-promotion option for XP13512, we would share marketing and commercialization costs and would be entitled to a share of operating profits from sales of XP13512 in the United States, as well as receive payments on details we perform on Requip XL, GSK’s development-stage product candidate for Parkinson’s disease in the United States. Subject to approval from the FDA of an NDA for XP13512, we would co-promote XP13512 in the United States to those same prescribers. If we elect the co-promotion option for XP13512, we plan to establish our own specialty sales force to sell and market our products. Under the terms of our collaboration with Xanodyne, we are entitled to a percentage of sales of XP21510 in the United States for a specified period of time and a specified percentage of sales of XP12B, Xanodyne’s formulation of tranexamic acid that is in Phase 3 clinical testing.
Factors that may inhibit our efforts to commercialize our products include:
| • | our inability to recruit and retain adequate numbers of effective sales and marketing personnel; | |
| • | the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe our products; | |
| • | the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and | |
| • | unforeseen costs and expenses associated with creating an independent sales and marketing organization. |
Because of the numerous risks and uncertainties involved with establishing our own sales and marketing capabilities, we are unable to predict when we will establish our own sales and marketing capabilities. If we are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will
45
Table of Contents
have difficulty commercializing our product candidates, which would adversely affect our business and financial condition.
Our ability to generate revenue from any products that we may develop will depend on reimbursement and drug pricing policies and regulations.
Many patients may be unable to pay for any products that we or our collaborative partners may develop. In the United States, many patients will rely on Medicare, Medicaid, private health insurers and other third-party payors to pay for their medical needs. Our and our partners’ ability to achieve acceptable levels of reimbursement for drug treatments by governmental authorities, private health insurers and other organizations will have an effect on our and our partners’ ability to successfully commercialize, and attract additional collaborators to invest in the development of, our product candidates. We cannot be sure that reimbursement in the United States, Europe or elsewhere will be available for any products that we or our partners may develop, and any reimbursement that may become available may be decreased or eliminated in the future. Third-party payors increasingly are challenging prices charged for medical products and services, and many third-party payors may refuse to provide reimbursement for particular drugs when an equivalent generic drug is available. Although we believe any products that may result from our product candidates will represent an improvement over the parent drugs upon which they are based and be considered unique and not subject to substitution by a generic parent drug, it is possible that a third-party payor may consider our product candidate and the generic parent drug as equivalents and only offer to reimburse patients for the generic drug. Even if we show improved efficacy or improved convenience of administration with our product candidate, pricing of the existing parent drug may limit the amount we will be able to charge for our product candidate. If reimbursement is not available or is available only at limited levels, we or our partners may not be able to successfully commercialize our product candidates, and may not be able to obtain a satisfactory financial return on such products.
The trend toward managed healthcare in the United States and the changes in health insurance programs, as well as legislative proposals to reform healthcare or reduce government insurance programs, may result in lower prices for pharmaceutical products, including any products that may result from our product candidates. In addition, any future regulatory changes regarding the healthcare industry or third-party coverage and reimbursement may affect demand for any products that we may develop and could harm our sales and profitability.
In December 2003, the Medicare Prescription Drug Improvement and Modernization Act of 2003, or the 2003 Medicare Act, was enacted. Under this legislation, Medicare beneficiaries are now eligible to obtain a Medicare-endorsed, drug-discount card from a choice of private sector providers. It remains difficult to predict the long-term impact of the 2003 Medicare Act on pharmaceutical companies. Usage of pharmaceuticals is likely to increase as the result of the expanded access to medicines afforded by the coverage under Medicare. Such expanded utilization, however, may be offset by the increased pricing pressure and competition due to the enhanced purchasing power of the private sector providers that negotiate on behalf of Medicare beneficiaries.
If our competitors are able to develop and market products that are more effective, safer or less costly than any products that we may develop, our commercial opportunity will be reduced or eliminated.
We face competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. In addition, significant delays in the development of our product candidates could allow our competitors to bring products to market before us and impair our ability to commercialize our product candidates.
We estimate that we have at least five competitors in the neuropathic pain, migraine prophylaxis and RLS therapeutic areas, including GSK, Eli Lilly and Company, Johnson & Johnson and Pfizer. Competition for XP13512 could include: approved drugs that act on the same target as XP13512, such as pregabalin, Neurontin and generic gabapentin; anti-Parkinson’s disease products and product candidates, such as ropinirole from GSK and pramipexole from Boehringer Ingelheim GmbH, which are each approved for the treatment of moderate-to-severe RLS, and the rotigotine patch from Schwarz Pharma AG (member of the UCB group), which had its NDA filed with the
46
Table of Contents
FDA in the fourth quarter of 2007 and is currently under FDA review for the treatment of moderate-to-severe RLS; antiepileptics, such as topiramate from Johnson & Johnson, which is approved for the prevention of migraines; and serotonin norepinephrine inhibitors, such as duloxetine from Eli Lilly, which is approved for the management of painful diabetic neuropathy. We are aware that generic gabapentin is marketed by Alpharma Inc., Pfizer, Teva and IVAX Corp, among others, and that it is prescribed off-label to treat a variety of conditions. We estimate that XP19986 could have several generic drug competitors in the spasticity area. There are several drugs approved for the treatment of spasticity, such as racemic baclofen, diazepam, dantrolene sodium and tizanidine, and many therapies in development, such as Fampridine-SR from Acorda Therapeutics, Inc. and tolperisone from Avigen, Inc., that could compete with XP19986. We estimate that we have at least six competitors in the GERD therapeutic area, including Wyeth, TAP Pharmaceutical Products Inc., Novartis, Addex Pharmaceuticals and AstraZeneca. Competition for XP21279 could include generic L-Dopa/carbidopa drugs and other drugs approved for the treatment of Parkinson’s disease. These include a combination therapy of L-Dopa/carbidopa/entecapone (marketed in the United States by Novartis as Stalevo) and dopamine agonists (marketed by Boehringer-Ingelheim, GSK and UCB as Mirapex, Requip and Neupro, respectively). In addition, there may be other compounds of which we are not aware that are at an earlier stage of development and may compete with our product candidates. If any of those compounds are successfully developed and approved, they could compete directly with our product candidates.
Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Established pharmaceutical companies may invest heavily to quickly discover and develop novel compounds that could make product candidates obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do. We are also aware of other companies that may currently be engaged in the discovery of medicines that will compete with the product candidates that we are developing. In addition, in the markets that we are targeting, we expect to compete against current market-leading medicines. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition will suffer.
Off-label sale or use of generic gabapentin products could decrease sales of XP13512 and could lead to pricing pressure if such products become available at competitive prices and in dosages that are appropriate for the indications for which we or our collaborative partners are developing XP13512.
Physicians are permitted to prescribe legally available drugs for uses that are not described in the drug’s labeling and that differ from those uses tested and approved by the FDA. Such off-label uses are common across medical specialties. Various products are currently sold and used off-label for some of the diseases and conditions that we or our partners are targeting, and a number of companies are, or may be, developing new treatments that may be used off-label. The occurrence of such off-label uses could significantly reduce our or our partners’ ability to market and sell any products that we or our partners may develop.
We believe that in all countries in which we hold or have licensed rights to patents or patent applications related to XP13512, the composition-of-matter patents relating to gabapentin have expired. Off-label prescriptions written for gabapentin could adversely affect our ability to generate revenue from the sale of XP13512, if approved for commercial sale. This could result in reduced sales and pricing pressure on XP13512, if approved, which in turn would reduce our ability to generate revenue and have a negative impact on our results of operations.
If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop or commercialize our product candidates.
Our success depends on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and maintain important relationships with leading clinicians. If we are not able to retain Drs. Ronald Barrett, Kenneth Cundy, Mark Gallop and David Savello, we may
47
Table of Contents
not be able to successfully develop or commercialize our product candidates. Competition for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms. In addition, none of our employees have employment commitments for any fixed period of time and could leave our employment at will. We do not carry “key person” insurance covering members of senior management or key scientific personnel. If we fail to identify, attract and retain qualified personnel, we may be unable to continue our development and commercialization activities.
We will need to hire additional employees in order to commercialize our product candidates. Any inability to manage future growth could harm our ability to commercialize our product candidates, increase our costs and adversely impact our ability to compete effectively.
In order to commercialize our product candidates, we will need to expand the number of our managerial, operational, financial and other employees. We currently anticipate that we will need at least 150 additional employees by the time that XP13512 or XP19986 is initially commercialized, including at least 50 sales representatives. Because the projected timeframe of hiring these additional employees depends on the development status of our product candidates and because of the numerous risks and uncertainties associated with drug development, we are unable to project when we will hire these additional employees. The competition for qualified personnel in the pharmaceutical and biotechnology field is intense, and we may experience difficulties in recruiting, hiring and retaining qualified individuals.
Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to commercialize our product candidates and compete effectively will depend, in part, on our ability to manage any future growth effectively.
If product liability lawsuits are brought against us, we will incur substantial liabilities and may be required to limit commercialization of any products that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products that we may develop caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
| • | decreased demand for any product candidates or products that we may develop; | |
| • | injury to our reputation; | |
| • | withdrawal of clinical trial participants; | |
| • | costs to defend the related litigation; | |
| • | substantial monetary awards to clinical trial participants or patients; | |
| • | loss of revenue; and | |
| • | the inability to commercialize any products that we may develop. |
We have product liability insurance that covers our clinical trials up to a $10.0 million annual aggregate limit. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any products that we may develop. Insurance coverage is increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy any liability that may arise.
If we use biological and hazardous materials in a manner that causes contamination or injury or violates laws, we may be liable for damages.
Our research and development activities involve the use of potentially harmful biological materials as well as hazardous materials, chemicals and various radioactive compounds. We cannot completely eliminate the risk of
48
Table of Contents
accidental contamination or injury from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We, the third parties that conduct clinical trials on our behalf and the third parties that manufacture our product candidates are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and waste products. The cost of compliance with these laws and regulations could be significant. The failure to comply with these laws and regulations could result in significant fines and work stoppages and may harm our business.
Our facility is located in California’s Silicon Valley, in an area with a long history of industrial activity and use of hazardous substances, including chlorinated solvents. Environmental studies conducted prior to our leasing of the site found levels of metals and volatile organic compounds in the soils and groundwater at our site. While these constituents of concern predated our occupancy, certain environmental laws, including the U.S. Comprehensive, Environmental Response, Compensation and Liability Act of 1980, impose strict, joint and several liability on current operators of real property for the cost of removal or remediation of hazardous substances. These laws often impose liability even if the owner or operator did not know of, or was not responsible for, the release of such hazardous substances. As a result, while we have not been, we cannot rule out the possibility that we could in the future be held liable for costs to address contamination at the property beneath our facility, which costs could be material.
Our facility is located near known earthquake fault zones, and the occurrence of an earthquake, extremist attack or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.
Our facility is located near known earthquake fault zones and, therefore, is vulnerable to damage from earthquakes. In October 1989, a major earthquake struck this area and caused significant property damage and a number of fatalities. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fire, floods and similar events. If any disaster were to occur, our ability to operate our business could be seriously impaired. In addition, the unique nature of our research activities and of much of our equipment could make it difficult for us to recover from this type of disaster. We currently may not have adequate insurance to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business and financial condition.
Risks Related to Ownership of our Common Stock
Our stock price is volatile, and purchasers of our common stock could incur substantial losses.
The market prices for securities of biopharmaceutical companies in general have been highly volatile. The market price of our common stock may be influenced by many factors, including:
| • | adverse results or delays in our or our collaborative partners’ clinical trials; | |
| • | the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the receipt of regulatory approval or the establishment of commercial partnerships for one or more of our product candidates; | |
| • | announcement of FDA approvability, approval or non-approval of our product candidates or delays in the FDA review process; | |
| • | actions taken by regulatory agencies with respect to our product candidates, our clinical trials or our sales and marketing activities; | |
| • | actions taken by regulatory agencies with respect to products or drug classes related to our product candidates; | |
| • | the commercial success of any of our products approved by the FDA or its foreign counterparts; |
49
Table of Contents
| • | changes in our collaborators’ business strategies; | |
| • | regulatory developments in the United States and foreign countries; | |
| • | changes in the structure of healthcare payment systems; | |
| • | any intellectual property matter involving us, including infringement lawsuits; | |
| • | announcements of technological innovations or new products by us or our competitors; | |
| • | market conditions for the biotechnology or pharmaceutical industries in general; | |
| • | changes in financial estimates or recommendations by securities analysts; | |
| • | sales of large blocks of our common stock; | |
| • | sales of our common stock by our executive officers, directors and significant stockholders; | |
| • | restatements of our financial resultsand/or material weaknesses in our internal controls; and | |
| • | the loss of any of our key scientific or management personnel. |
The stock markets in general, and the markets for biotechnology stocks in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock. In the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such litigation brought against us could result in substantial costs, which would hurt our financial condition and results of operations, divert management’s attention and resources and possibly delay our clinical trials or commercialization efforts.
Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our stock price.
Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require annual management assessments of the effectiveness of our internal control over financial reporting and a report by our independent registered public accounting firm attesting to, and reporting on, these assessments. If we fail to maintain the adequacy of our internal control over financial reporting, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. If we cannot favorably assess, or our independent registered public accounting firm is unable to provide an unqualified attestation report on, the effectiveness of our internal control over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on our stock price.
Fluctuations in our operating results could cause our stock price to decline.
The following factors are likely to result in fluctuations of our operating results from quarter to quarter and year to year:
| • | adverse results or delays in our or our collaborative partners’ clinical trials; | |
| • | the timing and achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the receipt of regulatory approval or the establishment of a commercial partnership for one or more of our product candidates; | |
| • | announcement of FDA approvability, approval or non-approval of our product candidates or delays in the FDA review process; | |
| • | actions taken by regulatory agencies with respect to our product candidates, our clinical trials or our sales and marketing activities; |
50
Table of Contents
| • | actions taken by regulatory agencies with respect to products or drug classes related to our product candidates; | |
| • | the commercial success of any of our products approved by the FDA or its foreign counterparts; | |
| • | changes in our collaborators’ business strategies; | |
| • | regulatory developments in the United States and foreign countries; | |
| • | changes in the structure of healthcare payment systems; | |
| • | any intellectual property matter involving us, including infringement lawsuits; and | |
| • | announcements of technological innovations or new products by us or our competitors. |
Due to these fluctuations in our operating results, a period-to-period comparison of our results of operations may not be a good indication of our future performance. For example, due to the recognition of revenues fromup-front and milestone payments from our collaborations with Astellas, GSK and Xanodyne, we were profitable in the three-month periods ended June 30, September 30, and December 31, 2007 and may have profitable quarters from time to time. However, while recognition of these revenues resulted in a profitable year for 2007, we continue to expect to incur losses for the next several years. In any particular financial period, the actual or anticipated fluctuations could be below the expectations of securities analysts or investors and our stock price could decline.
Because a small number of existing stockholders own a large percentage of our voting stock, they may be able to exercise significant influence over our affairs, acting in their best interests and not necessarily those of other stockholders.
As of February 1, 2008, our executive officers, directors and holders of 5% or more of our outstanding common stock beneficially owned approximately 29.4% of our common stock. The interests of this group of stockholders may not always coincide with our interests or the interests of other stockholders. This concentration of ownership could also have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquiror from attempting to obtain control of us, which in turn could reduce the price of our common stock.
Our stockholder rights plan and anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our amended and restated certificate of incorporation and bylaws may delay or prevent an acquisition of us, a change in our management or other changes that stockholders may consider favorable. These provisions include:
| • | a classified board of directors; | |
| • | a prohibition on actions by our stockholders by written consent; | |
| • | the ability of our board of directors to issue preferred stock without stockholder approval, which could be used to make it difficult for a third party to acquire us; | |
| • | notice requirements for nominations for election to the board of directors; and | |
| • | limitations on the removal of directors. |
Moreover, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
We have adopted a rights agreement under which certain stockholders have the right to purchase shares of a new series of preferred stock at an exercise price of $140.00 per one one-hundredth of a share, if a person acquires more than 15% of our common stock. The rights plan could make it more difficult for a person to acquire a majority of our outstanding voting stock. The rights plan could also reduce the price that investors might be willing to pay for
51
Table of Contents
shares of our common stock and result in the market price being lower than it would be without the rights plan. In addition, the existence of the rights plan itself may deter a potential acquiror from acquiring us. As a result, either by operation of the rights plan or by its potential deterrent effect, mergers and acquisitions of us that our stockholders may consider in their best interests may not occur.
If there are large sales of our common stock, the market price of our common stock could drop substantially.
If our existing stockholders sell a large number of shares of our common stock or the public market perceives that existing stockholders might sell shares of our common stock, the market price of our common stock could decline significantly. As of February 1, 2008, we had 25,087,907 outstanding shares of common stock. Of these shares, up to 15,437,482 shares of common stock are tradable under Rule 144 or Rule 701 under the Securities Act of 1933, as amended, or the Securities Act, subject in some cases to various vesting agreements, volume limitations and holding periods, and the remainder of the shares have been registered under the Securities Act and are freely tradable. In addition, 1,396,857 shares are held by our directors and executive officers and their affiliates and will be subject to volume, manner of sale and other limitations under Rule 144 under the Securities Act and various vesting agreements.
| Item 1B. | Unresolved Staff Comments. |
Not applicable.
| Item 2. | Properties. |
We lease approximately 103,000 square feet of office and laboratory space in one building in Santa Clara, California where we conduct our operations. The lease expires in September 2011, although we have the option to extend the lease for two additional terms of five years each. The 2007 annual rental amount payable under this lease was approximately $3.8 million, subject to periodic increases. Although our facilities are adequate for our existing needs, we will require additional space as our business expands in 2008.
| Item 3. | Legal Proceedings. |
We are not a party to any material legal proceedings at this time.
| Item 4. | Submission of Matters to a Vote of Security Holders. |
Not applicable.
PART II.
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. |
Our common stock has traded on The NASDAQ Global Market under the symbol “XNPT” since June 2, 2005. As of February 1, 2008, there were approximately 136 holders of record of our common stock. No cash dividends have been paid on our common stock to date, and we currently intend to utilize any earnings for development of our business and for repurchases of our common stock. The following table sets forth, for the periods indicated, the
52
Table of Contents
range of high and low closing sales prices of our common stock as quoted on The NASDAQ Global Market for the two most recent fiscal years.
| High | Low | |||||||
2007 | �� | |||||||
| 4th Quarter | $ | 58.23 | $ | 48.05 | ||||
| 3rd Quarter | 48.85 | 38.33 | ||||||
| 2nd Quarter | 46.49 | 27.85 | ||||||
| 1st Quarter | 28.48 | 23.00 | ||||||
2006 | ||||||||
| 4th Quarter | $ | 27.48 | $ | 20.91 | ||||
| 3rd Quarter | 22.00 | 16.66 | ||||||
| 2nd Quarter | 24.79 | 16.52 | ||||||
| 1st Quarter | 25.77 | 14.25 | ||||||
The closing price for our common stock as reported by The NASDAQ Global Market on February 1, 2008 was $62.21 per share.
Issuer Purchases of Equity Securities
The following table provides information relating to repurchases of our common stock in the three months ended December 31, 2007:
| Approximate Dollar | ||||||||||||||||
| Total Number of | Value of Shares | |||||||||||||||
| Total Number | Average | Shares Purchased as | that may yet be | |||||||||||||
| of Shares | Price Paid | Part of Publicly | Purchased under | |||||||||||||
Period | Purchased(1) | per Share | Announced Program | the Program | ||||||||||||
| October 1, 2007 — October 31, 2007 | 19,098 | $ | 2.70 | N/A | N/A | |||||||||||
| November 1, 2007 — November 30, 2007 | — | $ | — | N/A | N/A | |||||||||||
| December 1, 2007 — December 31, 2007 | — | $ | — | N/A | N/A | |||||||||||
Total | 19,098 | $ | 2.70 | N/A | N/A | |||||||||||
| (1) | The 19,098 shares of our common stock were repurchased by us from an employee upon termination of service pursuant to the terms and conditions of our 1999 Stock Plan, which permits us to elect to purchase such shares at the original issuance price. |
53
Table of Contents
Performance Measurement Comparison(1)
The following graph shows the total stockholder return of an investment of $100 in cash on June 2, 2005 for: (i) our common stock; (ii) the Nasdaq Composite Index; and (iii) the Nasdaq Biotechnology Index as of December 31, 2007. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.
Comparison of Cumulative Total Return on Investment
| (1) | This section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of XenoPort under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. |
54
Table of Contents
| Item 6. | Selected Financial Data. |
You should read the following selected financial data together with our audited financial statements and related notes and the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section and other financial information included in this Annual Report onForm 10-K.
| Year Ended December 31, | ||||||||||||||||||||
| 2007 | 2006 | 2005 | 2004 | 2003 | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||||
Statement of Operations Data: | ||||||||||||||||||||
| Revenues: | ||||||||||||||||||||
| Collaboration revenue | $ | 113,822 | $ | 10,606 | $ | 4,667 | $ | 8,882 | $ | 5,157 | ||||||||||
| Grant revenue | — | — | 86 | 1,073 | 1,074 | |||||||||||||||
| Total revenues | 113,822 | 10,606 | 4,753 | 9,955 | 6,231 | |||||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Research and development | 74,397 | 65,434 | 38,698 | 33,384 | 25,718 | |||||||||||||||
| General and administrative | 18,652 | 14,834 | 10,989 | 8,154 | 5,852 | |||||||||||||||
| Total operating expenses | 93,049 | 80,268 | 49,687 | 41,538 | 31,570 | |||||||||||||||
| Income (loss) from operations | 20,773 | (69,662 | ) | (44,934 | ) | (31,583 | ) | (25,339 | ) | |||||||||||
| Interest income | 8,198 | 5,634 | 2,258 | 674 | 527 | |||||||||||||||
| Interest and other expense | (156 | ) | (285 | ) | (233 | ) | (333 | ) | (519 | ) | ||||||||||
| Income (loss) before income taxes | 28,815 | (64,313 | ) | (42,909 | ) | (31,242 | ) | (25,331 | ) | |||||||||||
| Income tax provision | 622 | — | — | — | — | |||||||||||||||
| Net income (loss) | 28,193 | (64,313 | ) | (42,909 | ) | (31,242 | ) | (25,331 | ) | |||||||||||
| Convertible preferred stock dividend | — | — | (969 | ) | (97 | ) | — | |||||||||||||
| Income (loss) applicable to common stockholders | $ | 28,193 | $ | (64,313 | ) | $ | (43,878 | ) | $ | (31,339 | ) | $ | (25,331 | ) | ||||||
| Basic income (loss) per share applicable to common stockholders | $ | 1.14 | $ | (2.91 | ) | $ | (3.69 | ) | $ | (25.51 | ) | $ | (26.79 | ) | ||||||
| Diluted income (loss) per share applicable to common stockholders | $ | 1.08 | $ | (2.91 | ) | $ | (3.69 | ) | $ | (25.51 | ) | $ | (26.79 | ) | ||||||
| Shares used to compute basic income (loss) per share applicable to stockholders | 24,773 | 22,101 | 11,898 | 1,229 | 946 | |||||||||||||||
| Shares used to compute diluted income (loss) per share applicable to stockholders | 25,992 | 22,101 | 11,898 | 1,229 | 946 | |||||||||||||||
Balance Sheet Data: | ||||||||||||||||||||
| Cash, cash equivalents and short-term investments | $ | 160,141 | $ | 118,854 | $ | 91,918 | $ | 60,245 | $ | 28,318 | ||||||||||
| Working capital | 138,685 | 101,527 | 84,602 | 51,997 | 21,451 | |||||||||||||||
| Restricted investments | 1,771 | 1,699 | 3,205 | 3,169 | 3,020 | |||||||||||||||
| Total assets | 172,877 | 128,665 | 101,908 | 71,693 | 39,636 | |||||||||||||||
| Current portion of equipment financing obligations | 176 | 500 | 714 | 1,068 | 2,416 | |||||||||||||||
| Noncurrent portion of equipment financing obligations | 5 | 181 | 680 | 1,325 | 668 | |||||||||||||||
| Accumulated deficit | 176,063 | 204,256 | 139,943 | 96,065 | 64,726 | |||||||||||||||
| Total stockholders’ equity (deficit) | 125,537 | 83,285 | 65,642 | (91,379 | ) | (63,694 | ) | |||||||||||||
55
Table of Contents
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
Overview
We are a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. We intend to focus our development and commercialization efforts on potential treatments of central nervous system, or CNS, disorders. Our most advanced product candidate, XP13512 is currently being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program in the United States and has also successfully completed a Phase 2a clinical trial for the management of post-herpetic neuralgia, or PHN, in the United States. One of our partners, Astellas Pharma Inc., is evaluating this product candidate in two separate Phase 2 clinical trials in Japan for the treatment of painful diabetic neuropathy, or PDN, and RLS. Another of our partners, Glaxo Group Limited, or GSK, plans to evaluate XP13512 for PHN, PDN and migraine prophylaxis. We are evaluating our second product candidate, XP19986, for the potential treatment of gastroesophageal reflux disease, or GERD, and for the potential treatment of spasticity in separate Phase 2 clinical trials. We initiated a Phase 1 clinical trial of our third product candidate, XP21279, that we plan to evaluate as a potential treatment for Parkinson’s disease.
Our current portfolio of proprietary product candidates includes the following:
| • | XP13512 for RLS. XP13512 is a Transported Prodrug of gabapentin. XP13512 is currently being evaluated for the treatment of RLS in a Phase 3 clinical program in the United States and in a Phase 2 clinical trial in Japan. RLS is characterized by an irresistible urge to move one’s legs, usually accompanied by unpleasant sensations or pain in the legs. We have announced top-line data from two RLS Phase 3 clinical trials that demonstrated statistically significant improvements compared to placebo on the primary endpoints of these trials and that XP13512 was generally well tolerated. | |
| • | XP13512 for Neuropathic Pain. We have also shown in a Phase 2a clinical trial that XP13512 is effective for the management of PHN, a chronic type of neuropathic pain that can follow the resolution of shingles. XP13512 is being studied by our partner, Astellas, in a Phase 2 clinical trial in Japan for the treatment of PDN, a chronic type of neuropathic pain that results from diabetes. Our partner, GSK, has announced that it intends to initiate in the first quarter of this year a neuropathic pain program that will include two Phase 2 clinical trials designed to show the safety and efficacy of XP13512 in the management of PHN, as well as a Phase 2 clinical trial designed to show the safety and efficacy of XP13512 in the treatment of PDN. | |
| • | XP13512 for Migraine Prophylaxis. Migraine is a neurological disorder characterized by recurrent headache attacks that are usually accompanied by various combinations of symptoms, including nausea and vomiting, as well as distorted vision and sensitivity to light and sound. Migraine prophylaxis is designed to reduce the frequency and severity of migraine attacks. GSK has announced plans to initiate in the second half of this year parallel, pivotal Phase 3 clinical trials designed to show the safety and efficacy of XP13512 in preventing migraines in patients, along with a long-term clinical trial designed to establish safety in this patient population, following agreement with the U.S. Food and Drug Administration, or FDA. | |
| • | XP19986 for GERD. XP19986 is a Transported Prodrug of R-baclofen that we are developing for the treatment of GERD, which is a digestive system disorder caused primarily by transient relaxations of the lower esophageal sphincter, which is a combination of muscles that controls the junction between the esophagus and the stomach. GERD is characterized by the frequent, undesirable passage of stomach contents into the esophagus that results in discomfort and potential damage to the lining of the esophagus. We have successfully completed a Phase 2a clinical trial indicating that single doses of XP19986 were well tolerated and produced statistically significant reductions in the number of reflux episodes in patients with GERD. We initiated a second Phase 2 clinical trial of XP19986 in patients with GERD in the fourth quarter of 2007. | |
| • | XP19986 for Spasticity. XP19986 is also a potential treatment for spasticity, a condition in which certain muscles are continuously contracted, causing stiffness or tightness of muscles that interferes with movement or speech. Racemic baclofen, which contains both R-baclofen and S-baclofen, is currently approved in the United States for the treatment of spasticity resulting from multiple sclerosis, spinal cord injury and other |
56
Table of Contents
| spinal cord diseases. We believe that spasticity patients may benefit from XP19986 due to less frequent dosing and a more desirable pharmacokinetic profile than racemic baclofen. We initiated a Phase 2 clinical trial of XP19986 in spinal cord injury patients with spasticity in the fourth quarter of 2007. |
| • | XP21279 for Parkinson’s Disease. XP21279 is a Transported Prodrug of levodopa, or L-Dopa, that we are developing for the treatment of Parkinson’s disease, a neurological disorder of the elderly, characterized by tremor, rigidity and loss of reflexes. We initiated a Phase 1 clinical trial to evaluate the safety and pharmacokinetics of XP21279 in the fourth quarter of 2007. | |
| • | XP20925 for Migraine. XP20925 is a Transported Prodrug of propofol that is in preclinical development for the treatment of migraine. We have commenced preclinical development activities to support the filing of an investigational new drug application, or IND, for XP20925. | |
| • | XP21510 for the Treatment of Women with Menorrhagia. XP21510 is a Transported Prodrug of tranexamic acid. Tranexamic acid is a man-made derivative of the naturally occurring amino acid lysine and works to inhibit, on a molecular basis, the break down of blood clots. It is approved in many countries in Europe and Asia for the treatment of women with menorrhagia, or heavy menstrual bleeding. In October 2007, we announced an exclusive license agreement for the development and commercialization of XP21510 by Xanodyne Pharmaceuticals, Inc. in the United States. |
We were incorporated in May 1999 and commenced active operations in August 1999. To date, we have not generated any product revenues. We have funded our research and development operations primarily through sales of our preferred stock, our initial and follow-on public offerings, non-equity payments from our collaborators and government grants. We have received additional funding from capital lease financings and interest earned on investments. Prior to the three months ended June 30, 2007, we had incurred net losses since our inception. However, due to the recognition of revenues from up-front and milestone payments from our collaborations with GSK, Astellas and Xanodyne we were profitable in the three-month periods ended June 30, September 30, and December 31, 2007 and may have profitable quarters from time to time. While recognition of these revenues resulted in a profitable year for 2007, we continue to expect to incur losses for the next several years as we expand our research and development activities and seek to advance our product candidates into later stages of development. We expect our research and development expenses to increase in the foreseeable future due to increasing headcount, investment in our preclinical development programs and XP19986 development costs, partially offset by decreasing expenses for our XP13512 Phase 3 RLS clinical program. Subject to regulatory approval of any of our product candidates, we expect to incur significant expenses associated with the establishment of a North American specialty sales force. Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of increased expenses if we establish a North American specialty sales force. As of December 31, 2007, we had an accumulated deficit of approximately $176.1 million.
From our inception in 1999 through 2001, our principal activities were focused on identifying and characterizing natural nutrient transporter mechanisms and developing the technology necessary to utilize them for the active transport of drugs. Beginning in 2002, our activities expanded to include the preclinical and clinical development of internally discovered product candidates based on this proprietary technology. In addition to our ongoing research program, the process of carrying out the development of our product candidates to later stages of development will require significant additional research and development expenditures, including preclinical testing, clinical trials, manufacturing development efforts and regulatory activities. We outsource a substantial portion of our preclinical studies, clinical trials and manufacturing activities to third parties to maximize efficiency and minimize our internal overhead.
In December 2002, we entered into a collaboration with ALZA Corporation to discover, develop and commercialize Transported Prodrugs of certain generic parent drugs that are poorly absorbed in the intestines. This collaboration ended in March 2005. ALZA made an up-front, non-refundable cash payment upon initiation of the collaboration and provided annual research funding on a full-time equivalent employee basis.
In November 2003, we entered into a collaboration with Pfizer Inc to develop technologies to assess the role of active transport mechanisms in delivering drugs into the central nervous system. Pfizer made an up-front payment
57
Table of Contents
and supported a number of full-time equivalent employees through November 2005. The program was exclusive during the term of the collaboration and provided Pfizer with non-exclusive rights to resulting technologies.
In December 2004, we issued 1,666,651 shares of our Series D convertible preferred stock, raising net proceeds of approximately $24.9 million. Holders of the Series D convertible preferred stock were entitled to receive dividends in shares of Series D convertible preferred stock at the rate of $1.35 per share per annum. We have reported the loss applicable to common stockholders after giving effect to the dividends paid. In connection with the closing of our initial public offering in June 2005, 71,080 shares of our Series D convertible preferred stock were issued as in-kind dividends payable on our Series D convertible preferred stock, and all of the outstanding shares of Series D convertible preferred stock, including the in-kind dividends, were automatically converted into 1,737,731 shares of common stock.
In June 2005, in connection with our initial public offering, we issued 5,000,000 shares of our common stock, raising net cash proceeds of approximately $46.3 million, after deducting underwriting discounts and commissions and other offering expenses. In July 2005, the underwriters partially exercised their over-allotment option and purchased an additional 9,569 shares of our common stock, for which we received net cash proceeds of approximately $63,000, after deducting underwriting discounts and commissions and other offering expenses.
In December 2005, we entered into an agreement in which we licensed to Astellas exclusive rights to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan (collectively referred to as the Astellas territory). We received an initial license payment of $25.0 million from Astellas. The terms of the agreement also specify clinical and regulatory milestone payments totaling up to a maximum of $60.0 million, including milestone payments of $10.0 million upon initiation of our first Phase 3 clinical trial of XP13512 in RLS patients in the United States, which we received in April 2006, and $5.0 million at the completion of our first Phase 3 clinical trial of XP13512 in RLS patients in the United States, which we received in May 2007. We will receive royalties on any sales of XP13512 in the Astellas territory at a royalty rate in the mid-teens on a percentage basis. As of December 31, 2007, we had recognized an aggregate of $18.2 million of revenue pursuant to this agreement.
In June 2006, in connection with a follow-on public offering, we issued 4,500,000 shares of our common stock, raising net cash proceeds of approximately $71.5 million, after deducting underwriting discounts and commissions and other offering expenses. Also in June 2006, the underwriters partially exercised their over-allotment option and purchased an additional 140,856 shares of our common stock, resulting in net cash proceeds of approximately $2.3 million, after deducting underwriting discounts and commissions and other offering expenses.
In February 2007, we announced an exclusive collaboration with GSK to develop and commercialize XP13512 worldwide, excluding the Astellas territory (collectively referred to as the GSK territory). GSK made an up-front, non-refundable license payment to us of $75.0 million, that we received in March 2007, and GSK has agreed to make additional payments of up to $275.0 million upon the achievement of clinical and regulatory milestones, of which $32.0 million has been received to date, and up to $290.0 million upon the achievement of specified sales levels. Under the terms of the agreement, GSK is responsible for all future development costs, with the exception of specified development costs that we will assume in connection with the development of XP13512 for RLS in the United States. We are entitled to receive royalties based upon a percentage of sales of XP13512 in the GSK territory for a specified period of time, unless we elect the option to co-promote XP13512 in United States. In the event that we elect the co-promotion option for XP13512, we would share marketing and commercialization costs and would be entitled to a share of operating profits from sales of XP13512 in the United States for so long as XP13512 is sold, as well as receive payments on details we perform in the United States on Requip XL, GSK’s development-stage product candidate for Parkinson’s disease. Subject to FDA approval of the new drug application, or NDA, for XP13512, we would co-promote XP13512 in the United States to those same prescribers. As of December 31, 2007, we had recognized an aggregate of $104.9 million of revenue pursuant to this agreement.
In October 2007, we announced an exclusive license agreement for the development and commercialization of XP21510 in the United States by Xanodyne for the potential treatment of women diagnosed with menorrhagia. In exchange for these rights, we are entitled to receive up-front, non-refundable cash payments totaling $12.0 million, of which $6.0 million was paid to us upon execution of the agreement and the remaining $6.0 million is due on the12-month anniversary of the execution date. We are eligible to receive aggregate cash payments of up to
58
Table of Contents
$130.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to XP21510, as well as aggregate cash payments of up to $5.0 million upon the achievement of certain development, regulatory and commercial milestones with respect to Xanodyne’s tranexamic acid product candidate, known as XP12B, that is currently in Phase 3 clinical development. In addition, we are entitled to receive tiered, double-digit royalty payments on potential future sales of XP21510, as well as escalating single-digit royalties on potential future sales of XP12B. As of December 31, 2007, we had recognized an aggregate of $1.5 million of revenue pursuant to this agreement.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments related to revenue recognition and clinical development costs. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Revenue Recognition
We have entered into collaboration agreements with ALZA, Astellas, GSK, Pfizer and Xanodyne, each of which contains multiple elements. We account for these agreements in accordance with the provisions of Securities and Exchange Commission, or SEC, Staff Accounting Bulletin, or SAB, No. 104,Revenue Recognition, and Emerging Issues Task Force, or EITF,No. 00-21,Revenue Arrangements with Multiple Deliverables. We considered a variety of factors in determining the appropriate method of revenue recognition under these arrangements, such as whether the various elements can be considered separate units of accounting, whether there is objective and reliable evidence of fair value for these elements and whether there is a separate earnings process associated with a particular element of an agreement. Specifically, we account for each of these typical elements as follows:
| • | Up-front, licensing-type fees. To date, these types of fees have been classified within the collaboration agreements as license fees, access fees, rights fees and initial licensing fees, and each of them was non-refundable and payable in connection with the execution of the contract. Up-front, licensing-type payments are assessed to determine whether or not the licensee is able to obtain any stand-alone value from the license. Where this is not the case, we do not consider the license deliverable to be a separate unit of accounting, and we defer the revenue with revenue recognition for the license fee being assessed in conjunction with the other deliverables that constitute the combined unit of accounting. | |
| • | Milestones. We assess milestones on an individual basis and recognize revenue from these milestones when earned, as evidenced by acknowledgment from our collaborator, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, (ii) the milestone represents the culmination, or progress towards the culmination, of an earnings process and (iii) the milestone payment is non-refundable. Where separate milestones do not meet these criteria, we typically default to a performance-based model, with revenue recognition following delivery of effort as compared to an estimate of total expected effort. Milestones that are received after all substantive deliverables have occurred are considered to be bonus payments and are recognized upon receipt of the cash, assuming all of the other revenue recognition criteria are met. | |
| • | Collaborative research payments. Generally, the payments received are based on a contractual cost per full-time equivalent employee working on the project, and we recognize revenue related to these payments as the services are performed over the related funding periods for each agreement. |
59
Table of Contents
| • | Grant revenues. Grant revenues are recognized as research is performed. Grant revenues are non-refundable. | |
| • | Combined units of accounting. Where there are multiple deliverables combined as a single unit of accounting, revenues are deferred and recognized over the period which we remain obligated to perform services or deliver product. The specific methodology for the recognition of the revenue (e.g., straight-line or according to specific performance criteria) is determined on acase-by-case basis according to the facts and circumstances applicable to a given contract. |
Our collaboration agreements also include potential payments for commercial product supply, product royalties and sharing of operating profits. To date, we have not received revenue from these sources.
Accrued Expenses
As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us. We periodically confirm the accuracy of our estimates with selected service providers and make adjustments, if necessary. To date, we have not adjusted our estimate at any particular balance sheet date in any material amount. Examples of estimated accrued expenses include:
| • | fees paid to contract research organizations in connection with preclinical and toxicology studies and clinical trials; | |
| • | fees paid to investigative sites in connection with clinical trials; | |
| • | fees paid to contract manufacturers in connection with the production of clinical trial materials; and | |
| • | professional service fees. |
We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.
Stock-Based Compensation
Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards, or SFAS, No. 123R,Share-Based Payment, issued by the Financial Accounting Standards Board, or FASB. SFAS 123R establishes accounting for stock-based awards exchanged for employee services. Accordingly, for stock options and stock purchase rights granted under the 2005 Employee Stock Purchase Plan, or the ESPP, stock-based compensation cost is measured on the grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. We previously applied Accounting Principles Board, or APB, Opinion No. 25,Accounting for Stock Issued to Employees, and related interpretations and provided the required pro forma disclosures of SFAS No. 123,Accounting for Stock Compensation.
Prior to the adoption of SFAS 123R, we accounted for stock-based employee compensation arrangements using the intrinsic value method in accordance with the provisions of APB 25, and related interpretations, and provided the disclosures required under SFAS 123, as amended by SFAS No. 148,Accounting for Stock-Based Compensation — Transition and Disclosures.Prior to our initial public offering in June 2005, we had granted
60
Table of Contents
certain stock options with exercise prices that were below the estimated fair value of the common stock at the date of grant. During the year ended December 31, 2005, we recorded employee stock-based compensation expense associated with the amortization of deferred stock compensation of $2.4 million.
We elected to adopt SFAS 123R using the modified prospective application method, which was applied to the unvested portion of options granted prior to January 1, 2006 and all options granted after January 1, 2006. The effect of recording stock-based compensation under SFAS 123R for the years ended December 31, 2007 and 2006 was $8.9 million and $5.4 million, respectively. As of December 31, 2007, the total compensation cost related to unvested options and awards not yet recognized was $20.2 million. This amount will be recognized over an estimated weighted-average amortization period of 2.78 years.
In connection with the adoption of SFAS 123R, we reassessed our valuation method and related assumptions. We estimate the fair value of stock options and stock purchase rights using a Black-Scholes valuation model, consistent with the provisions of SFAS 123R and Staff Accounting Bulletin No. 107 and with the method used to compute our prior period pro forma disclosures of loss available to common stockholders, including stock-based compensation (determined under a fair value method as prescribed by SFAS 123). The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model, and the resulting charge is expensed using the straight-line attribution method over the vesting period. Restricted stock units are measured at the fair value of our common stock on the date of grant and expensed over the period of vesting using the straight-line attribution approach.
Upon the adoption of SFAS 123R on January 1, 2006, we reversed all of the existing balance of deferred stock compensation of $4.8 million with a corresponding reduction in additional paid-in capital.
SFAS 123R requires the use of option-pricing models that were not developed for use in valuing employee stock options. The Black-Scholes option-pricing model was developed for use in estimating the fair value of short-lived exchange traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Both the expected stock price volatility and the weighted-average expected life assumptions were determined using data obtained from similar entities, taking into consideration factors such as industry, stage of life cycle, size and financial leverage. Prior to the adoption of SFAS 123R, we had also used this approach in calculating both expected stock price volatility and weighted-average expected life assumptions.
We account for stock compensation arrangements to non-employees in accordance with EITFNo. 96-18,Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services, using a fair value approach. The compensation costs of these arrangements are subject to remeasurement over the vesting terms as earned.
Income Taxes
Effective January 1, 2007, we adopted the provisions of Financial Accounting Standard Board, Financial Interpretation No. 48,Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109,or FIN 48. FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with SFAS No. 109,Accounting for Income Taxes, or SFAS 109. The interpretation applies to all tax positions accounted for in accordance with SFAS 109 and requires a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in an income tax return. Subsequent recognition, derecognition and measurement is based on management’s best judgment given the facts, circumstances and information available at the reporting date.
We file income tax returns in the U.S. federal jurisdiction and the California state jurisdiction. To date, we have not been audited by the Internal Revenue Service or any state income tax jurisdiction.
Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged to us in relation to the underpayment of income taxes.
61
Table of Contents
We generated net losses since inception through the year ended December 31, 2006 and accordingly did not record a provision for income taxes. For the year ended December 31, 2007, we generated net income and as a result recognized an income tax expense of $0.6 million related to U.S. federal and state Alternative Minimum Tax. As of December 31, 2007, our total deferred tax assets were $82.9 million. The deferred tax assets were primarily comprised of federal and state tax net operating loss, or NOL, carryforwards. Due to uncertainties surrounding our ability to continue to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset our deferred tax assets. Additionally, the future utilization of our NOL carryforwards to offset future taxable income may be subject to an annual limitation as a result of ownership changes that may have occurred previously or that could occur in the future. We have not yet determined whether such an ownership change has occurred. If necessary, the deferred tax assets will be reduced by any carryforwards that expire prior to utilization as a result of such limitations, with a corresponding reduction of the valuation allowance.
Research and Development Expenses
Research and development expenses consist of costs associated with both partnered and unpartnered research activities, as well as costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Research and development expenses are comprised of: external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, where a substantial portion of our preclinical studies and all of our clinical trials are conducted, third-party manufacturing organizations, where a substantial portion of our preclinical supplies and all of our clinical supplies are produced, and consultants; employee-related expenses, which include salaries and benefits; and facilities, depreciation and amortization and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies. We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We do not allocate our employee and infrastructure costs on aproject-by-project basis.
The following table summarizes our principal product development initiatives, including the related stages of development for each product candidate in development and the direct, third-party research and development expenses recognized in connection with each product candidate. The information in the column labeled “Estimated Completion of Current Phase” is our current estimate of the timing of completion. The actual timing of completion could differ materially from the estimates provided in the table. For a discussion of the risks and uncertainties associated with the timing of completing a product development phase, see the “If our preclinical studies do not produce successful results or our clinical trials do not demonstrate safety and efficacy in humans, we will not be able to commercialize our product candidates;” “Any failure or delay in commencing or completing clinical trials for our product candidates could severely harm our business;” “We rely on third parties to conduct our clinical trials. If these third parties do not perform as contractually required or expected, we may not be able to obtain regulatory approval for, or commercialize, our product candidates;” and “If third parties do not manufacture our product candidates in sufficient quantities or at an acceptable cost, clinical development and commercialization of our product candidates would be delayed” sections of “Risk Factors.”
62
Table of Contents
| Estimated | Related R&D Expenses | |||||||||||||||||
| Completion of | Year Ended December 31, | |||||||||||||||||
Product Candidate | Description | Phase of Development | Current Phase | 2007 | 2006 | 2005 | ||||||||||||
| (In thousands) | ||||||||||||||||||
| Clinical development | ||||||||||||||||||
| XP13512 | RLS | Phase 3 | 2008 | $ | 30,116 | $ | 31,834 | $ | 13,508 | |||||||||
| XP19986 | GERD | Phase 2 | 2008 | |||||||||||||||
| Spasticity | Phase 2 | 2008 | 9,718 | 4,112 | 3,857 | |||||||||||||
| XP21279 | Parkinson’s disease | Phase 1 | 2008 | 900 | — | — | ||||||||||||
| Other(1) | 13,752 | 12,874 | 6,195 | |||||||||||||||
| Total clinical development | 54,486 | �� | 48,820 | 23,560 | ||||||||||||||
| Research and preclinical(2) | 19,911 | 16,614 | 15,138 | |||||||||||||||
| Total research and development | $ | 74,397 | $ | 65,434 | $ | 38,698 | ||||||||||||
| (1) | “Other” constitutes internal clinical development costs for our product candidates that are not directly allocated to XP13512, XP19986 or XP21279. For the year ended December 31, 2007, “other” expenses consisted primarily of personnel costs of $10.4 million and office and facilities overhead costs of $2.7 million. | |
| (2) | For the year ended December 31, 2007, “research and preclinical” expenses consisted primarily of personnel costs of $12.3 million, office and facilities overhead costs of $3.8 million and equipment and services costs of $2.4 million. |
The largest component of our total operating expenses is our ongoing investment in our research and development activities, including the clinical development of our product candidate pipeline. We expect our research and development expenses to increase in the foreseeable future due to increasing headcount, investment in our preclinical development programs and clinical development costs for XP19986, partially offset by decreasing expenses for our XP13512 Phase 3 RLS clinical program. The process of conducting the clinical research necessary to obtain FDA approval is costly and time consuming. We consider the active management and development of our clinical pipeline to be crucial to our long-term success. The actual probability of success for each product candidate and clinical program may be impacted by a variety of factors, including, among others, the quality of the product candidate, early clinical data, investment in the program, competition, manufacturing capability and commercial viability. Furthermore, our strategy includes entering into additional collaborations with third parties to participate in the development and commercialization of at least some of our product candidates. In situations in which third parties have control over the preclinical development or clinical trial process for a product candidate, the estimated completion date is largely under the control of that third party and not under our control. We cannot forecast with any degree of certainty which of our product candidates, if any, will be subject to future collaborations or how such arrangements would affect our development plans or capital requirements.
As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenues from the commercialization and sale of any of our product candidates.
63
Table of Contents
Results of Operations
Years Ended December 31, 2007, 2006 and 2005
Revenues
| 2006 to 2007 | 2005 to 2006 | |||||||||||||||||||||||||||
| Year Ended December 31, | Change | Change | ||||||||||||||||||||||||||
| 2007 | 2006 | 2005 | $ | % | $ | % | ||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||||
| Revenues | $ | 113,822 | $ | 10,606 | $ | 4,753 | $ | 103,216 | 973 | % | $ | 5,853 | 123 | % | ||||||||||||||
Revenues in 2007 resulted from our collaborations with Astellas, GSK and Xanodyne. Revenues in 2006 resulted from our collaboration with Astellas. Revenues in 2005 resulted primarily from our research collaborations with ALZA and Pfizer.
The increase in revenues in 2007 compared to 2006 was primarily the result of a $104.9 million increase in revenues in 2007 due to revenues recognized from up-front and milestone payments under our GSK agreement that was executed in February 2007.
The increase in revenues in 2006 compared to 2005 was primarily the result of the following factors:
| • | a $10.5 million increase in revenues in 2006 due to the recognition of revenues associated with up-front and milestone payments from our collaboration with Astellas; partially offset by | |
| • | a $1.9 million decrease in revenues due to the conclusion of the ALZA collaboration in March 2005; and | |
| • | a $2.6 million decrease in revenues due to the conclusion of the Pfizer collaboration in November 2005. |
We expect revenues to fluctuate in the future primarily depending upon our progress against the deliverables specified in the terms of our collaboration with GSK, the timing of milestone-related activities under our Astellas and Xanodyne collaborations and the extent to which we enter into new collaborative agreements.
Research and Development Expenses
Of the total research and development expenses for the years ended December 31, 2007, 2006 and 2005, the costs associated with research and preclinical and clinical development activities approximated the following:
| 2006 to 2007 | 2005 to 2006 | |||||||||||||||||||||||||||
| Year Ended December 31, | Change | Change | ||||||||||||||||||||||||||
| 2007 | 2006 | 2005 | $ | % | $ | % | ||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||||
| Research and preclinical | $ | 19,911 | $ | 16,614 | $ | 15,138 | $ | 3,297 | 20 | % | $ | 1,476 | 10 | % | ||||||||||||||
| Clinical development | 54,486 | 48,820 | 23,560 | 5,666 | 12 | % | 25,260 | 107 | % | |||||||||||||||||||
| Total research and development | $ | 74,397 | $ | 65,434 | $ | 38,698 | $ | 8,963 | 14 | % | $ | 26,736 | 69 | % | ||||||||||||||
The increase in research and development expenses for 2007 compared to 2006 was principally due to the following:
| • | increased net costs for XP19986 of $5.6 million due to increased manufacturing, clinical and toxicology costs; | |
| • | increased personnel costs of $5.9 million, including non-cash stock-based compensation of $2.3 million, and facilities costs of $0.4 million, partially offset by; | |
| • | decreased net costs for XP13512 of $1.7 million due to decreased manufacturing and toxicology costs, offset by increased clinical and consulting costs; and | |
| • | decreased net costs for XP21279 of $1.3 million due to increased clinical costs, offset by decreased toxicology and absorption, distribution, metabolism and excretion, or ADME, costs. |
64
Table of Contents
The increase in research and development expenses for 2006 compared to 2005 was principally due to the following:
| • | increased net costs for XP13512 of $18.3 million due to increased clinical trial, manufacturing and consulting costs, offset by decreased toxicology costs; | |
| • | increased net costs for XP19986 of $0.3 million due to increased clinical trial and manufacturing costs, offset by decreased toxicology costs; | |
| • | increased net costs for XP21279 of $2.1 million due to manufacturing, toxicology and preclinical costs; and | |
| • | increased personnel costs of $5.0 million, including non-cash stock-based compensation of $1.9 million, service and travel costs of $0.6 million and consulting costs of $0.4 million. |
We expect our research and development expenses to increase in the foreseeable future due to increasing headcount, investment in our preclinical development programs and XP19986 development costs, partially offset by decreasing expenses for our XP13512 Phase 3 RLS clinical program. The timing and amount of these increases will primarily depend upon the costs associated with our Phase 3 clinical program in RLS for XP13512, our Phase 2 clinical trials in GERD and spasticity for XP19986 and the outcomes of current and future clinical trials for XP19986 and XP21279, as well as the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs and product candidate manufacturing costs.
General and Administrative Expenses
| 2006 to 2007 | 2005 to 2006 | |||||||||||||||||||||||||||
| Year Ended December 31, | Change | Change | ||||||||||||||||||||||||||
| 2007 | 2006 | 2005 | $ | % | $ | % | ||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||||
| General and administrative | $ | 18,652 | $ | 14,834 | $ | 10,989 | $ | 3,818 | 26 | % | $ | 3,845 | 35 | % | ||||||||||||||
The increase in general and administrative expenses in 2007 compared to 2006 was primarily due to increased personnel and related costs of $3.1 million, including non-cash stock-based compensation of $1.3 million, resulting from an increase in headcount.
The increase in general and administrative expenses in 2006 compared to 2005 was primarily due to increased personnel and related costs of $3.3 million, including non-cash stock-based compensation of $0.9 million, resulting from an increase in headcount.
We expect that general and administrative expenses will continue to increase in the future due to increased personnel, expanded infrastructure and increased consulting and legal services.
Interest Income and Interest and Other Expense
| 2006 to 2007 | 2005 to 2006 | |||||||||||||||||||||||||||
| Year Ended December 31, | Change | Change | ||||||||||||||||||||||||||
| 2007 | 2006 | 2005 | $ | % | $ | % | ||||||||||||||||||||||
| (In thousands, except percentages) | ||||||||||||||||||||||||||||
| Interest income | $ | 8,198 | $ | 5,634 | $ | 2,258 | $ | 2,564 | 46 | % | $ | 3,376 | 150 | % | ||||||||||||||
| Interest and other expense | 156 | 285 | 233 | (129 | ) | (45 | )% | 52 | 22 | % | ||||||||||||||||||
Interest income for 2007, 2006 and 2005 resulted primarily from earnings on investments. The increase in interest income in 2007 compared to 2006, and 2006 compared to 2005, was due to higher average cash and cash equivalents and short-term investment balances.
The decrease in interest and other expense in 2007 compared to 2006 was due to the continuing reduction of our equipment financing obligations. The increase in interest and other expense in 2006 compared to 2005 was due to an increase in franchise tax costs and loss on sale of capital assets.
65
Table of Contents
Income Taxes
We recorded $0.6 million, $0 million and $0 million, respectively, of current income tax expense for the years ended December 31, 2007, 2006 and 2005. The income tax expense recognized for the year ended December 31, 2007 resulted from our full year effective tax rate of 2.2% related to federal and state Alternative Minimum Tax and other temporary differences. We incurred net operating losses in 2006 and 2005 and accordingly did not record a provision for income taxes in either of these years. While recognition of revenues resulted in a profitable year for 2007, we continue to expect to incur losses for the next several years as we expand our research and development activities and seek to advance our product candidates into later stages of development. As a result, we do not expect to incur income taxes in the next several years.
Liquidity and Capital Resources
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| Cash provided by (used in): | ||||||||||||
| Operating activities | $ | 36,374 | $ | (49,851 | ) | $ | (14,859 | ) | ||||
| Investing activities | (37,093 | ) | (32,380 | ) | (46,942 | ) | ||||||
| Financing activities | 3,823 | 75,000 | 47,335 | |||||||||
| Capital expenditures (included in investing activities above) | (5,260 | ) | (1,355 | ) | (872 | ) | ||||||
Due to our significant research and development expenditures and the lack of regulatory agency approvals to sell products, we have generated cumulative operating losses since we incorporated in 1999. As such, we have funded our research and development operations primarily through sales of our preferred stock, our initial and follow-on public offerings, non-equity payments from our collaborators and government grants. We have received additional funding from capital lease financings and interest earned on investments, each as described more fully below. At December 31, 2007, we had available cash and cash equivalents and short-term investments of $160.1 million. Our cash and investment balances are held in a variety of interest-bearing instruments, including corporate debt securities and money market accounts. Cash in excess of immediate requirements is invested with regard to liquidity and capital preservation, and we seek to minimize the potential effects of concentration and degrees of risk.
Net cash provided by (used in) operating activities was $36.4 million, $(49.9) million and $(14.9) million in the years ended December 31, 2007, 2006 and 2005, respectively. The net cash provided by operating activities in 2007 primarily reflected the net income for the period, and to a lesser extent, adjustments for non-cash items and changes in operating assets and liabilities. The net cash used in operating activities 2006 and 2005 primarily reflected the net loss for those periods, offset in part by the impact of non-cash depreciation and amortization, stock-based compensation and changes in operating assets and liabilities.
Net cash used in investing activities was $37.1 million, $32.4 million and $46.9 million in the years ended December 31, 2007, 2006 and 2005, respectively. Cash used in investing activities was primarily related to purchases of investments, net of proceeds from sales and maturities of investments, and to a lesser extent, purchases of property and equipment.
Net cash provided by financing activities was $3.8 million, $75.0 million and $47.3 million in the years ended December 31, 2007, 2006 and 2005, respectively. Net cash provided by financing activities was primarily attributable to the proceeds from the issuances of common stock and the exercise of stock options and warrants in 2007 of $4.4 million and proceeds from our follow-on public offering of $73.8 million in 2006 and our initial public offering of $46.4 million in 2005, partially offset in all periods by principal payments on our equipment financings.
We believe that our existing capital resources and expected milestone payments, together with interest thereon, will be sufficient to meet our projected operating requirements through the end of 2009. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently
66
Table of Contents
have no credit facility or committed sources of capital other than potential milestones receivable under our collaborations. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in “Risk Factors.” Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, and the extent to which we enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, including:
| • | the scope, rate of progress, results and cost of our preclinical testing, clinical trials and other research and development activities; | |
| • | the cost of manufacturing clinical, and establishing commercial, supplies of our product candidates and any products that we may develop; | |
| • | the timing of any milestone payments under our collaborative arrangements; | |
| • | the number and characteristics of product candidates that we pursue; | |
| • | the cost, timing and outcomes of regulatory approvals; | |
| • | the cost and timing of establishing sales, marketing and distribution capabilities; | |
| • | the terms and timing of any other collaborative, licensing and other arrangements that we may establish; | |
| • | the timing, receipt and amount of sales, profit sharing or royalties, if any, from our potential products; | |
| • | the cost of preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and | |
| • | the extent to which we acquire or invest in businesses, products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions. |
If we need to raise additional money to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, we may not be able to continue clinical trials for one or more of our product candidates, we may delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates or we could be required to delay, scale back or eliminate some or all of our research and development programs. We may seek to raise any necessary additional funds through equity or debt financings, collaborative arrangements with corporate partners or other sources. To the extent that we raise additional capital through licensing arrangements or arrangements with collaborative partners, we may be required to relinquish, on terms that are not favorable to us, rights to some of our technologies or product candidates that we would otherwise seek to develop or commercialize ourselves. To the extent that we raise additional capital through equity financings, dilution to our stockholders would result. Any debt financing or additional equity that we raise may contain terms that are not favorable to our stockholders or us.
Contractual Obligations
Our future contractual obligations at December 31, 2007 were as follows (in thousands):
| Less Than | 1-3 | 3-5 | ||||||||||||||
Contractual Obligations | Total | 1 Year | Years | Years | ||||||||||||
| Equipment financing obligations | $ | 188 | $ | 183 | $ | 5 | $ | — | ||||||||
| Operating lease obligations | 16,240 | 3,956 | 8,303 | 3,981 | ||||||||||||
| Total fixed contractual obligations | $ | 16,428 | $ | 4,139 | $ | 8,308 | $ | 3,981 | ||||||||
67
Table of Contents
Recent Accounting Pronouncements
In June 2007, the EITF reached a consensus on EITFNo. 07-03,Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, orEITF 07-03.EITF 07-03 specifies the timing of expense recognition for non-refundable advance payments for goods or services that will be used or rendered for research and development activities.EITF 07-03 is effective for fiscal years beginning after December 15, 2007, and early adoption is not permitted. As a result,EITF 07-03 is effective for us in the first quarter of fiscal 2008. We do not expect the adoption ofEITF 07-03 to have a material impact on either our financial position or results of operations.
In December 2007, the EITF reached a consensus on EITFNo. 07-01,Accounting for Collaborative Arrangements Related to the Development and Commercialization of Intellectual Property, orEITF 07-01.EITF 07-01 discusses the appropriate income statement presentation and classification for the activities and payments between the participants in arrangements related to the development and commercialization of intellectual property. The sufficiency of disclosure related to these arrangements is also specified.EITF 07-01 is effective for fiscal years beginning after December 15, 2008. As a result,EITF 07-01 is effective for us in the first quarter of fiscal 2009. We do not expect the adoption ofEITF 07-01 to have a material impact on either our financial position or results of operations.
| Item 7A. | Quantitative and Qualitative Disclosures About Market Risk. |
The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. As of December 31, 2007, we had cash and cash equivalents and short-term investments of $160.1 million consisting of cash and highly liquid investments deposited in highly rated financial institutions in the United States. A portion of our investments may be subject to interest rate risk and could fall in value if market interest rates increase. However, because our investments are short-term in duration, we believe that our exposure to interest rate risk is not significant and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We actively monitor changes in interest rates.
We contract for the conduct of certain manufacturing activities with a contract manufacturer in Europe. We made payments in the aggregate amount of $4.5 million, $4.2 million and $5.6 million during the years ended December 31, 2007, 2006 and 2005, respectively, to this European contract manufacturer. We are subject to exposure to fluctuations in foreign exchange rates in connection with these agreements. To date, the effect of the exposure to these fluctuations in foreign exchange rates has not been material, and we do not expect it to be material in the foreseeable future. We do not hedge our foreign currency exposures. We have not used derivative financial instruments for speculation or trading purposes.
| Item 8. | Financial Statements and Supplementary Data. |
The information required by this item is incorporated herein by reference to the financial statements and schedule listed in Item 15 (1) and (2) of Part IV of this Annual Report onForm 10-K.
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. |
Not applicable.
| Item 9A. | Controls and Procedures. |
Evaluation of Disclosure Controls and Procedures
Based on their evaluation as of December 31, 2007, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures (as defined inRules 13a-15(e) and15d-15(e) of the Securities Exchange Act of 1934, as amended) were effective.
68
Table of Contents
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Securities Exchange ActRules 13a-15(f) and15d-15(f). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations and can provide only reasonable assurance that the objectives of the internal control system are met.
Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) inInternal Control — Integrated Framework. Based on our evaluation, we concluded that our internal control over financial reporting was effective as of December 31, 2007.
Ernst & Young LLP, an independent registered public accounting firm, has audited our financial statements included herein and has issued an audit report on the effectiveness of our internal control over financial reporting, which report is included below.
69
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders of XenoPort, Inc.
We have audited XenoPort, Inc.’s internal control over financial reporting as of December 31, 2007 based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). XenoPort Inc.’s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
In our opinion, XenoPort, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2007, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the balance sheets of XenoPort, Inc. as of December 31, 2007 and 2006, and the related statements of operations, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2007 of XenoPort, Inc. and our report dated February 20, 2008 expressed an unqualified opinion thereon.
/s/ Ernst & Young LLP
Palo Alto, California
February 20, 2008
70
Table of Contents
Changes in Internal Controls over Financial Reporting
There were no significant changes in our internal controls over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
| Item 9B. | Other Information. |
None.
PART III.
Certain information required by Part III is omitted from this Annual Report onForm 10-K since we intend to file our definitive proxy statement for our 2008 annual meeting of stockholders, or the Proxy Statement, pursuant to Regulation 14A of the Securities Exchange Act, not later than 120 days after the end of the fiscal year covered by this Annual Report onForm 10-K, and certain information to be included in the Proxy Statement is incorporated herein by reference.
| Item 10. | Directors, Executive Officers and Corporate Governance. |
The information required by this item with respect to our executive officers may be found under the caption, “Executive Officers of the Registrant” in Item 1 of this Annual Report onForm 10-K. The information required by this item relating to our directors and nominees, including information with respect to our audit committee, audit committee financial experts and procedures by which stockholders may recommend nominees to our board of directors, may be found under the section entitled “Proposal 1 — Election of Directors” appearing in the Proxy Statement. Such information is incorporated herein by reference. Information regarding compliance with Section 16(a) of the Securities Exchange Act may be found under the section entitled “Section 16(a) Beneficial Ownership Reporting Compliance” appearing in our Proxy Statement. Such information is incorporated herein by reference.
In 2005, we adopted a code of ethics that applies to our employees, officers and directors and incorporates guidelines designed to deter wrongdoing and to promote the honest and ethical conduct and compliance with applicable laws and regulations. In addition, the code of ethics incorporates our guidelines pertaining to topics such as conflicts of interest and workplace behavior. We have posted the text of our code of ethics on our Web site at www.XenoPort.com in connection with “Investor Relations/Corporate Governance” materials. In addition, we intend to promptly disclose (1) the nature of any amendment to our code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our code of ethics that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our Web site in the future.
| Item 11. | Executive Compensation. |
The information required by this item is included in our Proxy Statement under the sections entitled “Executive Compensation,” “Director Compensation,” “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report” and is incorporated herein by reference.
71
Table of Contents
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. |
Equity Compensation Plan Information
The following table provides certain information regarding our equity compensation plans in effect as of December 31, 2007:
| Number of Securities | ||||||||||||
| Remaining Available for | ||||||||||||
| Number of Securities | Weighted-Average | Future Issuance Under | ||||||||||
| to be Issued Upon | Exercise Price of | Equity Compensation | ||||||||||
| Exercise of | Outstanding | Plans (Excluding | ||||||||||
| Outstanding Options, | Options, Warrants | Securities Reflected | ||||||||||
| Warrants and Rights | and Rights | in Column | ||||||||||
Plan Category | (a) | (b) | (a) | |||||||||
Equity compensation plans approved by security holders: | ||||||||||||
| 1999 Stock Option Plan(1) | 698,245 | $ | 3.97 | — | ||||||||
| 2005 Equity Incentive Plan(2) | 1,808,446 | $ | 22.70 | 1,268,627 | ||||||||
| 2005 Non-Employee Directors’ Stock Option Plan(3) | 206,666 | $ | 29.37 | 63,334 | ||||||||
| 2005 Employee Stock Purchase Plan(4) | — | — | 501,689 | |||||||||
Equity compensation plans not approved by security holders: | ||||||||||||
| None | — | — | — | |||||||||
| Total | 2,713,357 | $ | 18.52 | 1,833,650 | ||||||||
| (1) | In December 1999, we adopted the 1999 Stock Option Plan, or the 1999 Plan, which was terminated in June 2005 in connection with our initial public offering so that no further awards may be granted under the 1999 Plan. Although the 1999 Plan has terminated, all outstanding options will continue to be governed by their existing terms. | |
| (2) | In January 2005, we adopted the 2005 Equity Incentive Plan, or the 2005 Incentive Plan, which became effective in June 2005 in connection with our initial public offering. A total of 2,000,000 shares of common stock were initially authorized for issuance under the 2005 Incentive Plan. Our board of directors may increase the share reserve as of each January 1, from January 1, 2006 through January 1, 2015, by an amount determined by our board; provided, however that the increase for any year may not exceed the lesser of (1) 2.5% of the total number of shares of our common stock outstanding on the December 31st of the preceding calendar year or (2) 2,000,000 shares. During the year ended December 31, 2007, the annual increase to the 2005 Incentive Plan reserve was 617,663 shares. | |
| (3) | In January 2005, we adopted the 2005 Non-Employees Directors’ Stock Option Plan, or the Directors’ Plan, which became effective in June 2005 in connection with our initial public offering. The Directors’ Plan provides for the automatic grant of options to purchase shares of our common stock to non-employee directors. A total of 150,000 shares of our common stock were initially authorized for issuance under the Directors’ Plan. Our board of directors may increase the share reserve as of each January 1, from January 1, 2006 through January 1, 2015, by an amount determined by our board; provided, however that the increase for any year may not exceed the excess of (1) the number of shares of our common stock subject to options granted under the plan during the preceding calendar year over (2) the number of shares added back to the share reserve during the preceding calendar year. During the year ended December 31, 2007, the annual increase to the Directors’ Plan reserve was 70,000 shares. | |
| (4) | In January 2005, we adopted the 2005 Employee Stock Purchase Plan, or the ESPP, which became effective in June 2005 in connection with our initial public offering. The ESPP allows for qualified employees (as defined in the ESPP) to purchase shares of our common stock at a price equal to the lower of 85% of the closing price of our common stock at the beginning of the offering period or 85% of the closing price of our common stock on |
72
| the date of purchase. A total of 250,000 shares of our common stock were initially authorized for issuance under the ESPP. Our board of directors may increase the share reserve as of each January 1, from January 1, 2006 through January 1, 2015, by an amount determined by our board; provided, however that the increase for any year may not exceed the lesser of (1) 1% of the total number of shares of our common stock outstanding on the December 31st of the preceding calendar year or (2) 250,000 shares. During the year ended December 31, 2007, the annual increase to the ESPP reserve was 247,065 shares. |
The information required by this item relating to security ownership of certain beneficial owners and management is included in our Proxy Statement under the section entitled “Security Ownership of Certain Beneficial Owners and Management” and is incorporated herein by reference.
| Item 13. | Certain Relationships and Related Transactions, and Director Independence. |
The information required by this item is included in our Proxy Statement under the sections entitled “Transactions with Related Persons” and “Proposal 1 — Election of Directors” and is incorporated herein by reference.
| Item 14. | Principal Accountant Fees and Services. |
The information required by this item is incorporated herein by reference to the information included in our Proxy Statement under the section entitled “Proposal 2 — Ratification of Selection of Independent Registered Public Accounting Firm.”
PART IV.
| Item 15. | Exhibits, Financial Statement Schedules. |
1. Index to Financial Statements
The following Financial Statements are included herein:
| Page | ||||
| Number | ||||
| 82 | ||||
| 83 | ||||
| 84 | ||||
| 85 | ||||
| 86 | ||||
| 87 | ||||
2. Index to Financial Statement Schedules
None.
All other schedules are omitted because they are not applicable, or not required, or because the required information is included in the consolidated statements or notes thereto.
3. Exhibits — The following exhibits are included herein or incorporated herein by reference:
| Exhibit | ||||
Number | Description of Document | |||
| 3 | .1 | Amended and Restated Certificate of Incorporation(1) | ||
| 3 | .2 | Amended and Restated Bylaws(1) | ||
| 3 | .3 | Certificate of Designation of Series A Junior Participating Preferred Stock(2) | ||
| 4 | .1 | Specimen Common Stock Certificate(3) | ||
73
Table of Contents
| Exhibit | ||||
Number | Description of Document | |||
| 4 | .2 | Fifth Amended and Restated Investors Rights Agreement, dated December 16, 2004, by and among the Company and certain stockholders of the Company(4) | ||
| 4 | .3 | Form of Right Certificate(5) | ||
| 10 | .1* | Form of Indemnification Agreement between the Company and its officers and directors(6) | ||
| 10 | .2* | Form of Employee Proprietary Information Agreement between the Company and its executive officers(4) | ||
| 10 | .3 | Lease Agreement, dated September 24, 2001, by and between the Company and Sobrato Interests(4) | ||
| 10 | .4 | Sublease Agreement, dated April 30, 2004, by and between the Company and ILYPSA, Inc.(4) | ||
| 10 | .4.1 | Sublease Termination Agreement, dated January 22, 2007, by and between the Company and ILYPSA, Inc.(7) | ||
| 10 | .5* | 1999 Stock Plan(4) | ||
| 10 | .6* | Form of Stock Option Agreement under the 1999 Stock Plan(4) | ||
| 10 | .7* | 2005 Equity Incentive Plan(6) | ||
| 10 | .8* | Form of Option Agreement under the 2005 Equity Incentive Plan(6) | ||
| 10 | .9* | Form of Stock Unit Award Agreement under the 2005 Equity Incentive Plan(8) | ||
| 10 | .10* | 2005 Non-Employee Directors’ Stock Option Plan(3) | ||
| 10 | .11* | Form of Stock Option Agreement under the 2005 Non-Employee Directors’ Stock Option Plan(3) | ||
| 10 | .12* | 2005 Employee Stock Purchase Plan(6) | ||
| 10 | .13* | Form of 2005 Employee Stock Purchase Plan Offering Document(6) | ||
| 10 | .14* | Form of Change of Control Agreement between the Company and certain of its officers, dated November 7, 2007(9) | ||
| 10 | .15* | Change of Control Agreement between the Company and Ronald W. Barrett, dated November 7, 2007(10) | ||
| 10 | .16* | Change of Control Agreement between the Company and William J. Rieflin, dated November 7, 2007(11) | ||
| 10 | .17* | Change of Control Agreement between the Company and William G. Harris, dated November 7, 2007(12) | ||
| 10 | .18* | Change of Control Agreement between the Company and Kenneth C. Cundy, dated November 7, 2007(13) | ||
| 10 | .19* | Change of Control Agreement between the Company and Mark A. Gallop, dated November 7, 2007(14) | ||
| 10 | .20* | Change of Control Agreement between the Company and David R. Savello, dated November 7, 2007(15) | ||
| 10 | .21* | Amended and Restated Employment Agreement between the Company and William J. Rieflin, dated November 7, 2007(16) | ||
| 10 | .22* | Promissory note issued by Kenneth C. Cundy to the Company, dated December 20, 2001(4) | ||
| 10 | .23* | Promissory note issued by Mark A. Gallop to the Company, dated April 12, 2002(4) | ||
| 10 | .24* | Promissory note issued by William G. Harris to the Company, dated May 17, 2002(4) | ||
| 10 | .25* | XenoPort, Inc. Corporate Bonus Plan(17) | ||
| 10 | .26* | Termsheet for Director Cash Compensation(18) | ||
| 10 | .27* | Executive Compensation(19) | ||
| 10 | .28† | Distribution and License Agreement, dated as of December 1, 2005, between the Company and Astellas Pharma Inc.(20) | ||
| 10 | .29† | Development and Commercialization Agreement, dated February 7, 2007, by and between the Company and Glaxo Group Limited(21) | ||
| 10 | .29.1 | First Amendment to Development and Commercialization Agreement, dated May 4, 2007, by and between the Company and Glaxo Group Limited(21) | ||
74
Table of Contents
| Exhibit | ||||
Number | Description of Document | |||
| 10 | .30†† | Licensing Agreement, dated as of October 12, 2007, between the Company and Xanodyne Pharmaceuticals, Inc.(22) | ||
| 10 | .31 | Rights Agreement, dated as of December 15, 2005, by and between the Company and Mellon Investor Services LLC(23) | ||
| 23 | .1 | Consent of Independent Registered Public Accounting Firm | ||
| 24 | .1 | Power of Attorney (included in the signature page hereto) | ||
| 31 | .1 | Certification of the Chief Executive Officer pursuant to Securities Exchange ActRules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 31 | .2 | Certification of the Chief Financial Officer pursuant to Securities Exchange ActRules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 32 | .1 | Certification required byRule 13a-14(b) orRule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(24) | ||
| * | Represents a management contract or compensation plan or arrangement. | |
| † | Confidential treatment has been granted for portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission pursuant toRule 24b-2 of the Securities Exchange Act of 1934, as amended. | |
| †† | Confidential treatment has been requested for portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission pursuant toRule 24b-2 of the Securities Exchange Act of 1934, as amended. | |
| (1) | Incorporated herein by reference to the same numbered exhibit of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended June 30, 2005, as filed with the SEC on August 11, 2005. | |
| (2) | Incorporated herein by reference to Exhibit 3.1 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (3) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1, as amended (File No.333-122156), as filed with the SEC on April 13, 2005. | |
| (4) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1 (FileNo. 333-122156), as filed with the SEC on January 19, 2005. | |
| (5) | Incorporated herein by reference to Exhibit 4.1 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (6) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1 (FileNo. 333-122156), as filed with the SEC on March 2, 2005. | |
| (7) | Incorporated herein by reference to the same numbered exhibit of our annual report onForm 10-K (FileNo. 000-51329) for the period ended December 31, 2007, as filed with the SEC on March 7, 2007. | |
| (8) | Incorporated herein by reference to Exhibit 10.30 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended June 30, 2007, as filed with the SEC on August 9, 2007. | |
| (9) | Incorporated herein by reference to Exhibit 10.13 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (10) | Incorporated herein by reference to Exhibit 10.14 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (11) | Incorporated herein by reference to Exhibit 10.15 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (12) | Incorporated herein by reference to Exhibit 10.17 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (13) | Incorporated herein by reference to Exhibit 10.31 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. |
75
Table of Contents
| (14) | Incorporated herein by reference to Exhibit 10.32 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (15) | Incorporated herein by reference to Exhibit 10.33 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (16) | Incorporated herein by reference to Exhibit 10.18 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (17) | Incorporated herein by reference to Exhibit 10.21 of our current report ofForm 8-K, filed with the SEC on February 2, 2007. | |
| (18) | Incorporated herein by reference to Exhibit 10.25 of our current report ofForm 8-K, filed with the SEC on August 4, 2006, and incorporated herein by reference. | |
| (19) | Incorporated herein by reference to Exhibit 10.28 of our current report ofForm 8-K, filed with the SEC on February 1, 2008. | |
| (20) | Incorporated herein by reference to Exhibit 10.27 of our current report ofForm 8-K, filed with the SEC on December 2, 2005. | |
| (21) | Incorporated herein by reference to the same numbered exhibit of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended March 31, 2007, as filed with the SEC on May 9, 2007. | |
| (22) | Incorporated herein by reference to Exhibit 10.34 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (23) | Incorporated herein by reference to Exhibit 4.2 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (24) | This certification accompanies the annual report onForm 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of theForm 10-K), irrespective of any general incorporation language contained in such filing. |
76
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| XenoPort, Inc. (Registrant) | ||
| February 22, 2008 | /s/ Ronald W. Barrett Ronald W. Barrett Chief Executive Officer and Director | |
| February 22, 2008 | /s/ William G. Harris William G. Harris Senior Vice President of Finance and Chief Financial Officer (Principal Financial and Accounting Officer) | |
| February 22, 2008 | /s/ Martyn J. Webster Martyn J. Webster Vice President of Finance |
77
Table of Contents
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ronald W. Barrett and William G. Harris, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution for him or her, and in his or her name and in any and all capacities, to sign any and all amendments to this Annual Report onForm 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
Signature | Title | Date | ||||
/s/ Ronald W. Barrett Ronald W. Barrett | Chief Executive Officer and Director(Principal Executive Officer) | February 22, 2008 | ||||
/s/ William G. Harris William G. Harris | Senior Vice President of Finance and Chief Financial Officer (Principal Financial and Accounting Officer) | February 22, 2008 | ||||
/s/ Paul L. Berns Paul L. Berns | Director | February 22, 2008 | ||||
/s/ John G. Freund John G. Freund | Director | February 22, 2008 | ||||
/s/ Catherine J. Friedman Catherine J. Friedman | Director | February 22, 2008 | ||||
/s/ Jeryl L. Hilleman Jeryl L. Hilleman | Director | February 22, 2008 | ||||
/s/ Kenneth J. Nussbacher Kenneth J. Nussbacher | Director | February 22, 2008 | ||||
/s/ Gary D. Tollefson Gary D. Tollefson | Director | February 22, 2008 | ||||
/s/ Wendell Wierenga Wendell Wierenga | Director | February 22, 2008 | ||||
78
Table of Contents
EXHIBIT INDEX
| Exhibit | ||||
Number | Description of Document | |||
| 3 | .1 | Amended and Restated Certificate of Incorporation(1) | ||
| 3 | .2 | Amended and Restated Bylaws(1) | ||
| 3 | .3 | Certificate of Designation of Series A Junior Participating Preferred Stock(2) | ||
| 4 | .1 | Specimen Common Stock Certificate(3) | ||
| 4 | .2 | Fifth Amended and Restated Investors Rights Agreement, dated December 16, 2004, by and among the Company and certain stockholders of the Company(4) | ||
| 4 | .3 | Form of Right Certificate(5) | ||
| 10 | .1* | Form of Indemnification Agreement between the Company and its officers and directors(6) | ||
| 10 | .2* | Form of Employee Proprietary Information Agreement between the Company and its executive officers(4) | ||
| 10 | .3 | Lease Agreement, dated September 24, 2001, by and between the Company and Sobrato Interests(4) | ||
| 10 | .4 | Sublease Agreement, dated April 30, 2004, by and between the Company and ILYPSA, Inc.(4) | ||
| 10 | .4.1 | Sublease Termination Agreement, dated January 22, 2007, by and between the Company and ILYPSA, Inc.(7) | ||
| 10 | .5* | 1999 Stock Plan(4) | ||
| 10 | .6* | Form of Stock Option Agreement under the 1999 Stock Plan(4) | ||
| 10 | .7* | 2005 Equity Incentive Plan(6) | ||
| 10 | .8* | Form of Option Agreement under the 2005 Equity Incentive Plan(6) | ||
| 10 | .9* | Form of Stock Unit Award Agreement under the 2005 Equity Incentive Plan(8) | ||
| 10 | .10* | 2005 Non-Employee Directors’ Stock Option Plan(3) | ||
| 10 | .11* | Form of Stock Option Agreement under the 2005 Non-Employee Directors’ Stock Option Plan(3) | ||
| 10 | .12* | 2005 Employee Stock Purchase Plan(6) | ||
| 10 | .13* | Form of 2005 Employee Stock Purchase Plan Offering Document(6) | ||
| 10 | .14* | Form of Change of Control Agreement between the Company and certain of its officers, dated November 7, 2007(9) | ||
| 10 | .15* | Change of Control Agreement between the Company and Ronald W. Barrett, dated November 7, 2007(10) | ||
| 10 | .16* | Change of Control Agreement between the Company and William J. Rieflin, dated November 7, 2007(11) | ||
| 10 | .17* | Change of Control Agreement between the Company and William G. Harris, dated November 7, 2007(12) | ||
| 10 | .18* | Change of Control Agreement between the Company and Kenneth C. Cundy, dated November 7, 2007(13) | ||
| 10 | .19* | Change of Control Agreement between the Company and Mark A. Gallop, dated November 7, 2007(14) | ||
| 10 | .20* | Change of Control Agreement between the Company and David R. Savello, dated November 7, 2007(15) | ||
| 10 | .21* | Amended and Restated Employment Agreement between the Company and William J. Rieflin, dated November 7, 2007(16) | ||
| 10 | .22* | Promissory note issued by Kenneth C. Cundy to the Company, dated December 20, 2001(4) | ||
| 10 | .23* | Promissory note issued by Mark A. Gallop to the Company, dated April 12, 2002(4) | ||
| 10 | .24* | Promissory note issued by William G. Harris to the Company, dated May 17, 2002(4) | ||
| 10 | .25* | XenoPort, Inc. Corporate Bonus Plan(17) | ||
| 10 | .26* | Termsheet for Director Cash Compensation(18) | ||
| 10 | .27* | Executive Compensation(19) | ||
| 10 | .28† | Distribution and License Agreement, dated as of December 1, 2005, between the Company and Astellas Pharma Inc.(20) | ||
79
Table of Contents
| Exhibit | ||||
Number | Description of Document | |||
| 10 | .29† | Development and Commercialization Agreement, dated February 7, 2007, by and between the Company and Glaxo Group Limited(21) | ||
| 10 | .29.1 | First Amendment to Development and Commercialization Agreement, dated May 4, 2007, by and between the Company and Glaxo Group Limited(21) | ||
| 10 | .30†† | Licensing Agreement, dated as of October 12, 2007, between the Company and Xanodyne Pharmaceuticals, Inc.(22) | ||
| 10 | .31 | Rights Agreement, dated as of December 15, 2005, by and between the Company and Mellon Investor Services LLC(23) | ||
| 23 | .1 | Consent of Independent Registered Public Accounting Firm | ||
| 24 | .1 | Power of Attorney (included in the signature page hereto) | ||
| 31 | .1 | Certification of the Chief Executive Officer pursuant to Securities Exchange ActRules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 31 | .2 | Certification of the Chief Financial Officer pursuant to Securities Exchange ActRules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||
| 32 | .1 | Certification required byRule 13a-14(b) orRule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350)(24) | ||
| * | Represents a management contract or compensation plan or arrangement. | |
| † | Confidential treatment has been granted for portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission pursuant toRule 24b-2 of the Securities Exchange Act of 1934, as amended. | |
| †† | Confidential treatment has been requested for portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission pursuant toRule 24b-2 of the Securities Exchange Act of 1934, as amended. | |
| (1) | Incorporated herein by reference to the same numbered exhibit of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended June 30, 2005, as filed with the SEC on August 11, 2005. | |
| (2) | Incorporated herein by reference to Exhibit 3.1 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (3) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1, as amended (File No.333-122156), as filed with the SEC on April 13, 2005. | |
| (4) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1 (FileNo. 333-122156), as filed with the SEC on January 19, 2005. | |
| (5) | Incorporated herein by reference to Exhibit 4.1 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (6) | Incorporated herein by reference to the same numbered exhibit of our registration statement onForm S-1 (FileNo. 333-122156), as filed with the SEC on March 2, 2005. | |
| (7) | Incorporated herein by reference to the same numbered exhibit of our annual report onForm 10-K (FileNo. 000-51329) for the period ended December 31, 2007, as filed with the SEC on March 7, 2007. | |
| (8) | Incorporated herein by reference to Exhibit 10.30 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended June 30, 2007, as filed with the SEC on August 9, 2007. | |
| (9) | Incorporated herein by reference to Exhibit 10.13 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (10) | Incorporated herein by reference to Exhibit 10.14 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (11) | Incorporated herein by reference to Exhibit 10.15 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. |
80
Table of Contents
| (12) | Incorporated herein by reference to Exhibit 10.17 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (13) | Incorporated herein by reference to Exhibit 10.31 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (14) | Incorporated herein by reference to Exhibit 10.32 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (15) | Incorporated herein by reference to Exhibit 10.33 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (16) | Incorporated herein by reference to Exhibit 10.18 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (17) | Incorporated herein by reference to Exhibit 10.21 of our current report ofForm 8-K, filed with the SEC on February 2, 2007. | |
| (18) | Incorporated herein by reference to Exhibit 10.25 of our current report ofForm 8-K, filed with the SEC on August 4, 2006, and incorporated herein by reference. | |
| (19) | Incorporated herein by reference to Exhibit 10.28 of our current report ofForm 8-K, filed with the SEC on February 1, 2008. | |
| (20) | Incorporated herein by reference to Exhibit 10.27 of our current report ofForm 8-K, filed with the SEC on December 2, 2005. | |
| (21) | Incorporated herein by reference to the same numbered exhibit of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended March 31, 2007, as filed with the SEC on May 9, 2007. | |
| (22) | Incorporated herein by reference to Exhibit 10.34 of our quarterly report onForm 10-Q (FileNo. 000-51329) for the period ended September 30, 2007, as filed with the SEC on November 9, 2007. | |
| (23) | Incorporated herein by reference to Exhibit 4.2 of our current report ofForm 8-K, filed with the SEC on December 16, 2005. | |
| (24) | This certification accompanies the annual report onForm 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of theForm 10-K), irrespective of any general incorporation language contained in such filing. |
81
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders
XenoPort, Inc.
We have audited the accompanying balance sheets of XenoPort, Inc. as of December 31, 2007 and 2006, and the related statements of operations, convertible preferred stock and shareholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2007. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of XenoPort, Inc. at December 31, 2007 and 2006, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2007, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), XenoPort, Inc.’s internal control over financial reporting as of December 31, 2007, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 20, 2008, expressed an unqualified opinion thereon.
/s/ Ernst & Young LLP
Palo Alto, California
February 20, 2008
82
Table of Contents
XENOPORT, INC.
BALANCE SHEETS
| December 31, | ||||||||
| 2007 | 2006 | |||||||
| (In thousands) | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 17,961 | $ | 14,857 | ||||
| Short-term investments | 142,180 | 103,997 | ||||||
| Accounts receivable | 1,392 | 2,796 | ||||||
| Employee note receivable and other current assets | 2,682 | 1,332 | ||||||
| Total current assets | 164,215 | 122,982 | ||||||
| Property and equipment, net | 6,791 | 3,532 | ||||||
| Restricted investments | 1,771 | 1,699 | ||||||
| Employee notes receivable and other assets | 100 | 452 | ||||||
| Total assets | $ | 172,877 | $ | 128,665 | ||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,647 | $ | 144 | ||||
| Accrued compensation | 3,923 | 2,928 | ||||||
| Accrued preclinical and clinical costs | 8,726 | 13,430 | ||||||
| Other accrued liabilities | 2,809 | 1,737 | ||||||
| Deferred revenue | 8,117 | 2,424 | ||||||
| Current portion of equipment financing obligations | 176 | 500 | ||||||
| Current portion of liability for early exercise of employee stock options | 132 | 292 | ||||||
| Total current liabilities | 25,530 | 21,455 | ||||||
| Deferred revenue | 20,328 | 21,843 | ||||||
| Deferred rent and other | 1,455 | 1,696 | ||||||
| Noncurrent portion of equipment financing obligations | 5 | 181 | ||||||
| Noncurrent portion of liability for early exercise of employee stock options | 22 | 205 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, $0.001 par value; 60,000 shares authorized; 24,989 and 24,517 shares issued and outstanding, at December 31, 2007 and 2006, respectively | 25 | 24 | ||||||
| Additional paid-in capital | 301,084 | 287,513 | ||||||
| Notes receivable from stockholders | — | (33 | ) | |||||
| Accumulated other comprehensive income | 491 | 37 | ||||||
| Accumulated deficit | (176,063 | ) | (204,256 | ) | ||||
| Total stockholders’ equity | 125,537 | 83,285 | ||||||
| Total liabilities and stockholders’ equity | $ | 172,877 | $ | 128,665 | ||||
The accompanying notes are an integral part of these financial statements.
83
Table of Contents
XENOPORT, INC.
STATEMENTS OF OPERATIONS
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| (In thousands, except per share amounts) | ||||||||||||
| Revenues: | ||||||||||||
| Collaboration revenue | $ | 113,822 | $ | 10,606 | $ | 4,667 | ||||||
| Grant revenue | — | — | 86 | |||||||||
| Total revenues | 113,822 | 10,606 | 4,753 | |||||||||
| Operating expenses: | ||||||||||||
| Research and development | 74,397 | 65,434 | 38,698 | |||||||||
| General and administrative | 18,652 | 14,834 | 10,989 | |||||||||
| Total operating expenses | 93,049 | 80,268 | 49,687 | |||||||||
| Income (loss) from operations | 20,773 | (69,662 | ) | (44,934 | ) | |||||||
| Interest income | 8,198 | 5,634 | 2,258 | |||||||||
| Interest and other expense | (156 | ) | (285 | ) | (233 | ) | ||||||
| Income (loss) before income taxes | 28,815 | (64,313 | ) | (42,909 | ) | |||||||
| Income tax provision | 622 | — | — | |||||||||
| Net income (loss) | 28,193 | (64,313 | ) | (42,909 | ) | |||||||
| Convertible preferred stock dividends | — | — | (969 | ) | ||||||||
| Income (loss) applicable to common stockholders | $ | 28,193 | $ | (64,313 | ) | $ | (43,878 | ) | ||||
| Basic income (loss) per share applicable to common stockholders | $ | 1.14 | $ | (2.91 | ) | $ | (3.69 | ) | ||||
| Diluted income (loss) per share applicable to common stockholders | $ | 1.08 | $ | (2.91 | ) | $ | (3.69 | ) | ||||
| Shares used to compute basic income (loss) per share applicable to common stockholders | 24,773 | 22,101 | 11,898 | |||||||||
| Shares used to compute diluted income (loss) per share applicable to common stockholders | 25,992 | 22,101 | 11,898 | |||||||||
The accompanying notes are an integral part of these financial statements.
84
Table of Contents
XENOPORT, INC.
STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
| Accumulated | ||||||||||||||||||||||||||||||||||||||||
| Notes | Other | Total | ||||||||||||||||||||||||||||||||||||||
| Convertible | Additional | Receivable | Deferred | Comprehensive | Stockholders’ | |||||||||||||||||||||||||||||||||||
| Preferred Stock | Common Stock | Paid-In | from | Stock | Income | Accumulated | Equity | |||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Stockholders | Compensation | (Loss) | Deficit | (Deficit) | |||||||||||||||||||||||||||||||
| (In thousands, except share amounts) | ||||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2004 | 11,749,361 | $ | 148,804 | 1,574,830 | $ | 2 | $ | 8,238 | $ | (560 | ) | $ | (2,894 | ) | $ | (100 | ) | $ | (96,065 | ) | $ | (91,379 | ) | |||||||||||||||||
| Issuance of common stock upon exercise of warrants | — | — | 693,268 | — | 38 | — | — | — | — | 38 | ||||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of options and vesting of early exercised options | — | — | 451,397 | — | 1,516 | — | — | — | — | 1,516 | ||||||||||||||||||||||||||||||
| Issuance of common stock in connection with Employee Stock Purchase Plan | — | — | 40,811 | — | 362 | — | — | — | — | 362 | ||||||||||||||||||||||||||||||
| Repurchase of common stock | — | — | (4,696 | ) | — | (11 | ) | — | — | — | — | (11 | ) | |||||||||||||||||||||||||||
| Issuance of Series A convertible preferred stock upon exercise of warrants | 12,249 | 73 | — | — | (12 | ) | — | — | — | — | (12 | ) | ||||||||||||||||||||||||||||
| Conversion of preferred stock to common stock upon IPO | (11,761,610 | ) | (148,877 | ) | 11,761,610 | 12 | 148,866 | — | — | — | — | 148,878 | ||||||||||||||||||||||||||||
| Convertible preferred stock dividends | — | — | — | — | — | — | — | — | (969 | ) | (969 | ) | ||||||||||||||||||||||||||||
| Exercise and conversion of convertible preferred stock dividend to common stock upon IPO | — | — | 71,080 | — | 1,066 | — | — | — | — | 1,066 | ||||||||||||||||||||||||||||||
| Proceeds from common stock issued upon IPO, net of issuance costs | — | — | 5,000,000 | 5 | 46,349 | — | — | — | — | 46,354 | ||||||||||||||||||||||||||||||
| Proceeds from greenshoe, net of issuance costs | 9,569 | — | 63 | — | — | — | — | 63 | ||||||||||||||||||||||||||||||||
| Compensation expense relating to consultant options | — | — | — | — | 369 | — | — | — | — | 369 | ||||||||||||||||||||||||||||||
| Repayment of promissory notes from stockholders | — | — | — | — | — | 402 | — | — | — | 402 | ||||||||||||||||||||||||||||||
| Reclassification of unvested common stock | — | — | (155,253 | ) | — | (621 | ) | — | — | — | — | (621 | ) | |||||||||||||||||||||||||||
| Deferred stock compensation, net | — | — | — | — | 4,330 | — | (4,330 | ) | — | — | — | |||||||||||||||||||||||||||||
| Amortization of deferred stock compensation | — | — | — | — | — | 2,403 | — | — | 2,403 | |||||||||||||||||||||||||||||||
| Compensation expense relating to common stock option granted to an employee | — | — | — | — | 128 | — | — | — | — | 128 | ||||||||||||||||||||||||||||||
| Comprehensive income (loss): | ||||||||||||||||||||||||||||||||||||||||
| Change in unrealized gain/loss on investments | — | — | — | — | — | — | — | (36 | ) | — | (36 | ) | ||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | (42,909 | ) | (42,909 | ) | ||||||||||||||||||||||||||||
| Comprehensive income (loss): | (42,945 | ) | ||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2005 | — | — | 19,442,616 | $ | 19 | $ | 210,681 | $ | (158 | ) | $ | (4,821 | ) | $ | (136 | ) | $ | (139,943 | ) | $ | 65,642 | |||||||||||||||||||
| Issuance of common stock upon exercise of options and vesting of early exercised options | — | — | 346,593 | — | 1,199 | — | — | — | — | 1,199 | ||||||||||||||||||||||||||||||
| Issuance of common stock in connection with Employee Stock Purchase Plan | — | — | 93,837 | — | 1,110 | — | — | — | — | 1,110 | ||||||||||||||||||||||||||||||
| Repurchase of common stock | — | — | (4,134 | ) | — | (13 | ) | — | — | — | — | (13 | ) | |||||||||||||||||||||||||||
| Proceeds from common stock issued upon FPO, net of issuance costs | — | — | 4,500,000 | 5 | 71,534 | — | — | — | — | 71,539 | ||||||||||||||||||||||||||||||
| Proceeds from greenshoe, net of issuance costs | 140,856 | — | 2,257 | — | — | — | — | 2,257 | ||||||||||||||||||||||||||||||||
| Compensation expense relating to consultant options | — | — | — | — | 198 | — | — | — | — | 198 | ||||||||||||||||||||||||||||||
| Repayment of promissory notes from stockholders | — | — | — | — | — | 125 | — | — | — | 125 | ||||||||||||||||||||||||||||||
| Reclassification of unvested common stock | — | — | (3,251 | ) | — | (9 | ) | — | — | — | — | (9 | ) | |||||||||||||||||||||||||||
| Reversal of deferred stock compensation | — | — | — | — | (4,821 | ) | — | 4,821 | — | — | — | |||||||||||||||||||||||||||||
| Stock-based compensation expense — employees | — | — | — | — | 5,377 | — | — | — | — | 5,377 | ||||||||||||||||||||||||||||||
| Comprehensive income (loss): | ||||||||||||||||||||||||||||||||||||||||
| Change in unrealized gain/loss on investments | — | — | — | — | — | — | — | 173 | — | 173 | ||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | — | — | — | — | (64,313 | ) | (64,313 | ) | ||||||||||||||||||||||||||||
| Comprehensive income (loss): | (64,140 | ) | ||||||||||||||||||||||||||||||||||||||
| Balance at December 31, 2006 | — | — | 24,516,517 | $ | 24 | $ | 287,513 | $ | (33 | ) | $ | — | $ | 37 | $ | (204,256 | ) | $ | 83,285 | |||||||||||||||||||||
| Issuance of common stock upon exercise of warrants | — | — | 12,346 | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||
| Issuance of common stock upon exercise of options and vesting of early exercised options | — | — | 428,653 | 1 | 3,293 | — | — | — | — | 3,294 | ||||||||||||||||||||||||||||||
| Issuance of common stock in connection with Employee Stock Purchase Plan | — | — | 59,218 | — | 1,429 | — | — | — | — | 1,429 | ||||||||||||||||||||||||||||||
| Repurchase of common stock | — | — | (26,676 | ) | — | (82 | ) | — | — | — | — | (82 | ) | |||||||||||||||||||||||||||
| Compensation expense relating to consultant options | — | — | — | — | 17 | — | — | — | — | 17 | ||||||||||||||||||||||||||||||
| Repayment of promissory notes from stockholders | — | — | — | — | — | 33 | — | — | — | 33 | ||||||||||||||||||||||||||||||
| Reclassification of unvested common stock | — | — | (1,375 | ) | — | (8 | ) | — | — | — | — | (8 | ) | |||||||||||||||||||||||||||
| Stock-based compensation expense — employees | — | — | — | — | 8,922 | — | — | — | — | 8,922 | ||||||||||||||||||||||||||||||
| Comprehensive income (loss): | ||||||||||||||||||||||||||||||||||||||||
| Change in unrealized gain/loss on investments | — | — | — | — | — | — | — | 454 | — | 454 | ||||||||||||||||||||||||||||||
| Net income | — | — | — | — | — | — | — | — | 28,193 | 28,193 | ||||||||||||||||||||||||||||||
| Comprehensive income (loss): | — | — | — | — | — | — | — | 28,647 | ||||||||||||||||||||||||||||||||
| Balance at December 31, 2007 | — | — | 24,988,683 | $ | 25 | $ | 301,084 | $ | — | $ | — | $ | 491 | $ | (176,063 | ) | $ | 125,537 | ||||||||||||||||||||||
The accompanying notes are an integral part of these financial statements.
85
Table of Contents
XENOPORT, INC.
STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| (In thousands) | ||||||||||||
Operating activities | ||||||||||||
| Net income (loss) | $ | 28,193 | $ | (64,313 | ) | $ | (42,909 | ) | ||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||||||
| Depreciation and amortization | 2,007 | 1,630 | 2,095 | |||||||||
| Accretion of investment discounts, net | (5,974 | ) | (1,463 | ) | (141 | ) | ||||||
| Amortization of deferred compensation | — | — | 2,403 | |||||||||
| Stock-based compensation expense — employees | 8,922 | 5,377 | 128 | |||||||||
| Stock-based compensation expense — consultants | 17 | 198 | 369 | |||||||||
| Change in assets and liabilities: | ||||||||||||
| Accounts receivable | 1,404 | (2,741 | ) | 1,299 | ||||||||
| Deposit and other current and non-current assets | (1,198 | ) | 1,139 | (1,219 | ) | |||||||
| Notes receivable from employees | 200 | — | 191 | |||||||||
| Accounts payable | 1,503 | (2,846 | ) | 1,365 | ||||||||
| Accrued compensation | 995 | 1,247 | 334 | |||||||||
| Accrued preclinical and clinical costs | (4,704 | ) | 11,510 | (1,020 | ) | |||||||
| Other accrued liabilities | 1,072 | 1,129 | (537 | ) | ||||||||
| Deferred revenue | 4,178 | (607 | ) | 22,728 | ||||||||
| Deferred rent and other | (241 | ) | (111 | ) | 55 | |||||||
| Net cash provided by (used in) operating activities | 36,374 | (49,851 | ) | (14,859 | ) | |||||||
Investing activities | ||||||||||||
| Purchases of investments | (297,389 | ) | (172,826 | ) | (102,023 | ) | ||||||
| Proceeds from sales and maturities of investments | 265,628 | 140,295 | 55,989 | |||||||||
| Change in restricted investments | (72 | ) | 1,506 | (36 | ) | |||||||
| Purchases of property and equipment | (5,260 | ) | (1,355 | ) | (872 | ) | ||||||
| Net cash used in investing activities | (37,093 | ) | (32,380 | ) | (46,942 | ) | ||||||
Financing activities | ||||||||||||
| Proceeds from issuance of convertible preferred stock, net of issuance costs and exercise of warrants | — | — | 61 | |||||||||
| Proceeds from issuance of common stock and exercise of stock options and warrants | 4,372 | 75,601 | 48,284 | |||||||||
| Repurchases of common stock | (82 | ) | (13 | ) | (11 | ) | ||||||
| Proceeds from repayment of promissory notes from a stockholder | 33 | 125 | — | |||||||||
| Proceeds from equipment financing obligations | — | — | 84 | |||||||||
| Payments on capital leases and equipment financing obligations | (500 | ) | (713 | ) | (1,083 | ) | ||||||
| Net cash provided by financing activities | 3,823 | 75,000 | 47,335 | |||||||||
| Net increase (decrease) in cash and cash equivalents | 3,104 | (7,231 | ) | (14,466 | ) | |||||||
| Cash and cash equivalents at beginning of period | 14,857 | 22,088 | 36,554 | |||||||||
| Cash and cash equivalents at end of period | $ | 17,961 | $ | 14,857 | $ | 22,088 | ||||||
Supplemental schedule of noncash investing and financing activities | ||||||||||||
| Issuance of common stock in exchange for notes receivable from stockholders | $ | — | $ | — | $ | 402 | ||||||
| Conversion of preferred stock to common stock upon initial public offering | $ | — | $ | — | $ | 149,944 | ||||||
| Issuance of common stock in a cashless exercise of a warrant | $ | — | $ | — | $ | 12 | ||||||
| Reclassification of the unvested portion of common stock from early exercises of stock options to a liability | $ | 8 | $ | 9 | $ | 621 | ||||||
| Vesting of common stock from early exercises of stock options | $ | 351 | $ | 504 | $ | 452 | ||||||
| Deferred stock compensation, net of forfeitures | $ | — | $ | — | $ | 4,330 | ||||||
| Stock dividends payable to preferred stockholders | $ | — | $ | — | $ | 969 | ||||||
| Disposal of property and equipment at no gain or loss | $ | — | $ | 6,300 | $ | 49 | ||||||
Supplemental disclosure of cash flow information | ||||||||||||
| Interest paid | $ | 48 | $ | 122 | $ | 187 | ||||||
| Income taxes paid | $ | 794 | $ | — | $ | — | ||||||
The accompanying notes are an integral part of these financial statements.
86
Table of Contents
XENOPORT, INC.
NOTES TO FINANCIAL STATEMENTS
| 1. | Organization and Summary of Significant Accounting Policies |
Nature of Operations
XenoPort, Inc., or the Company, was incorporated in the state of Delaware on May 19, 1999. The Company is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs, with an emerging focus on potential treatments of central nervous system, or CNS, disorders. Its facilities are located in Santa Clara, California.
Use of Estimates
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.
Fair Value of Financial Instruments
The carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents and short-term investments, approximate fair value due to their short maturities. Based on borrowing rates currently available to the Company for loans and capital lease obligations with similar terms, the carrying value of the Company’s debt obligations approximates fair value.
Cash Equivalents and Short-Term Investments
The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents, which consist of money market funds, U.S. government debt securities, corporate debt securities and certificates of deposit.
Management determines the appropriate classification of securities at the time of purchase. All investments have been designated as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company has classified all investments as short-term, even though the stated maturity may be one year or more beyond the current balance sheet date. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity.
The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities, if any, are recorded in interest income and expense. The cost of securities sold is based on the specific-identification method. Interest and dividends are included in interest income.
Restricted Investments
Under a facilities operating lease agreement, the Company is required to secure a letter of credit with cash or securities. At December 31, 2007 and 2006, the Company recorded $1,607,000 and $1,541,000, respectively, of restricted investments related to the letter of credit (see Note 6).
In connection with the Company’s license to use radioactive materials in its research facilities, it must maintain a $150,000 letter of credit with the Radiological Health Branch of the State of California. This requirement has been fulfilled through a certificate of deposit with a financial institution. The fair value of the secured amount of $164,000 and $158,000 was classified as restricted investments on the accompanying balance sheets at December 31, 2007 and 2006, respectively.
87
Table of Contents
Concentrations of Risk
The Company invests cash that is not currently being used for operational purposes in accordance with its investment policy. The policy allows for the purchase of low risk debt securities issued by U.S. government agencies and very highly rated banks and corporations, subject to certain concentration limits. The maturities of these securities are maintained at no longer than 18 months. The Company believes its established guidelines for investment of its excess cash maintains safety and liquidity through its policies on diversification and investment maturity.
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and available-for-sale investment securities in high-credit quality debt securities issued by the U.S. government and government-sponsored enterprises. The carrying amounts of cash equivalents and available-for-sale investment securities approximate fair value due to their short-term nature. The carrying amounts of borrowings under the Company’s debt facilities approximate fair value based on the current interest rates for similar borrowing arrangements.
The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents and available-for-sale securities to the extent of the amounts recorded on the balance sheets.
The Company does not currently own or operate manufacturing facilities, and the Company relies and expects to continue to rely on a small number of third-party compound manufacturers and active pharmaceutical ingredient formulators for the production of clinical and commercial quantities of product candidates. The Company does not have long-term agreements with any of these third parties, and the agreements with these parties are generally terminable at will by either party at any time. If, for any reason, these third parties are unable or unwilling to perform under these agreements or enter into new agreements, the Company may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities of the Company’s product candidates in a timely manner from these third parties could delay clinical trials and prevent the Company or its partners from developing and commercializing their product candidates in a cost-effective manner or on a timely basis. In particular, Teva Pharmaceutical Industries, Ltd., Lonza Ltd., Patheon Pharmaceuticals, Inc., Heumann Pharma GmbH, Catalent Pharma Solutions, LLC (formerly Cardinal Health PTS, LLC), Xcelience, LLC, Ajinomoto Company, Raylo Chemicals, Inc., a subsidiary of Gilead Sciences, Inc., and UPM Pharmaceuticals, Inc. are all sole suppliers for various products used in the production of clinical and commercial product candidates.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Equipment under capital leases and leasehold improvements are amortized over their estimated useful lives or the remaining lease term, whichever is shorter.
Long-Lived Assets
The Company periodically assesses the impairment of long-lived assets in accordance with Statement of Financial Accounting Standards, or SFAS, No. 144,Accounting for the Impairment or Disposal of Long-Lived Assets.The Company reviews long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If indicators of impairment exist, impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. The impairment charge is determined based on the excess of the carrying value of the asset over its fair value, with fair value determined based on an estimate of discounted future cash flows or other appropriate measure of fair value. Since inception, the Company has not recorded any impairment charges.
Revenue Recognition
Revenue arrangements are accounted for in accordance with the provisions of Securities and Exchange Commission, or SEC, Staff Accounting Bulletin, or SAB, No. 104,Revenue Recognition, and Emerging Issues Task
88
Table of Contents
Force, or EITF,No. 00-21,Revenue Arrangements with Multiple Deliverables. A variety of factors are considered in determining the appropriate method of revenue recognition under these arrangements, such as whether the various elements can be considered separate units of accounting, whether there is objective and reliable evidence of fair value for these elements and whether there is a separate earnings process associated with a particular element of an agreement. Specifically, the Company accounts for each of these typical elements as follows:
| • | Up-front, licensing-type fees. Up-front, licensing-type payments are assessed to determine whether or not the licensee is able to obtain any stand-alone value from the license. Where this is not the case, the Company does not consider the license deliverable to be a separate unit of accounting, and the revenue is deferred with revenue recognition for the license fee being assessed in conjunction with the other deliverables that constitute the combined unit of accounting. | |
| • | Milestones. Milestones are assessed on an individual basis and revenue is recognized from these milestones when earned, as evidenced by acknowledgment from collaborators, provided that (i) the milestone event is substantive and its achievability was not reasonably assured at the inception of the agreement, (ii) the milestone represents the culmination, or progress towards the culmination, of an earnings process and (iii) the milestone payment is non-refundable. Where separate milestones do not meet these criteria, the Company typically defaults to a performance-based model, with revenue recognition following delivery of effort as compared to an estimate of total expected effort. Milestones that are received after all substantive deliverables have occurred are considered to be bonus payments and are recognized upon receipt of the cash, assuming all of the other revenue recognition criteria are met. | |
| • | Collaborative research payments. Generally, the payments received are based on a contractual cost per full-time equivalent employee working on the project, and are recognized as the services are performed over the related funding periods for each agreement. | |
| • | Grant revenues. Grant revenues are recognized as research is performed. |
Where there are multiple deliverables combined as a single unit of accounting, revenues are deferred and recognized over the period which the Company remains obligated to perform services or deliver product. The specific methodology for the recognition of the revenue (e.g., straight-line or according to specific performance criteria) is determined on acase-by-case basis according to the facts and circumstances applicable to a given contract. For contracts with specific performance criteria, the Company utilizes the performance-based expected revenue method of revenue recognition, which requires that the Company estimate the total amount of costs to be expended for a given unit of accounting and then recognize revenue equal to the portion of costs expended to date. The estimated total costs to be expended are necessarily subject to revision from time-to-time as the underlying facts and circumstances change.
Payments received in excess of revenues recognized are recorded as deferred revenue until such time as the revenue recognition criteria have been met.
The Company’s collaboration agreements also include potential payments for commercial product supply, product royalties and sharing of operating profits. To date, no revenues have been received from these sources.
Research and Development
All research and development costs, including those funded by third parties, are expensed as incurred. Research and development costs consist of salaries, employee benefits, laboratory supplies, costs associated with clinical trials, including amounts paid to clinical research organizations, other professional services and facility costs.
Clinical Trials
The Company accrues and expenses the costs for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with contract research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to progress or stage of
89
Table of Contents
completion of trials or services and the agreed upon fee to be paid for such services. Costs of setting up clinical trial sites for participation in the trials are expensed immediately as research and development expenses. Clinical trial site costs related to patient enrollment are accrued as patients are entered into the trial and reduced by any initial payment made to the clinical trial site when the first patient is enrolled.
Stock-Based Compensation
Effective January 1, 2006, the Company adopted the provisions of SFAS No. 123R,Share-Based Payment, or SFAS 123R. SFAS 123R establishes accounting for stock-based awards exchanged for employee services. Accordingly, for stock options and stock purchase rights granted under the 2005 Employee Stock Purchase Plan, or the ESPP, stock-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the requisite employee service period. The Company previously applied Accounting Principles Board Opinion No. 25,Accounting for Stock Issued to Employees, or APB 25, and related interpretations and provided the required pro forma disclosures of SFAS No. 123,Accounting for Stock Compensation, or SFAS 123.
Prior to the Adoption of SFAS 123R
Prior to the adoption of SFAS 123R, the Company accounted for stock-based employee compensation arrangements using the intrinsic value method in accordance with the provisions of APB 25, and related interpretations, and provided the disclosures required under SFAS 123, as amended by SFAS No. 148,Accounting for Stock-Based Compensation — Transition and Disclosures.Prior to the Company’s initial public offering in June 2005, the Company had granted certain stock options with exercise prices that were below the estimated fair value of the common stock at the date of grant. During the year ended December 31, 2005, the Company recorded employee stock-based compensation expense associated with the amortization of deferred stock compensation of $2,403,000.
The following table illustrates the effects on net loss if the Company had applied the fair value recognition provisions of SFAS 123 to all employee stock options:
| Year Ended | ||||
| December 31, 2005 | ||||
| (In thousands, except | ||||
| per share amounts) | ||||
| Net loss, as reported | $ | (42,909 | ) | |
| Add: Stock-based employee compensation expense based on intrinsic value method | 2,531 | |||
| Less: Stock-based employee compensation expense determined under the fair value method | (5,245 | ) | ||
| Pro forma net loss | (45,623 | ) | ||
| Convertible preferred stock dividends | (969 | ) | ||
| Pro forma net loss | $ | (46,592 | ) | |
| Loss per share: | ||||
| Basic and diluted, as reported | $ | (3.69 | ) | |
| Basic and diluted, pro forma | $ | (3.92 | ) | |
Impact of the Adoption of SFAS 123R
The Company elected to adopt SFAS 123R using the modified prospective application method, which was applied to the unvested portion of options granted prior to January 1, 2006 and all options granted after January 1, 2006. Accordingly, during the year ended December 31, 2006, the Company recorded stock-based compensation expense totaling the amount that would have been recognized had the fair value method been applied since the
90
Table of Contents
effective date of SFAS 123. Previously reported amounts have not been restated. The effect of recording stock-based compensation under SFAS 123R was as follows:
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | |||||||||||
| (In thousands, except per | ||||||||||||
| share amounts) | ||||||||||||
| Stock-based compensation by type of award: | ||||||||||||
| Employee stock options | $ | 8,470 | $ | 5,048 | ||||||||
| ESPP | 452 | 329 | ||||||||||
| Non-employee stock options | 17 | 198 | ||||||||||
| Total stock-based compensation | $ | 8,939 | $ | 5,575 | ||||||||
| Effect on basic income (loss) per share | $ | 0.36 | $ | (0.25 | ) | |||||||
| Effect on diluted income (loss) per share | $ | 0.34 | $ | (0.25 | ) | |||||||
| Tax effect on basic income (loss) per share | $ | 0.01 | $ | — | ||||||||
| Tax effect on diluted income (loss) per share | $ | 0.01 | $ | — | ||||||||
Upon the adoption of SFAS 123R on January 1, 2006, the Company reversed all of the existing balance of deferred stock compensation of $4,821,000 with a corresponding reduction in additional paid-in capital.
Upon the adoption of SFAS 123R, as of January 1, 2006, the total compensation cost related to unvested awards was $4,703,000, before estimated forfeitures, which were not significant. In the Company’s pro forma disclosures prior to the adoption of SFAS 123R, the Company accounted for forfeitures upon occurrence. SFAS 123R requires forfeitures to be estimated at the time of grant and revised if necessary in subsequent periods if actual forfeitures differ from those estimates.
Details of the Company’s employee stock-based compensation are as follows:
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| (In thousands) | ||||||||||||
| Research and development | $ | 5,044 | $ | 2,782 | $ | 849 | ||||||
| General and administrative | 3,878 | 2,595 | 1,554 | |||||||||
| $ | 8,922 | $ | 5,377 | $ | 2,403 | |||||||
Valuation Assumptions
The Company estimates the fair value of all of its stock options and stock purchase rights on the date of grant using a Black-Scholes valuation model, consistent with the provisions of SFAS 123R and Staff Accounting Bulleting 107, or SAB 107, and the Company expenses the resulting charge using the straight-line attribution
91
Table of Contents
method over the vesting period. The calculation of the Black-Scholes valuations used the followingweighted-average assumptions:
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| Dividend yield | 0 | % | 0 | % | 0 | % | ||||||
| Volatility for options | 0.63 | 0.70 | 0.75 | |||||||||
| Volatility for ESPP | 0.55 | 0.51 | 0.46 | |||||||||
| Weighted-average expected life of options (years) | 4.69 | 4.83 | 5 | |||||||||
| Weighted-average expected life of ESPP rights (years) | 0.5 | 0.5 | 0.5 | |||||||||
| Risk-free interest rate for options | 3.49-5.03 | % | 4.35-5.07 | % | 3.87-4.29 | % | ||||||
| Risk-free interest rate for ESPP rights | 4.55-5.15 | % | 3.69-5.15 | % | 3.69 | % | ||||||
SFAS 123R requires the use of option-pricing models that were not developed for use in valuing employee stock options. The Black-Scholes option-pricing model was developed for use in estimating the fair value of short-lived exchange traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The Company derives the expected stock price volatility and the weighted-average expected life assumptions using data obtained from similar entities, taking into consideration factors such as industry, stage of life cycle, size and financial leverage. The risk-free interest rate input is based on the U.S. Treasury yield curve in effect at the time of grant. Prior to the adoption of SFAS 123R, the Company had also used this approach in calculating its expected stock price volatility, weighted-average expected life and risk-free interest rate assumptions.
Income Taxes
Income tax expense is accounted for in accordance with SFAS No. 109,Accounting of Income Taxes, or SFAS 109. Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.
Effective January 1, 2007, the Company adopted the provisions of Financial Accounting Standard Board, Financial Interpretation No. 48,Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109,or FIN 48. FIN 48 specifies how tax benefits for uncertain tax positions are to be recognized, measured and derecognized in financial statements; requires certain disclosures of uncertain tax matters; specifies how reserves for uncertain tax positions should be classified on the balance sheet; and provides transition and interim-period guidance, among other provisions.
At the date of adoption of FIN 48, the Company had no unrecognized tax benefits and expected no significant changes in unrecognized tax benefits in the next 12 months.
The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes.
Comprehensive Income (Loss)
The Company displays comprehensive income (loss) and its components as part of the statements of convertible preferred stock and stockholders’ equity (deficit). Comprehensive income (loss) is comprised of net income (loss) and unrealized gains (losses) onavailable-for-sale securities.
92
Table of Contents
Income (loss) Per Share Applicable to Common Stockholders
Basic income (loss) per share applicable to common stockholders is calculated by dividing the income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding for the period less the weighted-average unvested common shares subject to repurchase, without consideration for potential common shares. Diluted income (loss) per share applicable to common stockholders is computed by dividing the income (loss) applicable to common stockholders by the weighted-average number of common shares outstanding for the period less the weighted-average unvested common shares subject to repurchase and dilutive potential common shares for the period determined using the treasury-stock method. For purposes of this calculation, preferred stock, options to purchase stock and warrants are considered to be potential common shares and are only included in the calculation of diluted income (loss) per share applicable to common stockholders when their effect is dilutive.
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| (In thousands, except | ||||||||||||
| per share amounts) | ||||||||||||
| Numerator: | ||||||||||||
| Income (loss) applicable to common stockholders | $ | 28,193 | $ | (64,313 | ) | $ | (43,878 | ) | ||||
| Denominator: | ||||||||||||
| Weighted-average common shares outstanding | 24,893 | 22,372 | 12,402 | |||||||||
| Less: Weighted-average unvested common shares subject to repurchase | (120 | ) | (271 | ) | (504 | ) | ||||||
| Denominator for basic income (loss) per share applicable to common stockholders | 24,773 | 22,101 | 11,898 | |||||||||
| Dilutive effect of: | ||||||||||||
| Restricted stock units and options to purchase common stock | 1,202 | — | — | |||||||||
| Warrants outstanding | 17 | — | — | |||||||||
| Denominator for diluted income (loss) per share applicable to common stockholders | 25,992 | 22,101 | 11,898 | |||||||||
| Basic income (loss) per share applicable to common stockholders | $ | 1.14 | $ | (2.91 | ) | $ | (3.69 | ) | ||||
| Diluted income (loss) per share applicable to common stockholders | $ | 1.08 | $ | (2.91 | ) | $ | (3.69 | ) | ||||
Outstanding dilutive securities not included in the computation of diluted income (loss) per share applicable to common stockholders as they had an antidilutive effect: | ||||||||||||
| Restricted stock units and options to purchase common stock | 447 | 2,254 | 1,624 | |||||||||
| Warrants outstanding | — | 39 | 39 | |||||||||
| 447 | 2,293 | 1,663 | ||||||||||
Recent Accounting Pronouncements
In June 2007, the EITF reached a consensus on EITFNo. 07-03,Accounting for Nonrefundable Advance Payments for Goods or Services to Be Used in Future Research and Development Activities, orEITF 07-03.EITF 07-03 specifies the timing of expense recognition for non-refundable advance payments for goods or services that will be used or rendered for research and development activities.EITF 07-03 is effective for fiscal years beginning after December 15, 2007, and early adoption is not permitted. As a result,EITF 07-03 is effective for the Company in the first quarter of fiscal 2008. The Company does not expect the adoption ofEITF 07-03 to have a material impact on either its financial position or results of operations.
93
Table of Contents
In December 2007, the EITF reached a consensus on EITFNo. 07-01,Accounting for Collaborative Arrangements Related to the Development and Commercialization of Intellectual Property, orEITF 07-01.EITF 07-01 discusses the appropriate income statement presentation and classification for the activities and payments between the participants in arrangements related to the development and commercialization of intellectual property. The sufficiency of disclosure related to these arrangements is also specified.EITF 07-01 is effective for fiscal years beginning after December 15, 2008. As a result,EITF 07-01 is effective for the Company in the first quarter of fiscal 2009. The Company does not expect the adoption ofEITF 07-01 to have a material impact on either its financial position or results of operations.
| 2. | Collaboration Agreements |
The Company entered into collaborations with ALZA Corporation and Pfizer Inc in December 2002 and November 2003, respectively. These collaborations included non-refundable, up-front fees, research funding fees, as well as the potential to earn milestone payments and royalties. Obligations under these collaborations had been discharged by December 31, 2005.
In December 2005, the Company entered into a license agreement with Astellas Pharma Inc. for exclusive rights in the Astellas territory to develop and commercialize XP13512. The Company received an initial license payment of $25,000,000 in December 2005, which has been deferred and is being recognized on a straight-line basis over a period that approximates the expected patent life of XP13512. In April 2006, the Company received a milestone payment of $10,000,000 upon initiation of the Company’s first Phase 3 clinical trial of XP13512 in restless legs syndrome, or RLS, patients in the United States that was recognized on a straight-line basis over the period of the Phase 3 clinical trial. In May 2007, the Company received and recognized a milestone payment of $5,000,000 upon completion of the Company’s first Phase 3 clinical trial of XP13512 in RLS. In addition, the Company is eligible to receive potential clinical and regulatory milestone payments totaling up to $45,000,000 and is entitled to receive percentage-based royalties on any sales of XP13512 in the Astellas territory. In the year ended December 31, 2007, the Company recognized revenue of $7,424,000, representing amortization of the up-front license payment and the first milestone payment as well as recognition of the second milestone payment under this agreement. At December 31, 2007, $21,843,000 of revenue was deferred under this agreement, of which $1,515,000 was classified within current liabilities and the remaining $20,328,000 was recorded as a noncurrent liability. In addition, the agreement also requires Astellas to source all product from the Company under a specified supply agreement and Astellas may request the Company to conduct development activities. In the years ended December 31, 2007, 2006 and 2005, the Company recorded reimbursements of $7,058,000, $3,372,000 and $0, respectively, under the supply arrangement and the requested development activities as an offset to research and development expenses.
In February 2007, the Company entered into an exclusive collaboration with Glaxo Group Limited, or GSK, to develop and commercialize XP13512 worldwide, excluding the Astellas territory (collectively referred to as the GSK territory). In March 2007, GSK made an up-front, non-refundable license payment of $75,000,000. In addition, GSK has agreed to make additional payments of up to $275,000,000 upon the achievement of additional clinical and regulatory milestones, of which $32,000,000 has been received to date including milestone payments of $10,000,000, $11,000,000 and $11,000,000 received in May, June and November 2007, respectively, and up to $290,000,000 upon the achievement of specified XP13512 sales levels. Under the terms of the agreement, GSK is responsible for all future development costs, with the exception of specified development costs that the Company will assume in connection with the development of XP13512 for RLS in the United States and GSK is solely responsible for the manufacturing of XP13512 to support its development and commercialization within the GSK territory. In 2007, the Company transferred XP13512 manufacturing responsibilities for the GSK territory to GSK. In addition, the Company received a non-recurring reimbursement of $3,600,000 related to the transfer of XP13512 drug substance to GSK, which the Company recorded as an offset to research and development expenses. Under the terms of the agreement, the Company is entitled to receive royalties based upon a percentage of sales of XP13512 in the GSK territory for a specified period of time, unless the Company elects the option to co-promote XP13512 in the United States. In the event that the Company elects the co-promotion option for XP13512, the Company would share marketing and commercialization costs and would be entitled to a share of operating profits from sales of XP13512 in the United States for so long as XP13512 is sold, as well as receive payments on details that the
94
Table of Contents
Company performs in the United States on Requip XL, GSK’s development-stage product candidate for Parkinson’s disease. Subject to U.S. Food and Drug Administration, or FDA, approval of the new drug application, or NDA, for XP13512, the Company would co-promote XP13512 in the United States to those same prescribers. The Company has concluded that the up-front license payment does not have value to GSK on a stand-alone basis without the benefit of the specified development activities that the Company will perform in connection with XP13512 and that $65,000,000 of milestones payable for clinical trial and pre-clinical activities were either not sufficiently substantive or not sufficiently at risk to be accounted for using the “when-earned” model. Accordingly, these milestones and the up-front payment were combined into a separate unit of accounting that is being recognized over the best estimate of the development period to commercialization of the product during which time delivery of substantially all of the efforts required for the completion of the Company’s contractual responsibilities under the GSK agreement is expected to occur. In the year ended December 31, 2007, the Company recognized revenue of $104,898,000 under this agreement. At December 31, 2007, $2,102,000 of revenue was deferred under this agreement and was classified within current liabilities.
In October 2007, the Company entered into an exclusive license agreement for the development and commercialization of XP21510 in the United States by Xanodyne Pharmaceuticals, Inc. for the potential treatment of women diagnosed with menorrhagia. In exchange for these rights, the Company is entitled to receive up-front, non-refundable cash payments totaling $12,000,000, of which $6,000,000 was paid to the Company upon execution of the agreement and the remaining $6,000,000 is due on the12-month anniversary of the execution date. The Company is eligible to receive aggregate cash payments of up to $130,000,000 upon the achievement of certain development, regulatory and commercial milestones with respect to XP21510, as well as aggregate cash payments of up to $5,000,000 upon the achievement of certain development, regulatory and commercial milestones with respect to Xanodyne’s tranexamic acid product candidate, known as XP12B, that is in Phase 3 clinical development. In addition, the Company is entitled to receive tiered, double-digit royalty payments on potential future sales of XP21510, as well as escalating single-digit royalties on potential future sales of XP12B. In the year ended December 31, 2007, the Company recognized revenue of $1,500,000 under this agreement. At December 31, 2007, $4,500,000 of revenue was deferred under this agreement and was classified within current liabilities.
The following table presents the Company’s total revenue that has been recognized pursuant to all of its collaborations (in thousands):
| Year Ended December 31, | ||||||||||||
| 2007 | 2006 | 2005 | ||||||||||
| ALZA | $ | — | $ | — | $ | 1,895 | ||||||
| Pfizer | — | — | 2,646 | |||||||||
| Astellas | 7,424 | 10,606 | 126 | |||||||||
| GSK | 104,898 | — | — | |||||||||
| Xanodyne | 1,500 | — | — | |||||||||
| $ | 113,822 | $ | 10,606 | $ | 4,667 | |||||||
The Company’s accounts receivable balance is comprised of trade receivables from its collaborative research agreements. At December 31, 2007 and 2006, Astellas represented 100% of accounts receivable.
95
Table of Contents
| 3. | Cash and Cash Equivalents, Short-Term Investments and Restricted Investments |
The following are summaries of cash and cash equivalents, short-term investments and restricted investments (in thousands):
| Gross | ||||||||||||
| Unrealized Gains | Estimated | |||||||||||
| Cost | (Losses) | Fair Value | ||||||||||
| As of December 31, 2007: | ||||||||||||
| Cash | $ | 1,770 | $ | — | $ | 1,770 | ||||||
| Money market funds | 10,104 | — | 10,104 | |||||||||
| Corporate debt securities | 147,776 | 491 | 148,267 | |||||||||
| Certificate of deposit | 1,771 | — | 1,771 | |||||||||
| $ | 161,421 | $ | 491 | $ | 161,912 | |||||||
| Reported as: | ||||||||||||
| Cash and cash equivalents | $ | 17,961 | ||||||||||
| Short-term investments | 142,180 | |||||||||||
| Restricted investments | 1,771 | |||||||||||
| $ | 161,912 | |||||||||||
| Gross | ||||||||||||
| Unrealized Gains | Estimated | |||||||||||
| Cost | (Losses) | Fair Value | ||||||||||
| As of December 31, 2006: | ||||||||||||
| Cash | $ | 3,048 | $ | — | $ | 3,048 | ||||||
| Money market funds | 11,809 | — | 11,809 | |||||||||
| Corporate debt securities | 103,960 | 37 | 103,997 | |||||||||
| Certificate of deposit | 1,699 | — | 1,699 | |||||||||
| $ | 120,516 | $ | 37 | $ | 120,553 | |||||||
| Reported as: | ||||||||||||
| Cash and cash equivalents | $ | 14,857 | ||||||||||
| Short-term investments | 103,997 | |||||||||||
| Restricted investments | 1,699 | |||||||||||
| $ | 120,553 | |||||||||||
At December 31, 2007 and 2006, the contractual maturities of all investments held were less than one year. There were no gross realized gains or losses from sales or maturities of securities in the periods presented.
96
Table of Contents
| 4. | Property and Equipment |
Property and equipment consist of the following (in thousands):
| December 31, | ||||||||
| 2007 | 2006 | |||||||
| Laboratory equipment | $ | 8,021 | $ | 5,332 | ||||
| Furniture and fixtures | 935 | 168 | ||||||
| Computer equipment and software | 1,961 | 691 | ||||||
| Leasehold improvements | 2,238 | 2,021 | ||||||
| Construction in-progress | 307 | — | ||||||
| 13,462 | 8,212 | |||||||
| Less: Accumulated depreciation and amortization | (6,671 | ) | (4,680 | ) | ||||
| Property and equipment, net | $ | 6,791 | $ | 3,532 | ||||
| 5. | Employee Notes Receivable |
At December 31, 2007 and 2006, the Company had outstanding full recourse notes receivable totaling $250,000 and $450,000, respectively, to employees and officers to finance the purchases of personal assets. The notes are secured by the deeds of trust on the residences of the employees and officers and require interest at rates ranging from 4.13% to 4.99% per annum. The principal and any accrued interest on the notes are payable on the earlier of termination of employment or seven years from the date of issuance. The maturity dates range from December 2008 to May 2009. Accrued interest is forgiven on each note’s anniversary date.
| 6. | Commitments and Contingencies |
Operating Leases
The Company has entered into an operating lease arrangement for office and laboratory space in Santa Clara, California. The Santa Clara operating lease, which commenced in December 2001, has an initial term of ten years, may be extended at the end of the term for two additional periods of five years each and contains contractual rent escalation over the life of the lease. The Company is recognizing rent expense evenly over the lease term. Deferred rent of $1,696,000 and $1,811,000 at December 31, 2007 and 2006, respectively, represents the difference between rent expense recognized and actual cash payments related to the Company’s operating lease.
In connection with the Santa Clara operating lease, the Company entered into a letter of credit agreement in the amount of $3,000,000 with a financial institution that required the Company, at its option, to secure the letter of credit with either $3,000,000 of cash or certificate of deposit, or securities with a fair market value of at least $3,750,000. Under the terms of the operating lease agreement, the amount of the letter of credit was reduced to $1,500,000 in December 2006. The fair value of the certificate of deposit is presented as restricted investments on the balance sheet at $1,607,000 and $1,541,000, at December 31, 2007 and 2006, respectively. This letter of credit will be required until the termination of the lease.
In April 2004, the Company entered into a sublease agreement to rent out a portion of its facilities not in use. The sublease agreement provided for monthly rental income of $52,000 for the first year and $66,000 monthly rental income for the second year, with a one-year extension at the end of the two-year term. In 2005, thesub-tenant exercised its option to extend the lease for another year. In January 2007, the Company entered into an agreement with the subtenant to terminate the sublease effective January 31, 2007. The Company recorded the monthly sublease income as an offset to rent expense. Sublease income recorded for the years ended December 31, 2007, 2006 and 2005 was $81,000, $822,000 and $744,000, respectively.
Rent expense, net of sublease income, was $3,630,000, $2,894,000 and $2,972,000 for the years ended December 31, 2007, 2006 and 2005, respectively.
97
Table of Contents
At December 31, 2007, future minimum payments under all non-cancelable operating leases were as follows (in thousands):
| Year ending December 31: | ||||||||
| 2008 | $ | 3,956 | ||||||
| 2009 | 4,085 | |||||||
| 2010 | 4,218 | |||||||
| 2011 | 3,981 | |||||||
| Total minimum lease payments | $ | 16,240 | ||||||
Equipment Financing Obligations
In July 2004, the Company entered into an equipment financing arrangement for borrowings of up to $1,800,000. Interest is based on a 36- or48-month U.S. Treasury note yield plus 5.75% or 5.55%, respectively. Obligations under the arrangement are secured by assets financed, and repayment terms are monthly over 36 to 48 months. In conjunction with this arrangement, the Company issued to the lender a warrant to purchase 1,041 shares of the Company’s Series C convertible preferred stock at $15.00 per share. The arrangement expired in May 2005, thus at December 31, 2007, no funds were available for future draw down. At December 31, 2007 and 2006, $181,000 and $654,000, respectively, were outstanding under this arrangement.
At December 31, 2007, future minimum principal payments under equipment financing arrangements were as follows (in thousands):
| Equipment | ||||
| Financing | ||||
| Arrangements | ||||
| Year ending December 31: | ||||
| 2008 | $ | 176 | ||
| 2009 | 5 | |||
| Total minimum payments required | 181 | |||
| Less: Current portion | (176 | ) | ||
| Noncurrent portion | $ | 5 | ||
In connection with the equipment financing arrangements, the Company is restricted from paying cash dividends or distributions on any equity with the exception of dividends payable solely in common stock.
Guarantees and Indemnifications
The Company, as permitted under Delaware law and in accordance with its bylaws, indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The Company may terminate the indemnification agreements with its officers and directors upon 90 days’ written notice, but termination will not affect claims for indemnification relating to events occurring prior to the effective date of termination. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future amounts paid. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company had not recorded any liabilities for these agreements as of December 31, 2007.
Contingencies
From time to time, the Company may become involved in claims and other legal matters arising in the ordinary course of business. Management is not currently aware of any matters that will have a material adverse affect on the financial position, results of operations or cash flows of the Company.
98
Table of Contents
| 7. | Stockholders’ Equity |
Common Stock
At December 31, 2007 and 2006, the Company was authorized to issue 60,000,000 shares of common stock.
Stockholders’ Rights Plan
On December 16, 2005, the Company adopted a preferred stock rights plan pursuant to which each share of common stock outstanding on January 13, 2006, and each subsequently issued share, will receive a non-taxable dividend. The dividend will confer the purchase right, or a right, that confers the right to purchase one one-hundredth of a share of a new class of preferred stock and will be exercisable only if a person or group acquires 15% or more of the Company’s common stock or announces a tender offer for 15% or more of the Company’s common stock. If such a person acquires 15% or more of the Company’s common stock, all rights holders, except the 15% acquiror, will be entitled to acquire the Company’s common stock at a discount through the exercise of the preferred stock. The rights plan has been designed to discourage acquisitions of more than 15% of the Company’s common stock without negotiations with the board of directors. The rights expire on January 13, 2016. The rights will trade with the Company’s common stock, unless and until they are separated upon the occurrence of certain future events. The board of directors may terminate the rights plan at any time or redeem the rights prior to the time the rights are triggered
Equity Incentive Plans
1999 Stock Plan
Under the terms of the 1999 Stock Plan, or the 1999 Plan, options or stock purchase rights were granted by the board of directors to employees, directors and consultants. Options granted were either incentive stock options or non-statutory stock options. Incentive stock options were granted to employees with exercise prices of no less than the fair value, and non-statutory options were granted to employees, directors or consultants at exercise prices of no less than 85% of the fair value, of the common stock on the grant date as determined by the board of directors. Options vest as determined by the board of directors, generally at the rate of 25% at the end of the first year, with the remaining balance vesting ratably over the next three years for initial employee grants and ratably over four years for subsequent grants. Options granted under the 1999 Plan expire no more than ten years after the date of grant.
Stock purchased under stock purchase rights, in connection with the 1999 Plan, is subject to a repurchase option by the Company upon termination of the purchaser’s employment or services. The repurchase right lapses over a period of time as determined by the board of directors.
The 1999 Plan allows for the early exercise of options prior to vesting. In accordance with EITFNo. 00-23,Issues Related to Accounting for Stock Compensation under APB Opinion No. 25 and FASB Interpretation No. 44, stock options granted or modified after March 21, 2002 that are subsequently exercised for cash prior to vesting are not deemed to be issued until those shares vest. Since March 21, 2002, the Company has issued an aggregate of 479,322 shares of common stock pursuant to the early exercise of stock options. As of December 31, 2007 and 2006, there were 30,139 and 139,000, respectively, of these shares issued subject to the Company’s right to repurchase at the original issuance price. The amounts received in exchange for these shares have been recorded as a liability for early exercise of stock options in the accompanying balance sheets and will be reclassified into equity as the shares vest.
Subsequent to the initial public offering of the Company’s stock in June 2005, no further options will be granted under the 1999 Plan. At the date of the initial public offering, the 64,617 shares remaining and available for future grant were cancelled.
2005 Equity Incentive Plan
In January 2005, the Company’s board of directors adopted the 2005 Equity Incentive Plan, or the 2005 Plan. Under the terms of the 2005 Plan, options, stock purchase rights, stock bonus rights, stock appreciation rights and other stock awards and rights may be granted by the board of directors to employees, directors and consultants.
99
Table of Contents
Options granted may be either incentive stock options or non-statutory stock options. Incentive stock options may be granted to employees with exercise prices of no less than the fair value, and non-statutory options may be granted to employees, directors or consultants at exercise prices of no less than 85% of the fair value, of the common stock on the grant date. Options vest as determined by the board of directors, generally at the rate of 25% at the end of the first year, with the remaining balance vesting ratably over the next three years for initial employee grants and ratably over four years for subsequent grants. Options granted under the 2005 Plan expire no more than ten years after the date of grant.
In January 2007, the Company’s board of directors approved the use of grants of restricted stock units to employees under the 2005 Plan as part of the Company’s long-term incentive compensation program. Restricted stock units have no exercise price, are valued using the closing market price on the date of grant and vest as determined by the board of directors, typically in annual tranches over a three-year period at the rate of 25% at the end of each of the first and second years and 50% at the end of the third year.
Stock purchase rights, stock bonus rights, stock appreciation rights and other stock awards and rights may be granted by the board of directors to employees, directors and consultants and may be subject to such terms and conditions as the board of directors deems appropriate, although such awards may not be granted with a purchase price below the par value of the stock. Under the terms of the 2005 Plan, the maximum number of shares that may be issued shall not exceed the total of 2,000,000, plus any shares issuable from options previously granted from the 1999 Plan at the date of the Company’s initial public offering, plus an annual increase equal to the lesser of (i) 2.5% of the total number of common shares outstanding at the end of the preceding calendar year and (ii) 2,000,000 common shares. During the year ended December 31, 2007, the annual increase to the 2005 Plan reserve was 617,663 shares. At December 31, 2007 and 2006, there were 1,268,627 and 1,395,202 shares, respectively, remaining and available for future grant under the 2005 Plan.
2005 Non-Employee Directors’ Stock Option Plan
In January 2005, the Company’s board of directors adopted the 2005 Non-Employee Directors’ Stock Option Plan, or the 2005 Directors’ Plan, under which non-statutory options are automatically granted to non-employee directors. Any individual who first becomes a non-employee director automatically receives an option to purchase 25,000 shares subject to vesting in four equal successive annual installments. Non-employee directors serving on the date of each annual meeting of stockholders receive an option to purchase 10,000 shares subject to vesting in 12 successive equal monthly installments measured from the grant date. Stock options may be granted at exercises prices no less than the fair value on the grant date and may expire no more than ten years after the date of grant. Under the terms of the 2005 Directors’ Plan, the maximum number of shares that may be issued shall not exceed the total of 150,000, plus an annual increase equal to the excess of (i) the number of shares subject to options granted in the preceding calendar year, over (ii) the number of shares added back to the share reserve from cancellations, provided that such increase shall not exceed 150,000 shares. During the year ended December 31, 2007, the annual increase to the 2005 Directors’ Plan reserve was 70,000 shares. At December 31, 2007 and 2006, there were 63,334 and 80,000 shares, respectively, remaining and available for future grant under the 2005 Directors’ Plan.
100
Table of Contents
A summary of option and award activity under the equity incentive plans, as of December 31, 2007 is presented below:
| Weighted- | ||||||||||||||||
| Weighted- | Average | |||||||||||||||
| Average | Remaining | Aggregate | ||||||||||||||
| Exercise | Contractual | Intrinsic | ||||||||||||||
| Shares | Price | Term | Value | |||||||||||||
| (In thousands) | ||||||||||||||||
| Outstanding at January 1, 2007 | 2,253,889 | $ | 12.51 | |||||||||||||
| Options and awards granted | 1,093,865 | $ | 26.96 | |||||||||||||
| Options and awards canceled | (228,414 | ) | $ | 20.85 | ||||||||||||
| Options and awards exercised | (405,983 | ) | $ | 6.56 | ||||||||||||
| Outstanding at December 31, 2007 | 2,713,357 | $ | 18.52 | 8.04 | $ | 104,338 | ||||||||||
| Exercisable at December 31, 2007 | 1,315,001 | $ | 11.35 | 7.39 | $ | 58,556 | ||||||||||
The aggregate intrinsic value of all options and awards outstanding and exercisable at December 31, 2007 was based on a closing stock price of $55.88.
The weighted-average grant date fair values of options and awards granted in the years ended December 31, 2007, 2006 and 2005 were $26.96, $18.68 and $13.66 per share, respectively.
The total intrinsic value of options exercised in the years ended December 31, 2007, 2006 and 2005 was $10,893,000, $2,686,000 and $2,703,000, respectively.
As of December 31, 2007, the total compensation cost related to unvested options and awards not yet recognized was $20,200,000. This amount will be recognized over an estimated weighted-average amortization period of 2.78 years.
A summary of the Company’s unvested shares under the equity incentive plans as of December 31, 2007 and changes during the year ended December 31, 2007 is as follows:
| Weighted- | ||||||||
| Average | ||||||||
| Grant Date | ||||||||
| Shares | Fair Value | |||||||
| Unvested at January 1, 2007 | 1,504,069 | $ | 13.46 | |||||
| Options granted | 1,093,865 | $ | 26.96 | |||||
| Options cancelled | (255,090 | ) | $ | 18.99 | ||||
| Options vested | (1,029,439 | ) | $ | 12.03 | ||||
| Unvested at December 31, 2007 | 1,313,405 | $ | 24.75 | |||||
Employee Stock Purchase Plan
As of December 31, 2007, the Company had reserved a total of 695,555 shares of common stock for issuance under the ESPP. In addition, the board of directors may increase the share reserve as of each January 1 through January 1, 2015, by an amount not to exceed the lesser of (i) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year or (ii) 250,000 shares. The ESPP permits eligible employees to purchase common stock at a discount through payroll deductions during defined offering periods. The price at which the stock is purchased is equal to the lower of 85% of the fair market value of the common stock at the beginning of an offering period or after a purchase period ends. During the years ended December 31, 2007 and 2006, 59,218 shares and 93,837 shares, respectively, were purchased under the ESPP. At December 31, 2007 and 2006, there were 501,689 and 313,842 shares, respectively, remaining and available for future grant under the ESPP.
101
Table of Contents
| 8. | Preferred Stock |
Preferred stock
At December 31, 2007 and 2006, the Company was authorized to issue 5,000,000 shares of preferred stock.
Convertible preferred stock
At December 31, 2007 and 2006, the Company was authorized to issue zero shares of convertible preferred stock. Prior to their conversion into common stock on the close of the Company’s initial public offering, each share of Series D preferred stock, prior and in preference to any declaration or payment of any dividend on the Company’s Series A, Series B and Series C preferred stock and common stock, was entitled to receive dividends in shares of Series D preferred stock at the rate of $1.35 per share of Series D preferred stock per annum (as adjusted for stock splits, stock dividends or similar events with respect to such shares). The Series D preferred stock dividend was payable upon a liquidation event as defined in the stock purchase agreement and, accordingly, this dividend was paid at the close of the Company’s initial public offering, having been previously accrued on a straight-line basis. For the years ended December 31, 2007, 2006 and 2005, the Company recorded $0, $0 and $969,000, respectively, of convertible preferred stock dividend charge in its statement of operations. At the Company’s initial public offering, 71,080 shares of common stock were issued upon conversion of the preferred stock dividend.
| 9. | Income Taxes |
In the years ended December 31, 2007, 2006 and 2005, the Company recorded $622,000, $0 and $0, respectively, of current income tax expense. The income tax expense for the year ended December 31, 2007 resulted from the Company’s full year effective tax rate of 2.2% related to U.S. federal and state Alternative Minimum Tax and other temporary differences. The Company incurred net operating losses in 2006 and 2005 and accordingly did not record a provision for income taxes.
Deferred income taxes reflect the net tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows (in thousands):
| December 31, | ||||||||
| 2007 | 2006 | |||||||
| Net operating loss carryforwards | $ | 29,871 | $ | 60,636 | ||||
| Research credit carryforwards | 16,903 | 14,171 | ||||||
| Capitalized research and development | 22,227 | 4,132 | ||||||
| Deferred revenue | 8,900 | 9,888 | ||||||
| Other | 5,001 | 2,525 | ||||||
| Total deferred tax assets | 82,902 | 91,352 | ||||||
| Valuation allowance | (82,902 | ) | (91,352 | ) | ||||
| Net deferred tax assets | $ | — | $ | — | ||||
Realization of deferred tax assets is dependent upon the Company generating future taxable income, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased (decreased) by $(8,450,000), $31,662,000 and $16,398,000 during 2007, 2006 and 2005, respectively.
As of December 31, 2007, the Company had net operating loss carry-forwards for federal income tax purposes of $75,983,000, which expire in the years 2022 through 2026, and federal research and development tax credits of $11,363,000, which expire in the years 2020 through 2027.
102
Table of Contents
As of December 31, 2007, the Company had net operating loss carry-forwards for state income tax purposes of $67,778,000, which expire in the years 2012 through 2017, and state research and development tax credits of $8,522,000, which do not expire.
Approximately $529,000 of the valuation allowance for deferred tax assets relates to benefits of stock option deductions that, when recognized, will be allocated directly to additional paid-in capital.
Utilization of the Company’s net operating loss and credit carry-forwards may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the net operating loss and credit carry-forwards before utilization.
| 10. | Quarterly Financial Data (Unaudited) |
The following tables summarize the unaudited quarterly financial data for the last two fiscal years (in thousands, except per share data):
| Dec. 31, | Sept. 30, | June 30, | March 31, | Dec. 31, | Sept. 30, | June 30, | March 31, | |||||||||||||||||||||||||
| 2007 | 2007 | 2007 | 2007 | 2006 | 2006 | 2006 | 2006 | |||||||||||||||||||||||||
Selected Quarterly Data: | ||||||||||||||||||||||||||||||||
| Total revenues | $ | 25,761 | $ | 35,425 | $ | 36,097 | $ | 16,539 | $ | 3,106 | $ | 3,106 | $ | 3,106 | $ | 1,288 | ||||||||||||||||
| Net income (loss) | 2,451 | 15,594 | 13,497 | (3,349 | ) | (18,617 | ) | (16,337 | ) | (14,381 | ) | (14,978 | ) | |||||||||||||||||||
| Basic net income (loss) per share | $ | 0.10 | $ | 0.63 | $ | 0.55 | $ | (0.14 | ) | $ | (0.76 | ) | $ | (0.67 | ) | $ | (0.72 | ) | $ | (0.77 | ) | |||||||||||
| Diluted net income (loss) per share | $ | 0.09 | $ | 0.60 | $ | 0.52 | $ | (0.14 | ) | $ | (0.76 | ) | $ | (0.67 | ) | $ | (0.72 | ) | $ | (0.77 | ) | |||||||||||
103